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Summary 
Vascular remodelling is an adaptive process that allows vessels to respond to 
changes in haemodynamic conditions, however this process also underlies the 
pathogenesis of atherosclerosis, vein graft failure following coronary artery 
bypass graft (CABG) surgery and restenosis following stent deployment to an 
atherosclerotic vessel. Injury to the vessel wall causes denudation of the 
endothelial cell (EC) layer and the resultant pathological vascular remodelling 
involves growth and migration of vascular smooth muscle cells (VSMC) and 
degradation and reorganisation of the extracellular matrix (ECM). Regeneration 
of the endothelial layer, known as re endothelialisation, is essential for healing 
of injured vessels and therefore therapies that specifically target VSMC growth 
and migration, without preventing re-endothelialisation are optimal in these 
pathologies. Dysregulation of the renin angiotensin system (RAS) is one of the 
key contributing factors to remodelling of the vasculature, with the majority of 
the pathological processes involved, being mediated by angiotensin II (Ang II) 
signalling at the angiotensin type I receptor (AT1R). A counter regulatory axis of 
the RAS has been identified, centred around the enzymatic actions of 
angiotensin converting enzyme 2 (ACE2), and the resultant production of 
Angiotensin-(1-9) [Ang-(1-9)] and Angiotensin-(1-7) [Ang-(1-7)] from Ang I and 
Ang II respectively. This axis counter-regulates the actions of Ang II via the AT1R, 
thereby providing a vasculoprotective role. Ang-(1-7) acts via the receptor Mas 
and inhibits Ang II induced VSMC cell migration, proliferation, and vascular 
remodelling in vivo. Comparatively, less is known about the actions of Ang-(1-9), 
however it has been identified as a functional ligand for the angiotensin type 2 
receptor (AT2R), inhibiting cardiac hypertrophy in vitro and cardiac fibrosis in 
vivo. However, the role of Ang-(1-9) in the vasculature is unexplored. Therefore, 
the main aim of this thesis was to investigate the interaction of Ang II and the 
counter-regulatory peptides Ang-(1-7) and Ang-(1-9) in the vasculature using 
primary human VSMC and EC, and to provide a direct comparison of Ang-(1-7) 
and Ang-(1-9) in order to further understand their signal transduction pathways. 
First, a model of VSMC proliferation was established in VSMC isolated from 
human saphenous vein tissue (HSVSMC). Here it was demonstrated that while 
Ang II had no effect on HSVSMC proliferation, foetal calf serum (FCS) induced 
HSVSMC proliferation in a concentration dependent manner. Ang-(1-7) and Ang-
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(1-9) blocked FCS induced proliferation of HSVSMC via Mas or the AT2R, 
respectively. Ang II-induced HSVSMC migration via the AT1R, and was inhibited 
by both Ang-(1-7) and Ang-(1-9) via Mas and the AT2R, respectively. Further 
investigation into the functional interplay of Ang II, Ang-(1-7) and Ang-(1-9) in 
HSVSMC migration identified alterations in extracellular signal-related kinase 1/2 
(ERK1/2) activity and matrix metalloproteinase 2 (MMP2) and MMP9 expression 
as potential mechanisms contributing to the observed results. Additionally, Ang 
II has recently been demonstrated to regulate expression of the microRNA-132/-
212 (miR-132/-212) cluster in rat aortic VSMC, thereby regulating a number of 
target genes involved in VSMC migration. This pathway was assessed in HSVSMC 
and it was found that Ang II-mediated HSVSMC migration was associated with an 
increase in miR-132 but not miR-212 expression, and a decrease in phosphatase 
and tensin homologue (PTEN) expression, a miR-132 target, at the messenger 
RNA level. These changes were found to be via the AT1R and were inhibited by 
Ang-(1-7) and Ang-(1-9). However, PTEN protein levels were unchanged and no 
changes were observed in key proteins involved in the downstream signalling 
pathways of PTEN, such as Akt and monocyte chemoattractant protein 1 ( MCP-
1). The role of miRNA-132 in Ang II induced HSVSMC migration was further 
investigated through the use of a miR-132 inhibitor and downregulation of DICER, 
a key enzyme involved in miRNA biogenesis. Here it was found that miR-132 or 
regulation of an alternative miRNA via DICER is not essential for Ang II induced 
HSVSMC migration. However, inhibition of miR-132 or DICER enhanced basal 
migration of unstimulated HSVSMC. 
Next, the effect of the RAS peptides, particularly Ang-(1-9), on EC growth, 
migration and function was assessed. Ang II, Ang-(1-7) or Ang-(1-9) have no 
effect on growth or migration of EC isolated from human saphenous veins 
(HSVEC). A direct effect of Ang-(1-9) on nitric oxide (NO) release from HSVEC 
and Chinese hamster ovary (CHO) cells expressing the AT2R was demonstrated. 
Although in cell culture Ang-(1-9) induced NO release in an AT2R sensitive 
manner, it was found that in vessels from AT2R knockout (AT2R
-/-) mice the 
biological effect of Ang-(1-9) was maintained and promoted vasodilation of both 
aortic and mesenteric artery rings. Furthermore, Ang-(1-9)-induced relaxation of 
AT2R
-/- aortic rings, but not mesenteric artery rings, was blocked by A779, 
suggesting that in large vessels Ang-(1-9) may mediate is vasodilatory effects via 
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conversion to Ang-(1-7) and signalling via Mas, while in resistance vessels Ang-(1-
9) promotes vasodilation through an alternative mechanism.  
The observation that Ang-(1-7) and Ang-(1-9) block HSVSMC, but not HSVEC, 
proliferation and migration, identified these peptides as potential therapeutic 
agents in vascular injury. A carotid artery wire injury model in mice was 
established, where injury to the carotid artery using a synthetic nylon fibre 
induced significant injury to the vessel, manifesting in the production of a large 
neointimal area at 28 days post injury. To assess the effects of Ang-(1-7) and 
Ang-(1-9), the peptides were delivered via subcutaneously via osmotic 
minipump. It was found that Ang-(1-7) infusion reduced neointimal formation 
and neointimal/media (NI/MA) ratio in comparison to control vessels via Mas. 
Similarly, Ang-(1-9) reduced neointimal formation and NI/MA ratio via the AT2R, 
as the AT2R antagonist PD123,319, but not the Mas antagonist A779,blocked the 
effects of Ang-(1-9), indicating that this was via a direct effect of Ang-(1-9), as 
opposed to conversion to Ang-(1-7) and signalling via Mas. 
An interesting finding from the in vivo study was that a large proportion of 
vessels from animals co-infused with Ang-(1-7) and A779, or Ang-(1-9) and 
PD123,319 developed more complex lesions with increased vessel remodelling 
and neovascularisation, largely within the media, in comparison to all other 
groups. Analysis of the composition of these complex lesions revealed that they 
were composed of disorganised ECM and were highly cellular, containing a large 
number of VSMC, macrophages and proliferating cells. Re-endothelialisation had 
occurred on the lumenal lining of these vessels and neovascularisation of the 
complex lesion was observed.  
In summary the data from this thesis demonstrates for the first time a direct 
biological role for Ang-(1-9) in the vasculature through inhibition of HSVSMC 
migration and proliferation, and increase NO bioavailability from HSVEC in vitro 
and reduced neointimal formation in an in vivo mouse model of vascular injury. 
Furthermore, this study provides a direct comparison of Ang-(1-9) and Ang-(1-7) 
in the vasculature and while the end biological effects are similar, they act via 
different receptors, the AT2R or Mas, respectively, and differences exist in their 
signal transduction mechanisms. These findings highlight the potential of Ang-(1-
9) and Ang-(1-7) as therapeutic agents in the setting of vascular remodelling. 
 
 
 
 
 
 
 
 
 
Chapter 1 
General Introduction 
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1.1 Cardiovascular disease 
The term cardiovascular disease (CVD) encompasses all diseases involving the 
heart and circulatory system, including coronary artery disease (CAD), 
hypertension and stroke. CVD is the main cause of death in the UK, claiming the 
lives of approximately 180,000 people in 2010, around one third of all deaths 
that year (British Heart Foundation, 2012). Furthermore, CVD is one of the main 
causes of premature death in the UK (deaths before the age of 75), accounting 
for 28 % of premature death in men and 19 % in women in 2010 (British Heart 
Foundation, 2012). CVD also places a heavy burden on the UK economy; overall 
CVD is estimated to cost the UK £19 billion per year, with approximately 46% of 
this due to direct health care costs, 34% to productivity losses associated with 
death and illness in those of working age, and 20% of the informal care of people 
with CVD (British Heart Foundation, 2012). Although the numbers of people with 
CVD has been falling in recent years, there is still a vital need for continued 
research within this area leading to new prevention strategies and treatments.  
1.1.1 Cardiovascular remodelling 
CVD development and progression is associated with remodelling of the 
vasculature, the heart and other organs including the kidney. Remodelling is 
usually an adaptive process that occurs in response to long term-changes in 
haemodynamic conditions or following injury, which subsequently contributes to 
the pathogenesis of various CVD (Glagov et al., 1987, Pasterkamp et al., 2000).  
Changes in haemodynamic conditions result in structural alterations of the vessel 
wall, indicated by changes in wall diameter and thickness (Gibbons and Dzau, 
1994, Pasterkamp et al., 2004, Ward et al., 2000). While this is initially an 
adaptive process, eventually this leads to enhanced vessel reactivity or impaired 
relaxation, limiting blood pressure control and leading to the development of 
hypertension (Ward et al., 2000, Gibbons and Dzau, 1994). Additionally, chronic 
changes in haemodynamic conditions leads to the production of reactive oxygen 
species (ROS), which creates an inflammatory environment resulting in 
endothelial damage and the development of atherosclerosis (Cai and Harrison, 
2000). In fact, remodelling of the vasculature is one of the major causes of all 
CVD and ultimately promotes remodelling of the heart. For example, 
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hypertension causes an increase in haemodynamic load within the heart, 
resulting in an increase in left ventricular mass due to cardiomyocyte 
hypertrophy and ECM remodelling (Selvetella et al., 2004). While this is initially 
an adaptive process to compensate for the increased haemodynamic load, it 
eventually becomes maladaptive leading to a reduction in left ventricular 
performance, cardiac impairment and an increased risk of cardiac events, which 
eventually culminates in heart failure (Selvetella et al., 2004). Furthermore, the 
presence of atherosclerosis within the coronary arteries restricts blood flow to 
the heart, causing the myocardium to become ischaemic and resulting in chest 
pain and shortness of breath under resting conditions, symptoms characteristic 
of angina (Ross, 1999a). Rupture of the atherosclerotic plaque can lead to 
complete occlusion of the coronary artery, resulting in myocardial infarction 
(Ross, 1999a).  
1.1.2 Vascular remodelling 
The vascular wall is continuously exposed to haemodynamic forces such as 
luminal pressure and sheer stress. Alterations in these forces, either 
physiological or pathological, lead to both functional and structural alterations 
in the vascular wall (Glagov et al., 1987, Ward et al., 2000) (Figure 1.1). Acute 
changes in haemodynamic force, as in vasoconstriction or vasodilation, can 
modify vessel diameter. Chronic changes in haemodynamic forces result in 
structural alterations in the vessel wall, known as vascular remodelling, 
indicated by changes in wall diameter or thickness (Gibbons and Dzau, 1994). 
Vascular remodelling is therefore an adaptive process of structural remodelling 
that occurs in response to long-term changes in haemodynamic forces (Gibbons 
and Dzau, 1994). Vascular remodelling involves changes in at least four different 
cellular processes; cell growth, cell migration, cell death, and production or 
degradation of extracellular matrix (ECM) (Gibbons and Dzau, 1994). While 
vascular remodelling is initially an adaptive process within the vessel to cope 
with the altered haemodynamic force, it contributes to the pathology of various 
CVDs including hypertension and atherosclerosis. However, vascular remodelling 
is not solely determined by haemodynamic force, and a role for inflammatory 
responses and changes in ECM components has been identified (Hacking et al., 
1996, Pasterkamp et al., 2000, Pasterkamp et al., 2004). Furthermore, the 
vascular wall is also drastically changed following injury, when a neointima 
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forms as part of the reparative response, and its formation involves thrombosis, 
migration and vascular smooth muscle cell (VSMC) proliferation, matrix 
production, and the infiltration of inflammatory cells (Gibbons and Dzau, 1994). 
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Figure 1.1 Schematic overview of vascular remodelling 
Diagram outlining the remodelling that occurs in small resistance and large conduit arteries as a result of hypertension, and remodelling of large conduit arteries in 
atherosclerosis and following revascularisation due to in-stent restenosis and late vein graft failure. 
Large conduit
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•Medial hyperplasia
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•Impaired vasomotion
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•Medial hyperplasia
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1.1.3 Endothelial dysfunction 
While vascular remodelling largely involves changes in the structure and function 
of VSMC, the process by which pathological vascular remodelling occurs begins 
with damage to the endothelial layer. In the vasculature the endothelium exists 
as a cell monolayer on the luminal surface of the vessel wall. The importance of 
the endothelium was first recognised by its effect on vascular tone, achieved by 
the production and release of several vasoactive molecules as well as by 
response to circulating vasoactive mediators, resulting in vessel relaxation or 
contraction. The pioneering experiments of Furchgott and Zawadzki first 
demonstrated an endothelium-derived relaxing factor that was subsequently 
shown to be nitric oxide (NO) (Furchgott and Zawadzki, 1980). NO is generated 
from L-arginine by the action of endothelial NO synthase (eNOS) and diffuses to 
the VSMC where guanylate cyclase becomes activated, leading to cGMP-
mediated vasodilation. The endothelium also mediates hyperpolarization of 
VSMC via an NO-independent molecule, endothelial derived hyperpolarizing 
factor (EDHF), which increases potassium conductance and subsequent 
propagation of depolarization of VSMC, to maintain vasodilator tone (Feletou and 
Vanhoutte, 1988). During states of reduced NO bioavailability EDHF can 
compensate for loss of NO-mediated vasodilator tone, particularly in the 
microcirculation (Feletou and Vanhoutte, 1988, Shimokawa et al., 1996). The 
endothelium also promotes vasoconstriction via the local generation of 
endothelin and angiotensin II (Ang II) [via the actions of endothelial angiotensin 
converting enzyme (ACE)] (Saye et al., 1984, Kinlay et al., 2001).  
In addition to regulating vascular tone, NO plays a key role in maintaining the 
vascular wall in a quiescent state through inhibition of inflammation, cellular 
proliferation, and thrombosis [reviewed by (Deanfield et al., 2007)]. This is in 
part achieved by s-nitrosylation of cysteine residues in a wide range of target 
proteins, including the pro-inflammatory transcription factor nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB), cell cycle–controlling 
proteins, and proteins involved in generation of tissue factor, which reduces 
their biological activity (Stamler et al., 2001, Ghosh and Karin, 2002). However, 
when the endothelium is damaged, NO bioavailability is reduced leading to 
impaired vasorelaxation and a switch in the state of the cells from the quiescent 
state to the active state, termed endothelial cell activation (Willms-Kretschmer 
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et al., 1967). Endothelial activation leads to a change in the endothelium to a 
pro-inflammatory and pro-thrombotic phenotype (Deanfield et al., 2007). 
Increased endothelial inflammation occurs as a result of expression of adhesion 
molecules, such as E-selectin, intercellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1), which promote inflammatory cell 
adhesion to the endothelium and migration to VSMC (Tummala et al., 1999, 
Gauthier et al., 1995, de Graaf et al., 1992, Kaplanski et al., 1998). 
Additionally, synthesis of various cytokines including interleulin-6 (IL-6) and IL-8, 
and chemoattractants such monocyte chemoattractant protein-1 (MCP-1) further 
enhances a pro-inflammatory state (Porreca et al., 1997, Mantovani et al., 
1997).  The prothrombotic phenotype occurs due to a loss of surface anti-
coagulant molecules such as thrombomodulin and herparan sulphate, reduced 
fibrinolytic effects due to enhanced plasminogen activator inhibitor type 1 (PAI-
1) release, loss of the platelet anti-aggregatory effects of ecto-ADPases and 
prostacyclin, and production of platelet activating factor (Cines et al., 1998). 
Increased vascular inflammation and thrombosis is a key process that contributes 
to remodelling of the vasculature, particularly in the setting of atherosclerosis.  
Reduced NO bioavailability occurs as a result of increased NO degradation or 
reduced NO production, both of which are largely caused by oxidative stress, 
which is caused by a number of CVD risk factors including as hypertension, 
hypercholesterolaemia and smoking (Deanfield et al., 2007). During oxidative 
stress there is an enhanced production of ROS, particularly superoxide (O2
-), 
which rapidly reacts with NO reducing NO bioavailability and producing 
peroxynitrite (ONOO-), a potent ROS that nitrosylates cellular proteins and 
lipoproteins, thereby increasing vascular inflammation (White et al., 1994, 
Darley-Usmar et al., 1992, Gryglewski et al., 1986). Additionally, O2
- directly 
stimulates VSMC growth and reduces eNOS expression and activity in endothelial 
function, further contributing to reduced NO levels and vascular disease (Suh et 
al., 1999, Peterson et al., 1999). Nicotinamide adenine dinucleotide phosphate-
oxidase (NAD(P)H) oxidase has been shown to be the main source of O2
- 
production within the vasculature (Griendling et al., 1994, Rajagopalan et al., 
1996). Importantly, Ang II is a potent activator of NAD(P)H, demonstrating a key 
role for this peptide in the generation of oxidative stress (Griendling et al., 
2000, Rajagopalan et al., 1996, Yan et al., 2003, Lassegue et al., 2001). 
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Furthermore, vascular ROS can also be produced via eNOS (Vasquez-Vivar et al., 
2003). eNOS generates NO through oxidation of L-arginine, and this reaction 
requires the co-factor tetrahydrobiopterin (BH4) (Schmidt et al., 2001, Vasquez-
Vivar et al., 2003). However, in the absence of L-arginine or BH4, eNOS is 
uncoupled resulting in the production of O2
- and hydrogen peroxide (H2O2) 
(Vasquez-Vivar et al., 2003). Uncoupling of eNOS contributes to enhanced 
oxidative stress and endothelial dysfunction through diminished NO production 
and increased production of ROS. Additionally, it has been demonstrated that 
eNOS can be partially uncoupled, resulting in the simultaneous production of NO 
and O2
-, thereby enhancing the production ONOO- (Cai and Harrison, 2000). In 
summary, alterations in NO levels due to vascular injury and oxidative stress 
promotes changes in the vascular endothelium leading to reduced endothelial 
function, increased VSMC growth and increased vascular inflammation, all 
processes which underlie the pathology of vascular remodelling and disease. 
1.1.4 Hypertension 
Hypertension has been identified as one of the most important risk factors for 
CVD and is defined as a systolic blood pressure of 140mmHg or above, or a 
diastolic blood pressure of 90mmHg and above. In very simplistic terms, 
hypertension can either be caused as an increase in fluid volume or an increase 
in peripheral resistance. Hypertension is a risk factor for various other CVD 
inclusing atheroscelrosis, myocardial infarction and stroke and induces long term 
changes in the haemodynamic conditions within the vasculature, thereby 
contributing to vascular remodelling. Hypertension induced remodelling can 
occur in both large conduit arteries and small resistance arteries.  
1.1.4.1 Remodelling of large conduit arteries 
During hypertension, the large arteries exhibit an increased lumen size, a 
thickened media with increased collagen deposition, and decreased vascular 
compliance (Folkow, 1982, Lee et al., 1995, Schiffrin, 2001b, Schiffrin, 2001a) 
(Figure 1.1). The thickening of the arterial wall is considered to be one of the 
main compensatory mechanisms to preserve circumferential wall stress (Girerd 
et al., 1994). The outward hypertrophic vascular remodelling is thought to be  
progressive as it increased with age in the carotid arteries of patients with 
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untreated hypertension (Sasaki et al., 2002). Hypertension-induced vascular 
hypertrophy it thought to lead to increased atherosclerotic disease in vessels 
such as the carotid artery (Frohlich and Susic, 2007).  
1.1.4.2 Remodelling of small resistance arteries 
In contrast to the outward hypertrophic remodelling of the large arteries during 
hypertension, small resistance arteries exhibit a smaller lumen and external 
diameter, a normal or increased media thickness and an increased media-to-
lumen ratio (Schieffer et al., 2000) (Figure 1.1). VSMC hypertrophy or 
hyperplasia may be present depending on the species, vascular bed, or severity 
of the disease. For example, in hypertensive patients, rearrangement of VSMCs 
around a smaller lumen has been reported, however, in patients with 
renovascular hypertension, remodelling of resistance arteries resulting from 
VSMC hypertrophy was also present (Korsgaard et al., 1993, Rizzoni et al., 2000). 
Changes in ECM content are also involved in this remodelling, as collagen and 
fibronectin deposits are observed in the resistance arteries of experimental 
models and patients with hypertension (Intengan and Schiffrin, 2000). 
Remodelling of the resistance arteries during hypertension may be one of the 
first signs of organ damage found in mild hypertension in humans. It appears to 
precede the development of left ventricular hypertrophy and thickening of the 
intima–media of the large conduit arteries (Park and Schiffrin, 2001). Small 
artery remodelling is also involved in the clinical complications of hypertension, 
such as stroke and myocardial infarction (Schiffrin, 2001a).  
1.1.5 Atherosclerosis 
Atherosclerosis is a progressive disease of the vasculature that affects large 
(aorta) and medium-sized (carotid, coronary, etc) arteries of the cardiovascular 
system (Ross, 1999a). The narrowing or complete occlusion of the luminal area 
of these arteries results in reduced blood flow resulting in ischaemia due to a 
reduction in oxygen supply (Figure 1.1). It is the most common underlying cause 
for many CVDs and various risk factors associated with atherosclerosis, such as 
hyperlipidaemia, hypercholesterolaemia, hypertension, smoking and obesity, are 
common within the UK (British Heart Foundation, 2012). The pathology of 
atherosclerosis matures over many years from an initial fatty streak to the 
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formation of an advanced complex lesion. The first clinical manifestations of 
atherosclerosis usually occur when the lumen diameter is reduced by 70 % and 
most often manifest as angina-like symptoms such as chest, shoulder or neck 
pain, alongside shortness of breath (Brown and Dodge, 1982). 
Atherosclerosis is widely accepted as an inflammatory disease with the first step 
in disease progression identified as endothelial dysfunction (Ross, 1999b), which 
can be caused by several factors including hypertension, the presence of free 
radicals from tobacco smoke and modified low density lipoproteins (LDL) (Ross, 
1999a, Bassiouny et al., 1994). Compensatory mechanisms that change the 
homeostatic control of the endothelium subsequently occur to overcome the 
initial damage (Ross, 1999a). Damage to the endothelium and the presence of 
high plasma levels of circulating LDL leads to the deposition of these lipids in the 
subendothelial space of the arterial wall (Davignon and Ganz, 2004). The 
cholesterol rich LDL is then subject to oxidation, leading to the activation of 
endothelial cells and expression of inflammatory cell adhesion molecules, 
including P-selectin, VCAM-1 and ICAM-1, and the recruitment of blood borne 
monocytes (Shih et al., 1999, Glass and Witztum, 2001). This in turn facilitates 
the adherence of leukocytes to the damaged endothelium and results in the 
transmigration of these cells into the intimal layer by the actions of chemokines 
such as MCP-1. Once inside the arterial wall, migrated monocytes mature into 
activated intimal macrophages by the action of macrophage colony-stimulating 
factor, which also results in the upregulation of scavenger receptors (Yan and 
Hansson, 2007). Macrophages internalise oxidised LDL particles in an 
uncontrolled manner giving rise to lipid-rich foam cells which secrete a variety 
of pro-inflammatory cytokines such as IL 1β and tumour necrosis factor-α (TNF-
α), which worsen the inflammatory response and initiate VSMC proliferation and 
migration (Bevilacqua et al., 1984). These cytokines also transform the surface 
of the endothelium from an anti- to pro-thombotic state by reducing the 
production of tissue plasminogen activator and protein-S, and increasing 
production of matrix metalloproteinases (MMPs), endothelin 1, ICAM-1 and 
VCAM-1 (Isoda et al., 2006, Tedgui and Mallat, 2006). Accumulation of foam cells 
results in the formation of fatty streaks, the earliest form of atherosclerotic 
plaque which consist mainly of inflammatory cells (Stary et al., 1994). The 
artery can then undergo positive vascular remodelling causing the lumenal 
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diameter to be unaffected. However, these fatty streaks continue to grow with 
the accumulation of foam cells, lipids and VSMCs forming advanced 
atherosclerotic plaques. Additionally, macrophage apoptosis within advanced 
plaques increases inflammation within the plaque, contributing to the 
development of a necrotic core (Seimon and Tabas, 2008). Atherosclerotic 
lesions contain fibrous connective tissue which forms a fibrous cap, which 
initially offers protection to the vessel by stabilising the plaque. As the disease 
advances and cells accumulate further within the plaque the fibrous cap 
becomes thinner and more vulnerable (Ross, 1999a). Fibrous cap erosion exposes 
the plaque contents and necrotic core to the circulating blood causing 
thrombosis formation, potentially inducing a fatal cardiovascular event.  
1.1.5.1 The role of vascular smooth muscle cells 
While it is clear that atherosclerosis is an inflammatory disease, with 
inflammatory cells being integrally involved at all stages of disease 
development, VSMC also play an important role and become more dominant as 
atherosclerosis advances (Raines and Ross, 1993). The phenotype of intimal 
VSMC within atherosclerotic plaques differs from that of those in the medial area 
(Mosse et al., 1985). Medial VSMC usually express high levels of smooth muscle 
myosin heavy chain (SM-MHC) and α-smooth muscle actin (α-SMA), proteins that 
are involved in the contractile function of the cell (Owens et al., 2004). In 
contrast, intimal VSMC have a high proliferative index and express much lower 
levels of the contractile proteins. VSMC exhibit this plasticity as they are not 
terminally differentiated and can therefore undergo phenotypic switching from a 
quiescent contractile state to an active synthetic state (Campbell and Campbell, 
1994). This can occur in response to numerous pro-inflammatory and atherogenic 
stimuli including MMPs, cytokines and modified lipids (Thyberg and Hultgardh-
Nilsson, 1994, Hautmann et al., 1997, Pidkovka et al., 2007). In addition to 
macrophages, VSMC are responsible for stimulating foam cells generation in 
atherosclerosis due to increased expression of scavenger receptors, which 
promote lipid uptake and foam cell formation (Stary et al., 1994, Rong et al., 
2003). Synthetic VSMC also promote remodelling as they are able to migrate and 
proliferate more readily than those in a contractile state. In addition to 
proliferation and migration, apoptosis plays a critical role in vascular 
remodelling and contributes to the development of atherosclerosis (Gibbons and 
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Dzau, 1994). VSMC apoptosis in atherosclerotic lesions occurs via a number of 
pathways but most commonly through activation of the caspase cascade 
(Bennett and Boyle, 1998, Mallat and Tedgui, 2000), leading to increased 
inflammation within the plaque and thinning of the fibrous cap (Clarke et al., 
2008, Mallat et al., 2007). Therefore, VSMC, as well as inflammatory cells, are 
integral to the development and progression of atherosclerosis.  
1.1.6 Neointimal formation and vein graft failure 
One of the main interventions employed to treat atherosclerosis is coronary 
artery bypass graft surgery (CABG), where a healthy segment of blood vessel 
from another part of the body is engrafted to bypass the obstructed portion of 
the diseased vessel, thereby restoring blood flow to the heart. Despite the fact 
that arterial conduits, such as the radial artery or internal mammary artery, 
have more successful long term patency than the saphenous vein, with 10 year 
patency rates of approximately 85% compared to 61% respectively, the 
saphenous vein is most commonly used due to the need to bypass multiple 
occlusions (Goldman et al., 2004).  Approximately 25,000 CABG procedures are 
performed per year in the UK and this form of revascularisation has been 
associated with reduced morbidity and re-occurrence of incapacitating angina, 
and increased quality of life, particularly in patients with three-vessel or left 
main coronary artery disease, in comparison with medical therapy (British Heart 
Foundation, 2012, Mayou and Bryant, 1987, Herlitz et al., 2001, European 
Coronary Surgery Study Group, 1982, CASS Principal Investigators, 1983). While 
the benefits of this procedure are evident, surgical revascularization presents a 
significant limitation for a large proportion of patients as approximately 50% 
require further intervention to alleviate the symptoms of graft occlusion within 
10-15 years due to neointimal thickening and superimposed atherosclerosis (Hata 
et al., 2007, Parang and Arora, 2009) (Figure 1.1).  
Various cellular processes are initiated immediately following engraftment of 
the vein to the arterial system that underlie the pathogenesis of vein graft 
failure, both at an early and late stage. Early vein graft failure can occur within 
the first few days as a result of thrombosis, initiated by endothelial damage 
which exposes the blood to a thrombogenic surface (Bryan and Angelini, 1994). 
The process of late failure begins immediately following implantation when the 
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vein is exposed to a period of ischaemia followed by reperfusion, resulting in the 
generation of ROS, which in turn trigger an inflammatory response within the 
graft (Shi et al., 2001, West et al., 2001). Due to the damaged endothelium and 
cytotoxic environment within the graft VSMC migrate from the media to the 
intima and proliferate, and deposit ECM components, contributing to the 
formation of a neointimal area (Lerner et al., 1986, Newby, 1997). This 
neointimal area is highly susceptible to an accelerated form of atherosclerosis 
due to the infiltration of inflammatory cells, which creates a cytotoxic 
environment within the plaque encouraging the uptake of lipids (Schwartz et al., 
1995).  The atherosclerotic plaques that form within the graft are more diffuse 
and unstable due to poorly developed or absent fibrous caps, and are therefore 
more prone to rupture (Shelton et al., 1988, Virmani et al., 1988). 
1.1.7 Restenosis 
A non-surgical alternative treatment for atherosclerosis is percutaneous coronary 
intervention (PCI) where a balloon catheter is advanced from an accessible 
vessel such as the femoral or radial artery to the occluded area, then the 
balloon inflated at a controlled rate to expand the vessel, followed by the 
deployment of a stent, a metal mesh tube that acts as a scaffold to help 
maintain the resultant increase in lumen diameter. PCI is the most common form 
of revascularisation in the UK, with approximately 80,000 procedures performed 
per year, and while in comparison with pharmacological therapies, PCI has been 
shown to reduce reoccurrence of angina and improve quality of life, evidence to 
suggest this form of revascularisation improves morbidity is conflicting and 
varies depending on the stability of the patients CAD (King, 2005, Schomig et al., 
2008, RITA-2 trial participants, 1997). Furthermore, the long-term success of PCI 
is limited by restenosis, which is thought to be an exaggerated form of wound 
healing after injury. Restenosis is characterized by a recurrence of luminal 
narrowing resulting from neointimal hyperplasia and remodelling of the injured 
vessel (Inoue and Node, 2009) (Figure 1.1). The formation of neointima is largely 
due to excessive VSMC migration and proliferation in addition to remodelling of 
the ECM and an increased inflammatory response at the site of injury (Libby and 
Clinton, 1992, Inoue and Node, 2009).  
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In an attempt to circumvent the issue of restenosis following bare metal stent 
employment drug eluting stents were developed, which were coated with 
polymers to elute cell cycle inhibitory drugs, such as paclitaxel or sirolimus 
(Htay and Liu, 2005). Drug eluting stents have been shown to inhibit restenosis in 
comparison to bare metal stents, confirming that inhibition of VSMC proliferation 
is beneficial in this setting, however they do not come without complications of 
their own (Schampaert et al., 2006, Stone et al., 2009, Caixeta et al., 2009). 
Several studies have reported that drug eluting stents are associated with an 
increased risk of late stent thrombosis as the drugs they are coated with also 
inhibit endothelial cell proliferation, thereby inhibiting regeneration of the 
endothelial layer, increasing the incidence of late in-stent thrombosis (Luscher 
et al., 2007, Karha et al., 2006, Joner et al., 2007). Therefore therapies that 
specifically target VSMC growth and migration, without preventing re-
endothelialisation are optimal in vein graft failure and in-stent restenosis (Inoue 
and Node, 2009).  
1.2 The renin-angiotensin system 
The renin angiotensin system (RAS) is a key component of cardiovascular 
physiology, playing an important role in the regulation of vascular tone, blood 
pressure and volume, and electrolyte balance. However, dysregulation of the 
system largely contributes to the pathogenesis of cardiovascular remodelling and 
the development of various CVDs. The extent to which chronic dysregulation of 
the RAS contributes to cardiovascular disease is demonstrated by the fact that 
inhibitors of this system, including ACE inhibitors and angiotensin II type 1 
receptor (AT1R) antagonists are among the most effective treatments for CVD. 
Clinical trials blocking the RAS have widely demonstrated a reduction in target 
organ damage in the heart and vasculature, associated with reduced morbidity 
and mortality (The SOLVD Investigators, 1991, The SOLVD Investigators, 1992, 
Yusuf et al., 2000, Mancini et al., 1996, Fox, 2003). 
The link between renal disease and CVD was first reported by Bright et al in the 
early 1800’s where it was shown that cardiac hypertrophy was associated with 
increased resistance to blood flow within small renal vessels (Bright, 1836). This 
relationship between systemic hypertension and pathological alterations in the 
kidney was explored for a number of years, leading to the discovery of renin by 
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Tigerstedt and Bergman in 1898 (Tigerstedt and Bergman, 1898). Renin was 
identified as a pressor compound in renal tissue of the rabbit and through a 
series of studies it was demonstrated that the association between renal disease 
and cardiac hypertrophy was due to the release of a vasoactive compound that 
acted directly on blood vessels to induce vasoconstriction (Tigerstedt and 
Bergman, 1898). To further investigate this relationship a number of attempts 
were made to develop an experimental model of arterial hypertension by 
manipulation of renal function, however it wasn’t until 1934 when Goldblatt et 
al linked renal ischaemia with hypertension (Goldblatt et al., 1934), and using 
this experimental protocol the presence of a pressor agent in the venous blood 
of the ischaemic kidney was detected in 1938 (Fasciolo et al., 1938). This 
pressor protein, originally named hypertensin and now known as angiotensin, 
was then isolated from the blood in 1939 (Braun-Menendez et al., 1939) and 
described as a potent short duration pressor protein. In order to investigate the 
relationship between renin and hypertension, semi-purified kidney extract was 
incubated with plasma and a vasoconstrictor agent similar to hypertensin, but 
different from renin and other known pressor agents such as epinephrine and 
vasopressin, was identified (Braun-Menendez et al., 1939). Based on these 
results renin was, for the first time, described as a protease acting on a plasma 
protein to release hypertensin as the final product. Subsequently, it was 
demonstrated that renin was secreted by the kidney, and hypertensin was 
formed in the plasma from a protein substrate that was initially named 
hypertensinogen, and later angiotensinogen (Leloir et al., 1940). The hepatic 
origin of the renin substrate was first suggested by Page et al however 
conclusive experiments were performed by Leloir et al (Page et al., 1941, Leloir 
et al., 1942). Further investigation into the actions of angiotensin revealed that 
there were in fact two forms of angiotensin, one being the product of the action 
of renin on angiotensinogen, designated angiotensin I (Ang I) (Skeggs et al., 
1954b, Skeggs et al., 1954a). Ang I was shown to be a decapeptide which can 
then be converted by a plasma enzyme to the octopeptide, named Ang II, by 
cleavage of the histidyl-leucine from the C terminus (Skeggs et al., 1954a, Lentz 
et al., 1956). Initially both peptides were thought to elicit pressor responses 
however it was later shown that only Ang II was able to achieve this (Bumpus et 
al., 1957). Since these findings over 50 years ago the depth of our knowledge of 
the RAS has greatly expanded and continues to do so. 
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1.3 The classical RAS 
Traditionally, the RAS was viewed as a linear enzymatic cascade initiated by the 
release of renin from the juxtaglomerular cells of the kidney in response to 
sympathetic nerve activation of β1 adrenoreceptors, renal artery hypotension or 
decreased sodium delivery to the distal tubules of the kidney. Once secreted, 
circulating renin promotes the hydrolysis of the prohormone angiotensinogen, a 
453 amino acid glycoprotein produced by the liver, of which the first 12 amino 
acids are the most important for its function. Cleavage of angiotensinogen by 
renin results in the production of the decapeptide Ang I. Ang I is then converted 
to the octapeptide Ang II by cleavage of the N-terminal amino acid residue via 
ACE (Skeggs et al., 1956). ACE is a membrane bound peptidyl dipeptidase and 
was first discovered by Skeggs et al in 1956 (Skeggs et al., 1956). The ACE gene 
is located on chromosome 17 and encodes for two different isoforms, the 
somatic and the germinal form (Soubrier et al., 1988, Rigat et al., 1992). 
Somatic ACE is expressed in the endothelium of various tissues including the 
lung, heart, vasculature and kidney, while the germinal form is expressed mainly 
in the testes. The overall action of ACE results in an increase in blood pressure 
as ACE not only promotes the production of Ang II, it also inactivates bradykinin, 
a potent  vasodilator (Turner and Hooper, 2002, Erdos and Skidgel, 1987) (Figure 
1.2). 
1.3.1 Angiotensin II 
Ang II is the main active peptide of the RAS and has an important role in blood 
pressure homeostasis via its effects on the kidney to conserve sodium, 
stimulation of aldosterone release, actions on smooth muscle to mediate 
vasoconstriction, and sympathetic activation in the central nervous system 
(CNS), all actions which maintain blood pressure. Ang II also has important roles 
in individual tissues which promote cell signalling leading to growth and cell 
differentiation. Once generated, Ang II has a half life of 30 seconds in the 
circulation and 15 to 30 minutes in tissues (van Kats et al., 1997). Ang II levels 
have been described as 2.4 ± 1.2 µg/100mL in arterial blood under normal 
physiological conditions (Catt et al., 1969). The effects of Ang II are mediated by 
two transmembrane G protein-coupled receptors (GPCRs), the AT1R and 
angiotensin type 2 receptors (AT2R), that tend to have opposing actions (Figure 
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1.2).  The AT1R is mainly responsible for the classical actions of Ang II as 
described above, whereas Ang II stimulation of the AT2R is reported to promote 
vasodilation and reduce cellular growth, as discussed in sections 1.3.2 and 1.3.3.   
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Figure 1.2 The renin angiotensin system 
The traditional view of the RAS is as a linear enzymatic cascade beginning with the release of 
renin, the enzyme responsible for the conversion of angiotensinogen to Ang I. Ang I is then 
converted to Ang II, the main active peptide of the RAS, via the action of ACE. Ang II signals via 
two GPCRs, the AT1R and AT2R.  ACE: Angiotensin converting enzyme; AT1R: Angiotensin type 1 
receptor; AT2R: Angiotensin type 2 receptor 
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1.3.2 The angiotensin type 1 receptor 
Ang II classically mediates the majority of its effects via the AT1R, a 40 kDa 
receptor which is composed of 359 amino acids and belongs to the GPCR 
superfamily. The AT1R is ubiquitously expressed throughout the body and found 
in a number of tissues of the cardiovascular system including the heart and both 
vascular endothelial and smooth muscle cells. Upon stimulation with Ang II the 
AT1R interacts with multiple heterotrimeric G-proteins, including Gq/11, Gi, G12 
and G13 (Griendling et al., 1997), resulting in the production of various second 
messengers and initiation of downstream signalling cascades. Once activated the 
AT1R is rapidly desensitised, internalised by endocytosis, and then recycled to 
the cell surface (Griendling et al., 1987). Desensitisation of the AT1R involves 
phosphorylation of the AT1R by G-protein related kinases (GRK), which mediate 
receptor desensitisation by uncoupling of the receptor from its activated G 
protein (Mehta and Griendling, 2007). Following this the receptor is internalised 
into clathrin-coated pits via the action of β-arrestins, a group of multifunctional 
proteins that not only initiate receptor internalization, but also promote 
activation of various downstream signalling pathways  such as mitogen-activated 
protein kinases (MAPK) and c-Jun terminal kinases (JNK) (Gaborik et al., 2001, 
Kim et al., 1997, Lefkowitz, 1998). It has also been suggested that the AT1R can 
be internalised via caveolae, specialised noncoated vesicles associated with 
caveolin (Ishizaka et al., 1998). Recycling of the AT1R has been suggested to be 
mediated via Ras-related GTPases that regulate intracellular vesicular transport 
(Somsel Rodman and Wandinger-Ness, 2000, Li et al., 2008). Alternatively, it has 
been shown that AT1R recycling may also be mediated via the type 1 Ang II 
receptor-associated protein (ARAP1) (Guo et al., 2001). 
As well as mediating recycling of receptors, AT1R associated proteins have also 
been shown to influence receptor signalling, via interaction with the C-terminal 
cytoplasmic domain of the AT1R. In addition to ARAP1, two other AT1R associated 
proteins have been identified, namely AT1R -associated protein (ATRAP) and 
GEF-like protein (GLP) (Guo et al., 2003, Guo et al., 2004). ARAP1 has 
functionally been implicated in the control of blood pressure as well as receptor 
recycling, as mice that overexpress ARAP1 in the proximal tubules have 
hypertension, suggesting that renal ARAP1 increases blood pressure through 
enhanced AT1R signalling (Guo et al., 2006). Conversely, ATRAP has been 
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suggested to function as a negative regulator of AT1R signalling (Lopez-Ilasaca et 
al., 2003, Tsurumi et al., 2006). Overexpression of ATRAP in VSMC increased 
AT1R internalization upon Ang II stimulation, resulting in reduced proliferation 
associated with reduced signal transducer and activator of transcription (STAT) 3 
and Akt activation (Cui et al., 2000). Furthermore following vascular injury, 
neointimal formation was attenuated in ATRAP overexpressing mice compared to 
wild-type controls and this was associated with reduced extracellular-signal-
related-kinase1/2 (ERK1/2), STAT1 and STAT3 activity (Oshita et al., 2006).  
In addition to ligand mediated GPCR signalling, there is mounting evidence to 
suggest that receptors can interact directly to form heteromeric complexes and 
that these interactions could be important for receptor function and signalling. 
In this respect the AT1R is the most widely studied of the RAS receptors and was 
one of the first GPCRs shown to form heteromers with other receptors (Monnot 
et al., 1996). A number of studies since have shown that the formation of such 
heterodimers alters AT1R signalling. For example, the AT1R forms heterodimers 
with receptors from the kinin-kallikrein-(AbdAlla et al., 2001b, AbdAlla et al., 
2001a, AbdAlla et al., 2005), adrenergic- (Barki-Harrington, 2004), 
dopaminergic- (Zeng et al., 2003) system and the cannabanoid family (Rozenfeld 
et al., 2011) resulting in enhanced Ang II potency at the AT1R, contributing to 
the progression and pathology of cardiovascular disease. Conversely, other AT1R 
dimers have been shown to reduce signalling via the AT1R and the effects of Ang 
II. For example, the AT2R has been reported to act as a functional antagonist of 
the AT1R via formation of constitutive heterodimers between the two receptors 
(AbdAlla et al., 2001a). This was shown in cells transiently transfected with 
receptors, foetal fibroblasts and human myometrial biopsies (AbdAlla et al., 
2001a). Importantly, this functional antagonism was independent of ligand 
binding at the AT2R, as confirmed by the use mutant forms of the AT2R, which 
were unable to bind ligand or activate intracellular protein phosphatases, and 
which produced similar levels of antagonism of the AT1R as wild type AT2R 
(AbdAlla et al., 2001a). This interaction has also been shown to have functional 
consequences in vivo as in human female myometria it has been reported that 
AT2R expression is reduced during pregnancy and this is associated with 
increased AT1R signalling (AbdAlla et al., 2001b). Another receptor of the RAS, 
Mas, also acts as a functional antagonist at the AT1R via direct interaction 
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(Kostenis et al., 2005, Canals et al., 2006). Co-expression of the Mas receptor 
with the AT1R in Chinese hamster ovary (CHO)-KI cells antagonized Ang II 
mediated calcium signalling via the AT1R (Kostenis et al., 2005). This was shown 
to be independent of Mas activation by its endogenous ligand Ang-(1-7). To 
further investigate this interaction, a series of bioluminescence resonance 
energy transfer (BRET) experiments were performed, with the conclusion that 
Mas can hetero-oligomerize with the AT1R to act as a physiological antagonist 
(Kostenis et al., 2005). Finally, it was shown that Mas knockout mice have 
increased vasoconstriction in response to Ang II, indicating that his functional 
antagonism can be observed in vivo (Kostenis et al., 2005). This functional 
interaction between the AT1R and Mas was further confirmed by Canals et al who 
demonstrated that co-expression of Mas with the AT1R reduced AT1R signalling 
while simultaneously increasing AT1R expression (Canals et al., 2006). However, 
the results of this study indicated that the effects of Mas at the AT1R were not 
necessarily a result of dimerization but potentially a result of constitutive 
activity of Mas, leading to PKC dependent AT1R phosphorylation and concurrent 
receptor-desensitisation (Canals et al., 2006).  
Furthermore, Ang II effects mediated via the AT1R have also been shown to 
involve transactivation of other receptors such as the epidermal growth factor 
receptor (EGFR) or platelet-derived growth factor receptor (PDGFR), resulting in 
the activation of various cell growth pathways (Heeneman et al., 2000, Du et 
al., 1996, Eguchi et al., 1996, Eguchi et al., 1998). 
1.3.3 The angiotensin type 2 receptor 
The AT2R is also a member of the 7 transmembrane receptor family (Mukoyama 
et al., 1993). The AT2R is a 41 kDa protein consisting of 363 amino acids and 
shares 34% sequence homology with the AT1R (Mukoyama et al., 1993). Various 
rodent studies have demonstrated that the AT2R is highly expressed in foetal 
tissue, including foetal aorta, intestine, brain and adrenal medulla; however its 
expression declines rapidly after birth, suggesting that it may play an important 
role in foetal development and cellular growth and differentiation (Shanmugam 
et al., 1996, Akishita et al., 1999). In adults the AT2R is less expressed than the 
AT1R, yet had been shown to be expressed in the heart, kidney, brain, adrenal 
gland and both vascular endothelial and VSMC (Viswanathan et al., 1992, Leung 
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et al., 1997, Wang et al., 1999, Roulston et al., 2003). Furthermore, AT2R 
expression is increased in a number of cardiovascular pathologies such as 
hypertension, atherosclerosis and neointimal formation (Savoia et al., 2006, 
Touyz et al., 1999c, Widdop et al., 2008, Johansson et al., 2005, Zulli et al., 
2006, Nakajima et al., 1995, Suzuki et al., 2002, Wu et al., 2001). 
The AT2R is generally thought to counteract the effects of Ang II at the AT1R, for 
which signalling pathways have been well delineated, however, signalling via the 
AT2R remains poorly understood.  Various AT2R signalling pathways have been 
suggested, including regulation of the NO cyclic guanosine monophosphate 
(cGMP) system, stimulation of phospholipase A2 (PLA2) and release of 
arachidonic acid, and activation of protein phosphatases and protein 
dephosphorylation (Siragy and Carey, 1996, Hannan et al., 2003, Stoll et al., 
1995, Tsuzuki et al., 1996, Lokuta et al., 1994) however further work is required 
to fully investigate signalling pathways initiated by activation of the AT2R. 
While the AT2R is a member of the GPCR superfamily and displays the hallmark 
motifs and residues of a GPCR it is well recognised that AT2R signal transduction 
does not always occur via classical G-protein-dependent pathways. Furthermore, 
the AT2R fails to demonstrate most of the classic features of GPCR signalling 
such as typical second messenger responses and rapid desensitization or 
downregulation of the receptor following ligand binding (Porrello et al., 2009). 
These non-classical GPCR characteristics of the AT2R have contributed to our 
lack of understanding of its signalling mechanisms however, recent studies of 
ligand independent GPCR modulation and function, particularly within areas 
such as constitutive activity, receptor dimerisation, and interaction with 
receptor-associated proteins have highlighted novel insights into GPCR signalling 
and provide avenues of research that may assist in delineating signalling via the 
AT2R (Miura and Karnik, 2000, Miura et al., 2005, Jin et al., 2002, Nouet et al., 
2004, Bockaert et al., 2003).  
It has been demonstrated that the AT2R can induce cell signalling effects 
independent of ligand binding, indicating that it may possess constitutive 
activity. For example, overexpression of AT2R in cultured fibroblasts, CHO cells 
or VSMC, triggers apoptosis via p38 MAPK and caspase-3 signalling pathways, 
independent of receptor activation (Miura and Karnik, 2000). Additionally, 
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overexpression of AT2R in VSMC has also been shown to downregulate AT1R 
expression and signalling, again in a ligand-independent manner (Jin et al., 
2002). While in these studies the AT2R was overexpressed to levels which would 
far exceed those observed under both physiological and pathophysiological 
conditions, this work has demonstrated that the AT2R may function through some 
degree of constitutive activity, providing further information about the signalling 
of this receptor. 
The AT2R has also been shown to form both homo- and hetero-dimers 
independent of ligand binding.  Homodimerisation of AT2R via disulphide bonding 
was shown to occur in CHO cells overexpressing this receptor, resulting in 
apoptosis via increased caspase-3 activity (Miura et al., 2005). While this effect 
was independent of ligand binding, it was prevented by inhibition of disulphide 
bonding, suggesting that this was not an effect mediated by expression of the 
receptor, but by the formation of homo-dimers (Miura et al., 2005). In addition 
to hetero-dimerisation with the AT1R, the AT2R has also been reported to form 
hetero-dimers with the bradykinin B2 receptor (BK2R) (Abadir et al., 2006). The 
formation of AT2R-BK2R hetero-dimers was independent of ligand binding and 
resulted in an increase in NO production, demonstrating that this interaction 
results in functional signalling processes (Abadir et al., 2006). 
Accessory proteins that bind to the carboxyl terminal of the AT2R and modulate 
receptor trafficking to the cell membrane and signalling have been identified 
(Bockaert et al., 2003). AT2R-interacting protein 1 (ATIP1), also known as 
mitochondrial tumour suppressor-I (MTUSI), has been shown to mediate 
transactivation of tyrosine kinases via binding to the C-terminal tail of the AT2R 
(Mogi et al., 2007). Overexpression of AT2R has also been shown to inhibit ERK2 
through interaction with ATIP1, an effect which was found to occur in the 
absence of stimuli but was potentiated by ligand mediated activation (Nouet et 
al., 2004). A similar protein, AT2R-binding protein of 50 kDa (ATBP50) was also 
found to associate with the AT2R resulting in increased surface expression of the 
AT2R and reduced ERK1/2 activation, suggesting an anti-mitotic role for this 
interaction (Wruck et al., 2005). However, the AT2R has also been shown to 
promote cellular growth through interaction with accessory proteins. Upon 
stimulation with Ang II, the AT2R has been shown to interact with the 
transcription factor promyelocytic zinc finger protein (PLZF), leading to 
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increased expression of phosphatidylinoistol-3 kinase p85α and activation of 
p70S6 kinase activation, which has an important role in protein synthesis 
(Senbonmatsu et al., 2003). Taken together these findings indicate that the AT2R 
may have different effects on cell growth depending on what accessory protein 
it interacts with and provides further insight into the cellular effects of the 
AT2R. 
1.4 Angiotensin cell signalling  
In the vasculature, Ang II activates various signalling pathways via the AT1R 
resulting in both acute responses such as vasoconstriction and increased blood 
pressure, and longer term responses such as cell proliferation and structural 
remodelling.  
1.4.1 G-protein coupled pathways 
Upon activation by Ang II, the AT1R couples predominantly to the Gαq/11 
complex, activating the second messenger phospholipase C (PLC) (Heineke and 
Molkentin, 2006, Inagami, 1995, Ohtsu et al., 2008). However, the AT1R has also 
been shown to couple to both Gα12/13 and Gβγ complexes, activating PLA2 and 
phospholipase D (PLD), respectively (Macrez-Lepretre et al., 1997). Activation of 
PLC leads to the production of inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG), both of which have direct effects on calcium handling, 
resulting in VSMC contraction and vasoconstriction (Heineke and Molkentin, 
2006, Griendling et al., 1997). Additionally, DAG also activates protein kinase C 
(PKC), which as well as participating in the contractile response, also activates 
the Ras/Raf/MAPK pathway, which is integrally involved in VSMC proliferation 
and migration (Liao et al., 1996).  
1.4.2 Mitogen-activated protein kinases 
Ang II interaction with the AT1R also initiates activation of various MAPK, such as 
ERK1/2, JNK and p38 MAPK, which play important roles in VSMC proliferation, 
migration and differentiation (Sugden and Clerk, 1997, Mehta and Griendling, 
2007).  
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The ERK1/2 pathway in VSMC is well characterised. Activation of the AT1R 
results in Src and proline-rich tyrosine kinase 2 (Pyk2) phorphorylation of the 
EGFR, leading to the formation of the Shc/growth factor receptor-bound protein 
2 (Grb2) complex, which in turn promotes activation of Raf through association 
with the small G protein Ras or PKC. Raf activation leads to phosphorylation of 
the mitogen-activated protein kinase-kinase (MEK), which in turn phosphorylates 
ERK1/2 on threonine/tyrosine residues (Sugden and Clerk, 1997, Liao et al., 
1996, Liao et al., 1997). ERK1/2 activation promotes VSMC contraction, 
proliferation, differentiation, migration, and inhibits apoptosis (Touyz et al., 
1999d, Touyz, 2004, Allen et al., 2005). 
In addition to activation of ERK1/2, Ang II also promotes phosphorylation of 
stress-related kinases such as JNK and p38MAPK which effect cell survival and 
induce vascular inflammation (Force et al., 1996). During oxidative stress, ROS 
are produced, which through various signalling cascades, activate MEK4/7 and 
MEK3/6, leading to phosphorylation of JNK and p38MAPK, respectively (Tobiume 
et al., 2001, Seko et al., 2003, Touyz et al., 2004, Ohtsu et al., 2005).  
1.4.3 Tyrosine kinases 
Ang II signalling is also mediated via cross-talk between the AT1R and various 
non-receptor tyrosine kinases and receptor tyrosine kinases. Non-receptor 
tyrosine kinase signalling includes activation of the cSrc pathway, the Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) pathway, and 
the focal adhesion kinase (FAK) pathway. c-Src is a tyrosine kinase that has been 
shown to be activated by Gβγ via ROS signalling, and is involved in a variety of 
downstream pathways, including Ras, PLC, JAK/STAT, and FAK, leading to cell 
growth, adhesion, migration and ECM formation (Berk and Corson, 1997, Sabri et 
al., 1998, Ishida et al., 1999, Taniyama et al., 2004).  
In addition to activation downstream of the cSrc pathway, Ang II activates 
JAK/STAT signalling through the association of JAK2 with the AT1R via Src 
homology domain containing tyrosine phosphatase 2 (SHP-2) (Marrero et al., 
1995, Marrero et al., 1998). JAK then activates STAT, leading to dimerisation of 
STAT proteins and translocation to the nucleus, resulting in transcription of early 
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growth response genes such as c-fos and c-myc (Ishida et al., 1999, Berk and 
Corson, 1997). 
Ang II promotes reorganisation of cytoskeletal structure, leading to cell adhesion 
and ECM remodelling, through interaction with the FAK pathway (Okuda et al., 
1995). AT1R mediated increase in intracellular calcium induces phosphorylation 
of FAK, thereby enabling activation of cytoskeletal proteins including Pyk2, 
p130Cas, paxillin and talin, all of which interact to regulate cell shape and 
movement (Eguchi et al., 1999, Leduc and Meloche, 1995, Sabe et al., 1997). 
Ang II also promotes VSMC proliferation and migration via AT1R mediated 
transactivation of tyrosine kinase receptors, such as the EGFR and PDGFR, which 
exhibit the intrinsic kinase activity that the AT1R lacks. Transactivation of EGFR 
is a major mechanism by which Ang II influences growth-related signalling 
pathways and occurs via calcium-dependent and -independent pathways (Eguchi 
et al., 1998). These pathways lead to activation of a disintegrin and 
metalloproteinase (ADAM), mainly ADAM 17, causing release of heparin-binding 
EGF (HB-EGF) (Andreev et al., 2001, Blobel, 2005, Mifune et al., 2005, Ohtsu et 
al., 2006). HB-EGF induces conformational changes the EGFR, allowing 
dimerization and autophosphorylation (Prenzel et al., 1999). Once activated, 
EGFRs interact with Shc/Grb2 complexes, inducing activation of the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt pathway, leading  to 
cellular growth, survival, and remodelling, and the Ras/Raf/ERK pathway which 
leads to cell growth and inflammation. 
Ang II has been shown to transduce growth-related signalling, independent of 
platelet-derived growth factor (PDGF), via the PDGF receptor. While the exact 
mechanism of PDGFR transactivation has yet to be identified a number of 
signalling events have been suggested. For example, it has been shown that Ang 
II stimulates PDGF-β-receptor phosphorylation via formation of the Shc/Grb2 
complex, an effect which is independent of calcium and blocked by losartan 
(Heeneman et al., 2000, Linseman et al., 1995). It has also been demonstrated 
that AT1R-mediated PDGFR transactivation requires activation of a ROS-sensitive 
tyrosine kinase, distinct from Src or JAK (Heeneman et al., 2000). 
Transactivation of the PDGFR has been linked to increased ERK activity 
downstream (Linseman et al., 1995, Kim et al., 2000). 
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1.4.4 Reactive oxygen species 
ROS, generated by oxidative stress, have been implicated in the regulation of 
various signalling cascades resulting in increased inflammation, VSMC 
proliferation and migration and impaired endothelial function. Ang II is widely 
accepted as a potent mediator of oxidative stress and has been shown to 
produce ROS such as O2
- and H2O2 via activation of NAD(P)H oxidases (Griendling 
and Ushio-Fukai, 2000, Rajagopalan et al., 1996, Touyz et al., 2004, Zafari et 
al., 1998, Taniyama and Griendling, 2003, Yan et al., 2003, Lassegue et al., 
2001).  Ang II mediated activation of of NAD(P)H oxidases involves induction of 
various signalling pathways, including those discussed above such as G-protein 
dependent signalling, cSrc signalling, and EGFR transactivation. In VSMC NAD(P)H 
oxidase subunit (NOX) 1 and NOX4 are the main NAD(P)H subunits involved in 
ROS production (Lambeth et al., 2000). 
1.5 The counter-regulatory axis of the RAS 
Until recently, the RAS was considered a linear process with Ang II as the major 
active peptide.  However, the conventional view of the RAS has undergone 
significant change based on two fundamental discoveries.  The first was the 
expression of the RAS in specific tissues, highlighting the existence of a local RAS 
in which Ang II could be generated within individual tissues, without recruitment 
from the systemic circulation. Genes coding for various components of the RAS, 
including ACE, Ang I, Ang II and the angiotensin receptors, are expressed in 
various tissues such as the heart, blood vessels, kidney, and brain, suggesting 
the presence of a functionally active RAS at the tissue level (Bader et al., 2001, 
Paul et al., 2006).  However, the role of the tissue-specific RAS in humans is still 
unclear. For example, elements of the RAS are present in the vasculature, in 
veins and arteries, suggesting that Ang II can be synthesised within and act 
locally on vessels to regulate blood pressure and cell growth (Oliver and Sciacca, 
1984, Paul et al., 1993). In fact, the concept of the a vascular-specific RAS was 
first suggested in 1986 when it was shown in the rat two clip, one kidney model 
of hypertension, that there was an increase in vascular ACE activity during the 
chronic phase of hypertension and increased vasoconstriction of isolated vessels 
to Ang II (Okamura et al., 1986). Importantly, plasma renin levels were 
unchanged in these rats, indicated that elevated vascular ACE activity increases 
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local production of Ang II, which results in vasoconstriction by acting directly on 
the vessels (Okamura et al., 1986). It has since been shown that Ang II generated 
in the vasculature can stimulate synthesis of prostaglandins, endothelin-1 and 
aldosterone in the endothelium and vessel wall, which in turn influences 
vascular function (Paul et al., 1995, Paul et al., 2006). In addition to influencing 
vascular tone, increased activity of RAS specifically in the vasculature has also 
been implicated in the progression and development of atherosclerosis (Ribichini 
et al., 2006, Diet et al., 1996, Schieffer et al., 2000, Fukuhara et al., 2000). 
Furthermore, elements of the RAS have been identified in the eye, which may be 
important in physiological maintenance of ocular pressure but also in vascular 
pathologies associated with ocular vessel damage, as observed in hypertension 
and diabetes (Fletcher et al., 2010, Wilkinson-Berka et al., 2011). 
The second discovery was the identification of novel components of the RAS, 
most importantly the enzyme angiotensin converting enzyme 2 (ACE2), a 
homologue of ACE which differs in its substrate specificity (Donoghue et al., 
2000, Harmer et al., 2002, Vickers et al., 2002). The discovery of ACE2 led to 
the recognition of functionally active Ang-derived peptides, particularly 
angiotensin 1-7 [Ang-(1-7)], which was previously described in the 1990s, and 
more recently peptides such as angiotensin-(1-9) [Ang-(1-9)] (Santos et al., 1992, 
Donoghue et al., 2000). Further investigation into the actions of ACE2 and the 
alternative angiotensin peptides, primarily Ang-(1-7), has revealed that they 
generally antagonise the actions of Ang II, forming the basis for alternative 
pathways within the RAS known as the counter-regulatory axis (Santos et al., 
1992, Santos et al., 2004, Donoghue et al., 2000, Nagata et al., 2006). Since the 
discovery of the tissue-specific, counter-regulatory RAS many studies have been 
performed in an attempt to elucidate the mechanisms of action of their 
components and characterise their roles within both physiological and 
pathophysiological settings. Together this has greatly expanded our knowledge 
of the RAS leading to the current understanding of this system as a cascade with 
multiple mediators, multiple receptors and multifunctional enzymes (Figure 
1.3).  
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1.5.1 Angiotensin converting enzyme 2 
ACE2 is a zinc metalloproteinase that shares about 42% homology with ACE at its 
active site, and is highly expressed in a number of tissues including the heart, 
vasculature and kidney (Donoghue et al., 2000, Harmer et al., 2002). Due to 
structural differences ACE acts mainly as a peptidyl dipeptidase, while ACE2 acts 
as a carboxypeptidase (Vickers et al., 2002). ACE2 functions in the RAS by 
cleaving the C terminal residues from Ang I and Ang II, producing Ang-(1-9) and 
Ang-(1-7), respectively (Donoghue et al., 2000) (Figure 1.3). The actions of ACE2 
leads to reduced production of Ang II thereby lessening its deleterious effects, 
and also increased production of Ang-(1-7) and Ang-(1-9), both of which have 
been shown to protect against the actions of Ang II (Donoghue et al., 2000). 
Additionally, while ACE can also break down the potent vasodilator bradykinin, 
ACE2 has no effect on bradykinin (Donoghue et al., 2000). The expression and 
activity of ACE2 in the heart and blood vessels has also been shown to be 
protective in various models of CVD (Crackower et al., 2002, Lovren et al., 2008, 
Sluimer et al., 2008, Dong et al., 2009, Kassiri et al., 2009, Patel et al., 2012). 
These protective effects were associated with both reduced levels of Ang II and 
increased levels of Ang-(1-7), suggesting a key role for ACE2 in balancing the 
activity of both axes of the RAS in CVD. However, it has also been shown that 
ACE2 expression in the heart worsens the disease phenotype; therefore further 
work is required to fully investigate the role of ACE2 expression, particularly in 
the heart (Masson et al., 2009, Donoghue et al., 2003). 
1.5.2 Angiotensin-(1-7) 
Ang-(1-7) is a seven amino acid peptide first described to be generated in the 
endothelium (Santos et al., 1992) and is one of the most well studied peptides of 
the counter-regulatory axis of the RAS. The majority of Ang-(1-7) is produced via 
the actions of ACE2 and it is the main product since ACE2 has approximately 400-
fold greater affinity for Ang II than Ang I (Tipnis et al., 2000). Ang-(1-7) can also 
be produced less efficiently via hydrolysis of Ang-(1-9) by ACE or via the actions 
of alternative enzymes including prolyl endopeptidase (POP), neutral 
endopeptidase (NEP) or thimet oligopeptidase (TOP) (Donoghue et al., 2000, 
Chappell, 1994, Rice et al., 2004) (Figure 1.3). The half life of Ang-(1-7) in the 
circulation is approximately 10 seconds (Chappell et al., 1998) and circulating 
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levels of Ang-(1-7) are reported to be 20 pg/mL (Vilas-Boas et al., 2009). Ang-(1-
7) is then converted to the inactive metabolite Ang-(1-5) by ACE (Chappell et 
al., 1998). Since its discovery, there has been a vast amount of research into its 
actions as it has been shown to antagonise many of the effects of Ang II. This 
was first demonstrated by Roks et al when it was shown that in human blood 
vessels Ang-(1-7) inhibited Ang II induced vasoconstriction (Roks et al., 1999). 
Since then Ang-(1-7) has been shown to oppose the actions of Ang II in a number 
of tissues, mainly by inhibiting cell growth, migration, and inflammation that 
occur as a result of Ang II, ultimately preventing adverse remodelling and 
subsequent dysfunction of the cardiovascular system.  
Originally the mechanism by which Ang-(1-7) exerted its effects was unknown. It 
was first suggested that Ang-(1-7) mediated its effects via the classical 
angiotensin receptors, but research by Rowe et al suggested that due to low 
affinity for both angiotensin receptors, the effects of Ang-(1-7) were unlikely to 
be mediated by signalling via either of these receptors (Rowe et al., 1995). 
Receptor binding studies later showed that Ang-(1-7) could bind to the orphan 
GPCR Mas and further research in Mas-deficient mice identified Ang-(1-7) as the 
endogenous ligand for this receptor (Santos et al., 2003). The gene encoding Mas 
has been mapped to chromosome 6q and encodes for a 325 amino acid protein 
(Alenina et al., 2008). Mas is expressed in a number of tissues involved in 
cardiovascular physiology including the heart, blood vessels, brain and kidney 
(Metzger et al., 1995) and is largely accepted to be the receptor through which 
Ang-(1-7) exerts its effects [reviewed by (Gironacci et al., 2013, McKinney et 
al., 2014, Passos-Silva et al., 2013)]. However, despite the wealth of evidence 
that indicates Ang-(1-7) is a Mas ligand, there is also more recent evidence that 
despite its low affinity for the AT2R Ang-(1-7) may also elicit certain biological 
effects via the AT2R. For example, in stable cell lines generated to express 
either AT1R or AT2R, Ang-(1-7) was found to bind the AT2R with higher affinity 
than the AT1R (Bosnyak et al., 2011). The Ang-(1-7)/AT2R interaction has also 
been observed in vivo. In isolated mouse hearts exposed to the AT2R antagonist 
PD123, 319, Ang-(1-7) increased perfusion pressure, an effect not observed 
following Ang-(1-7) infusion alone and which was independent of both the AT1R 
and Mas. It was also observed that in the presence of AT1R blockade, Ang-(1-7) 
reduced blood pressure in both normotensive and spontaneously hypertensive 
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stroke prone rats (SHRSP), an effect mediated via the AT2R (Walters et al., 
2005). This effect was preserved in aged normotensive rats under similar 
experimental conditions; however, the vasodepressor effect was via both the 
AT2R and Mas receptor in the aged rats (Bosnyak et al., 2012). In addition to 
inhibiting the effects of Ang II via engagement with Ang-(1-7), the Mas receptor 
also acts as a functional antagonist at the AT1R via direct receptor interaction 
(Kostenis et al., 2005, Canals et al., 2006). 
1.5.3 Angiotensin-(1-9) 
Ang-(1-9) is a 9 amino acid peptide member of the counter-regulatory axis of the 
RAS formed from Ang I, mainly via cleavage of the terminal amino acid of Ang I 
by ACE2 (Donoghue et al., 2000) (Figure 1.3). However, it has also been shown 
that following incubation of Ang I with human heart homogenates Ang-(1-9) is 
formed through the activity of carboxypeptidase A (CPA2) (Kokkonen et al., 
1997). This was further confirmed in ACE knockout (ACE-/-) and ACE2 knockout 
(ACE2-/-) mice where Ang-(1-9) was the main product of carboxypeptidase 
mediated cleavage of Ang I (Garabelli et al., 2008). Furthermore, in human 
heart extracts it was shown that Ang-(1-9) generation from Ang I was mediated 
via cathepsin A (CpA) (Jackman et al., 2002). These reports provide conclusive 
evidence that Ang-(1-9) is generated by Ang I by a number of different enzymes.  
Once formed Ang-(1-9) can be further converted to Ang-(1-7) via ACE. 
Additionally, it has recently been demonstrated that Ang-(1-9) can be converted 
to angiotensin-(2-9) [Ang-(2-9)] by aminopeptidase A (AmpA) in glomerular 
podocytes, however, a biological role for this novel peptide has yet to be 
identified (Schwacke et al., 2013). Analysis of Ang-(1-9) levels has revealed that 
while in healthy subjects circulating levels of Ang-(1-9) have been reported to be 
around 2-6 fmol/mL, these levels are thought to increase in pathological states 
(Campbell et al., 1993, Kokkonen et al., 1997, Ocaranza et al., 2006), 
suggesting that in pathological conditions the heart functions to increase levels 
of Ang-(1-9). For example, in human heart failure patients, Ang-(1-9) is formed 
at a rate of 1nM/min/mg in the myocardium and a large proportion of available 
Ang I is rapidly converted to equal levels of Ang-(1-9) and Ang II (Kokkonen et 
al., 1997). While the half life of Ang-(1-9) within the circulation has yet to be 
identified, it has been demonstrated that in cells stably transfected with human 
ACE Ang-(1-9) was hydrolysed 18 times slower than Ang I and 30 % slower than 
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Ang-(1-7), suggesting that Ang-(1-9) may have a longer half-life compared with 
other RAS peptides (Chen et al., 2005). 
There is currently little known about the biological effects of Ang-(1-9) in the 
cardiovascular system. Originally it was thought to be biologically inactive, 
contributing indirectly to counteregulate actions of Ang II by competing with Ang 
II for the ACE active site, resulting in reduced Ang II and increased Ang-(1-7) 
levels (Snyder, 1986). Additionally, Ang-(1-9) has been shown to stimulate 
bradykinin release in cardiac endothelial cells and to enhance the effects of 
bradykinin by augmenting NO and arachidonic acid release (Erdos et al., 2002, 
Jackman et al., 2002). Importantly, it was shown that not only was Ang-(1-9) an 
active peptide but that it more potent than Ang-(1-7) in achieving these results 
(Jackman et al., 2002). Recent research has demonstrated that Ang-(1-9) exerts 
direct biological effects in the cardiovascular system, and these effects may be 
via the AT2R (Flores-Munoz et al., 2011) (Figure 1.3). Using radioligand binding 
assays it was demonstrated that Ang-(1-9) could bind to both the AT1R and AT2R  
and in cardiomyocytes Ang-(1-9) mediated anti-hypertrophic effects via the AT2R 
as PD123,319, an AT2R antagonist, blocked these effects (Flores-Munoz et al., 
2011). This suggests that despite having approximately 100 fold lower affinity for 
the AT2R than Ang II, Ang-(1-9) may elicit functional effects via this receptor. 
Further work is required to elucidate Ang-(1-9)-mediated cell signalling. 
Moreover, selective functional activity at the AT2R is possibly due to the 
pharmacological concept of functional selectivity where ligands may induce 
unique, ligand specific conformations resulting in differential activation of 
signalling pathways (Clarke and Bond, 1998, Galandrin et al., 2007, Smith et al., 
2011, Nagata et al., 2006). While the AT1R is reported to exist in a constrained 
conformation, the AT2R exists in a relaxed state (Miura and Karnik, 1999). 
Therefore, it has been postulated that the additional histidine present in Ang-(1-
9) may stabilise the AT2R in a distinct conformational state, leading to its 
enhanced activation, and hence counter-regulation of Ang II actions at the AT1R 
(Flores-Munoz et al., 2011). However, this remains to be demonstrated 
experimentally. Alternatively, Ang-(1-9) may be metabolized to Ang-(1-7) or 
another peptide, and act at the AT2R or an alternative  receptor which is 
sensitive to PD123, 319, as has previously been shown for the recently reported 
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counter-regulatory RAS receptor, Mas related gene D receptor (MrgD) (Lautner et 
al., 2013). 
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Figure 1.3 The counter-regulatory axis of the RAS 
With the discovery of the counter-regulatory axis of the RAS, the view of this system has changed 
to that of a cascade of interconverted peptides that are mainly generated by the actions of ACE 
and ACE2. The traditional axis of the RAS is via ACE-mediated generation of Ang II which signals 
mainly via the AT1R and also the AT2R. The counter-regulatory axis of the RAS is centered around 
the actions of ACE 2 and production of Ang-(1-7) and Ang-(1-9) from Ang II and Ang I, respectively, 
counteracts pathological effects of Ang II at the AT1R.  Ang-(1-7) exerts protective effects via Mas 
while Ang-(1-9) has recently been reported to act via the AT2R. ACE: Angiotensin converting 
enzyme; AT1R: Angiotensin type 1 receptor; AT2R: Angiotensin type 2 receptor. 
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1.5.4 Other angiotensin peptide metabolites 
1.5.4.1 Angiotensin-(1-12) 
Although it is now apparent that the RAS contains multiple functional peptides, 
until recently it was thought that angiotensinogen acted as a precursor for the 
production of Ang I, from which all other peptides are derived either directly or 
indirectly. However, this concept has since been challenged with the discovery 
of angiotensin-(1-12) [Ang-(1-12)], a 12 amino acid peptide containing an 
additional two amino acids at the C terminal of Ang I (Nagata et al., 2006) 
(Figure 1.4). Ang-(1-12) was initially isolated and identified from the rat small 
intestine and has since been found to be present in concentrations comparable 
with those of Ang I and Ang II in other tissues such as the aorta, heart and 
kidneys (Nagata et al., 2006, Nagata et al., 2010). Importantly, tissue levels of 
Ang-(1-12) have been shown to be unaltered in response to manipulation of the 
systemic RAS, indicating that it may function as part of the local RAS (Nagata et 
al., 2006, Nagata et al., 2010, Trask et al., 2008). While it is currently unknown 
how Ang-(1-12) is formed from angiotensinogen, previous studies have shown 
that renin is not involved in either the formation or metabolism of Ang-(1-12), 
suggesting that it might serve as an alternative substrate for local production of 
angiotensin peptides by circumventing the classical renin dependent conversion 
of angiotensinogen to Ang I (Bujak-Gizycka et al., 2010, Ahmad et al., 2011, 
Ahmad et al., 2013). Functionally, Ang-(1-12) induces a vasoconstrictor response 
in the rat aorta that could be blocked by either an ACE inhibitor or an AT1R 
antagonist, suggesting that Ang-(1-12) may act as a peptide precursor of Ang II 
(Nagata et al., 2006, Bujak-Gizycka et al., 2010). However, it is not clear if this 
conversion to Ang II in the vasculature is direct (as has been shown in the heart 
via the actions of chymase) or via initial generation of Ang I (by the actions of 
ACE or CPA2) (Bujak-Gizycka et al., 2010, Ahmad et al., 2011, Ahmad et al., 
2013). 
1.5.4.2 Angiotensin-(2-10) 
Angiotensin-(2-10), also known as Des Asp1 Ang I, is an octapeptide that was first 
identified as a metabolite of Ang I, formed by aminopeptidase-mediated 
metabolism of the N-terminal residue of Ang I, in the cat adrenal gland (Ackerly 
et al., 1976) (Figure 1.4). Since its discovery few studies have attempted to fully 
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elucidate its action in the cardiovascular system and existing studies supporting 
a role for this peptide in the vasculature are conflicting. For example, one of the 
earliest studies on the effects of Ang-(2-10) demonstrated that in conscious rats, 
Ang-(2-10) acted as a pressor agent, largely via conversion to angiotensin III (Ang 
III) (Campbell and Pettinger, 1976). Conversely, in normotensive and 
hypertensive rats Ang-(2-10) attenuated the vasoconstriction of mesenteric and 
renal arteries induced by the pressor peptide Ang III and it has been shown to 
block Ang II-induced proliferation of rat aortic VSMC, suggesting a protective role 
for Ang-(2-10) in the vasculature (Mustafa et al., 2004, Min et al., 2000). It has 
been suggested that Ang-(2-10) may also play an important role in the kidneys, 
functioning as part of the ‘intrarenal RAS’. A functional intrarenal RAS was first 
discovered in 1977 (Kimbrough et al., 1977) and has since been demonstrated to 
be important in the control of renal sodium excretion and blood pressure (Navar 
et al., 2011). The intrarenal RAS is one part of the ‘tissue specific RAS’ which 
functions independent of changes in circulating RAS components. However, 
similar to the circulating RAS, overactivation of the intrarenal RAS has been 
shown to play a pivotal role in glomerular injury which is implicated in 
progressive kidney diseases. It has recently been shown that Ang-(2-10) is one of 
the main products of Ang I metabolism, generated via the action of 
aminopeptidase A, suggesting that it may play an important, but yet undefined, 
role in the intrarenal RAS (Velez et al., 2009). 
1.5.4.3 Angiotensin III 
Ang III is generated from cleavage of the N terminus amino acid of Ang II by 
AmpA (Zini et al., 1996) (Figure 1.4). Ang III has been shown to act in a similar 
manner to Ang II in that its physiological effects are similar to those elicited by 
Ang II and it acts at the AT1R, albeit with 10 times lower affinity for this 
receptor than Ang II (Pendleton et al., 1989). Ang III has been shown to have 
similar effects on vasoconstriction and blood pressure as Ang II both centrally 
and peripherally (van Esch et al., 2008, Li et al., 1995). 
1.5.4.4 Angiotensin IV 
Angiotensin IV (Ang IV) is generated from cleavage of the N terminus amino acid 
by aminopeptidase N (AmpN) (Figure 1.4). Originally Ang IV was considered to be 
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biologically inactive however a wide range of physiological effects have now 
been identified. Ang IV has been shown to have an important role in the CNS, 
including regulation of blood flow, and cognitive and sensory functions in the 
brain such as learning and memory (Braszko et al., 1988, Wright et al., 1993, 
Albiston et al., 2001). Additionally, Ang IV has been shown to be involved in 
proliferation of cardiac fibroblasts, endothelial cells and VSMC (Wang et al., 
1995, Hall et al., 1993). Ang IV binds with high affinity to the angiotensin II type 
4 receptor (AT4R), which has recently been identified as the enzyme insulin-
related aminopeptidase, with Ang IV functioning to inhibit this enzyme (Swanson 
et al., 1992, Albiston et al., 2001). Ang IV specific binding sites have been 
identified in various tissues and cells including the brain, blood vessels and 
heart, consistent with the fact that Ang IV elicits effects in all of these tissues 
(Miller-Wing et al., 1993, Kerins et al., 1995, Hall et al., 1993, de Gasparo et 
al., 2000, Chai et al., 2000). While Ang IV is widely accepted to have functional 
effects in the vasculature, current evidence as to whether it contributes to or 
protects against vascular disease is conflicting. For example, in cultured VSMC 
Ang IV via AT4R activated the transcription factor nuclear factor kappa-light-
chain-enhancer of B cells (NF-κB) and upregulates related genes involved in 
cardiovascular damage, such as the adhesion molecule ICAM-1, the cytokines IL-6 
and TNF-α, the chemokine MCP-1, and the prothrombotic factor PAI-1 (Esteban 
et al., 2005), suggesting that Ang IV may contribute to development of vascular 
disease. In various rodent models of vascular disease including the rabbit balloon 
injury model and the mouse model of atherosclerosis (the apolipoprotein E 
knockout [ApoE−/−] mouse), the AT4R has been shown to be upregulated within 
the vessel wall indicating that it may play an important role in disease 
development (Moeller et al., 1999, Vinh et al., 2008). However, it is not clear 
whether increased expression of AT4R enhances or retards disease development 
at this stage. Conversely, Ang IV via the AT4R has also been linked to an 
improved vascular phenotype. Ang IV has been shown in a number of studies to 
activate eNOS, leading to increased NO bioavailability and vasodilation (Patel et 
al., 1998, Chen et al., 2000). Furthermore,  chronic administration of Ang IV to 
ApoE−/− mice resulted in improved endothelial function associated with increase 
eNOS activation and reduced oxidative stress, as well as reduced atherosclerotic 
lesion size (Vinh et al., 2008). Therefore, while it is evident that Ang IV plays an 
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important role in the vasculature, its exact function is still unclear and requires 
further investigation. 
1.5.4.5 Angiotensin-(3-7) 
Angiotensin-(3-7) [Ang-(3-7)] can be generated from Ang II, Ang-(1-7) or Ang IV 
via the action of both aminopeptidases and carboxypeptidases (Greene et al., 
1982, Chappell et al., 1990, Welches et al., 1991) (Figure 1.4). Little is known 
about the effects of Ang-(3-7) in the cardiovascular system. Ang-(3-7) can be 
generated in the heart and kidney, however it is unclear whether it has any 
functional activity or acts as a waste product. It has been suggested that some 
of the actions of Ang-(1-7) in the kidney might depend on metabolism to Ang-(3-
7) and subsequent activation of AT4R (Handa, 1999). It was found that Ang-(1-7) 
mediated generation of Ang-(3-7) inhibited nystatin-stimulated proximal tubule 
O2 consumption, indicative of reduced basolateral Na
+,K+-ATPase activity. This 
effect was abolished by AT4R blockade (Handa, 1999). However, it has also been 
shown that Ang-(1-7) does not affect basolateral Na+,K+-ATPase activity, 
therefore further studies are required to fully understand the interaction 
between both Ang-(1-7) and Ang-(3-7), and angiotensin receptors within the 
kidney (Caruso-Neves et al., 2000). In fact, the majority of research on Ang-(3-7) 
has focussed on its role in the brain, particularly within the area of the brain 
that is involved in the central control of blood pressure, the rostral ventrolateral 
medulla (RVLM) (Ferreira et al., 2007). It has been shown that micro-injection of 
Ang-(3-7) into the RVLM induces an increase in mean arterial pressure and heart 
rate independent of AT1R, AT2R or Mas (Ferreira et al., 2007). While further 
work is required to identify the receptor for Ang-(3-7) in the RVLM it is possible 
it may initiate its effects via the AT4R as has been suggested in the kidney and 
through in vitro receptor binding studies (Handa, 1999, Albiston et al., 2001, 
Wright et al., 1993). 
1.5.4.6 Angiotensin A 
Angiotensin A (Ang A) was first identified in human plasma by Jankowski et al in 
2007 and is an octapeptide that differs from Ang II by the presence of an alanine 
residue in place of aspartate at its N-terminal residue (Jankowski et al., 2007) 
(Figure 1.4). Ang A is synthesised from Ang II by enzymatic decarboxylation of 
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aspartate in the presence of mononuclear leukocytes (Jankowski et al., 2007). 
Initially it was shown that Ang A possessed similar affinity to Ang II for the AT1R 
but higher affinity for the AT2R, however subsequent studies have revealed that 
the functional effects of Ang A are mediated via the AT1R (Jankowski et al., 
2007, Yang et al., 2011). Ang A was shown to promote renal vasoconstriction 
both ex vivo and in vivo in an AT1R dependent manner (Jankowski et al., 2007, 
Yang et al., 2011). Ang A has been shown to be elevated in human plasma of 
patients with end-stage renal failure compared to healthy patients, indicating 
that it may play a role in renal pathophysiology. However, the role of Ang A in 
the heart and vasculature, especially in pathophysiology, is poorly explored. 
Recently Coutinho et al demonstrated that in anaesthetised rats Ang A elevated 
systemic blood pressure via the AT1R in a concentration-dependent manner, to 
similar levels to those achieved by Ang II (Coutinho et al., 2013). Similarly, using 
an isolated heart preparation Ang A resulted in similar effects to those achieved 
by Ang II, as both peptides reduced cardiac flow, myocardial relaxation and 
contraction, and heart rate (Coutinho et al., 2013). However, while the effects 
of Ang II on cardiac function were fully blocked by losartan, the effects of Ang A 
were only partially blocked, indicating that Ang A may function at a different 
receptor in the heart (Coutinho et al., 2013). Furthermore, Ang II, but not Ang 
A, resulted in an increase in cardiac arrhythmias in the isolated heart and 
altered calcium handling in isolated cardiomyocytes, suggesting that these 
peptides may also function via separate receptors (Coutinho et al., 2013). 
Together these data provide further evidence as to the complexity of the RAS 
and identifies a potential new peptide, Ang A. However, more work is required 
to fully elucidate its role in the cardiovascular system.  
1.5.4.7 Alamandine 
The most recently discovered component of the RAS is alamandine (Lautner et 
al., 2013). Alamandine is a hectapeptide that differs from Ang-(1-7) only by the 
presence of an alanine residue in place of an aspartate residue at the amino 
terminus (Lautner et al., 2013). Alamandine can be formed either from catalytic 
hydrolysis of Ang A by ACE2 or via decarboxylation of the aspartate radical group 
of Ang-(1-7), as has previously been shown for Ang II (Lautner et al., 2013, 
Jankowski et al., 2007) (Figure 1.4). In addition to being structurally similar to 
Ang-(1-7), alamandine was also shown to produce several physiological actions 
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that resemble those induced by Ang-(1-7). For example, alamandine induces 
endothelium-dependent vasodilation in aortic rings of FVB/N mice and Wistar 
rats, an effect attenuated by pretreatment with the NOS-inhibitor, NG-nitro-L-
arginine methyl ester (L-NAME) (Lautner et al., 2013). Alamandine also reduced 
blood pressure when administered into the caudal ventrolateral medulla of 
anaethetised Fisher rats, as well as systemically in spontaneously hypertensive 
rat (SHR) (Lautner et al., 2013). Furthermore, an orally available form of 
alamandine produced an anti-hypertensive effect in the SHR and reduced 
cardiac remodelling in isoprotenelol treated rats (Lautner et al., 2013). 
However, despite being structurally and functionally similar to Ang-(1-7), 
alamandine was demonstrated to act independently of both Mas and the AT2R 
suggesting a different mechanism of action to that of Ang-(1-7) (Lautner et al., 
2013). While the vasodilator effects of alamandine in aortic rings were unaltered 
by the Mas antagonist A779 and in Mas receptor deficient mice, they were 
blocked by another Ang (1–7) antagonist, D-Pro7-Ang (1–7), suggesting that 
alamandine may act at an alternative receptor that is also sensitive to Ang-(1-7). 
Ang-(1-7) has previously been reported to act as a weak agonist of the MrgD 
therefore Lautner et al then investigated whether this could be the receptor 
through which alamandine acts (Lautner et al., 2013, Gembardt et al., 2008). 
Indeed, pre-incubation of aortic rings with β-alanine, an MrgD agonist, 
attenuated alamandine induced vasodilation. Furthermore, alamandine was 
shown to bind to MrgD-transfected cells, an effect which was competitively 
inhibited by D-Pro7-Ang (1–7) but not A779 (Lautner et al., 2013). Finally, in cells 
expressing MrgD, alamandine induced NO release, an effect which was not 
observed in cells expressing Mas. Although alamandine was shown to be present 
in human plasma and increased in patients with end-stage renal disease, the 
potential role of this peptide in humans requires further investigation (Lautner 
et al., 2013). Together, this data suggest that the novel peptide alamandine is a 
functionally active peptide within the RAS that acts via the MrgD receptor and 
indicates a novel interaction within the RAS that required further exploration. 
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Figure 1.4 Angiotensin peptide metabolites 
The discovery of the tissue specific and counter-regulatory axis of the RAS has resulted in the view 
of the RAS as a system of interconverted peptides, generated by a number of multifunctional 
enzymes. Black arrows indicate peptide formation via enzymatic metabolism. Blue dashed arrows 
indicate peptide formation via amino acid decarboxylation. ACE: angiotensin converting enzyme; 
ACE2: angiotensin converting enzyme 2 Amp A: aminopeptidase a; Amp N: aminopeptidase N; 
Ang: angiotensin; CpA: cathepsin A; CPA2: carboxypeptidase A2; Cx A: carboyxpeptidase A; 
NEP:Neutral endopeptidase; POP: Prolyl endopeptidase; TOP: Thimet oligopeptidase. 
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1.6 The renin angiotensin system and vascular 
remodelling 
Dysregulation of the RAS, resulting in increased Ang II activity via the AT1R, 
largely contributes to pathological remodelling of the vasculature in both 
hypertension and atherosclerosis, and contributes to the failure of 
revascularisation in coronary artery disease. 
1.6.1 Hypertension-induced remodelling 
The RAS has been shown to be one of the key pathways involved in hypertension-
induced vascular remodelling. In large, conduit arteries, Ang II has been shown 
to stimulate VSMC hypertrophy largely via interaction with NAD(P)H oxidases, 
resulting in ROS generation (Griendling et al., 1994). Additionally, Ang II 
mediates activation of various growth factors such as transforming growth 
factor-β (TGF-β) and PDGF (Naftilan et al., 1989a, Gibbons et al., 1992). Ang II–
induced VSMC hypertrophy and collagen deposition has been observed in various 
hypertensive animal models (Albaladejo et al., 1994, Levy et al., 1988). 
Similarly, various signalling pathways have been implicated for Ang II-induced 
resistance vessel remodelling in hypertension. In the SHR, ACE inhibitors or AT1R 
antagonists reduced blood pressure and vascular activity of ERK1/2, leading to 
improved endothelial function and Ang II-induced contractility of mesenteric 
resistance arteries, suggesting that Ang II induced changes in vascular function 
may be mediated by MAPK signalling (Kim et al., 1997, Touyz et al., 2002). 
Additionally, in Ang II–infused mice, inhibition of NAD(P)H oxidase by apocynin, 
attenuated blood presure elevation and prevented structural alterations, 
endothelial dysfunction, and collagen deposition in the media of small 
mesenteric arteries, indicating that NAD(P)H oxidase activity is also involved in 
Ang II–induced functional and structural alterations of the vascular wall (Virdis et 
al., 2004). 
1.6.2 Pro-atherogenic effects of angiotensin II 
It is largely accepted that Ang II is one of the key players involved in the 
development and progression of atherosclerosis; in fact ACE inhibitors are among 
the most commonly prescribed pharmacological therapies for atherosclerosis and 
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have been shown to reduce cardiovascular events in patients with multiple risk 
factors for atherosclerosis (Yusuf et al., 2000). Ang II regulates many processes 
implicated in atherogenesis, including ROS generation, VSMC growth, 
inflammatory responses, and ECM remodelling through activation of NAD(P)H 
oxidases, MAPK signalling and interaction with both receptor- and non receptor-
tyrosine kinase signalling pathways (reviewed by (Touyz and Schiffrin, 2000, 
Mehta and Griendling, 2007). Furthermore, in human atherosclerotic lesions the 
local RAS is activated, as evidenced by high lesion levels of ACE, Ang II and the 
AT1R (Schieffer et al., 2000). Additionally, inflammatory cells present in 
atherosclerotic lesions express high ACE activity (Diet et al., 1996).  
Ang II also influences the expression of a number of pro-inflammatory molecules 
in the vessel wall, contributing largely to the recruitment of inflammatory cells 
and ultimately the development of atherosclerosis. Through the AT1R, Ang II 
activates the transcription factor NF-κB, a protein that controls networks of 
chemokine-modulating, growth factor–modulating, translational control, and 
cellular survival genes (Ruiz-Ortega et al., 2000).  In endothelial cells, Ang II 
upregulates VCAM-1, ICAM-1, and E-selectin expression (Pueyo et al., 2000, 
Pastore et al., 1999, Grafe et al., 1997). In VSMCs, Ang II stimulates the 
production of VCAM-1, MCP-1, and the cytokine IL-6 (Tummala et al., 1999, 
Hernandez-Presa et al., 1997, Han et al., 1999). MCP-1 specifically attracts 
monocytes and memory T lymphocytes expressing the C-C chemokine receptor 2 
(CCR2) receptor, cell types that are present at all stages of the atherosclerotic 
lesion. MCP-1 is thought to function locally in the vessel wall by establishing a 
chemical gradient to attract adherent monocytes and T lymphocytes to the site 
of injury in the vessel media. IL-6 promotes VSMC proliferation involving the 
local production of PDGF (Ikeda et al., 1991). The ability of Ang II to induce 
coordinated expression of adhesion molecules and chemokines then ensures the 
recruitment of inflammatory cells into the vessel wall (Pastore et al., 1999). 
Furthermore, Ang II has been shown to be involved in cellular deposition of ECM, 
an important component in VSMC remodelling, migration and adhesion. Ang II-
induced EGFR- and MAPK-dependent pathways may participate in matrix 
formation and regulation (Matsubara et al., 2000, Touyz and Schiffrin, 2000). 
Ang II has also been shown to promote collagen synthesis within VSMC (Kato et 
al., 1991). Besides regulating structural components such as collagen, Ang II has 
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also been implicated in adhesive remodelling. Moriguchi et al reported that Ang 
II-mediated EGFR transactivation regulates fibronectin and TGF-β synthesis 
(Moriguchi et al., 1999). Furthermore, production of MMPs, for example, MMP-2, 
and breakdown of collagen IV is also modulated by Ang II (Libby and Lee, 2000). 
Thus, Ang II acts on several different components of ECM formation and 
deposition to influence matrix turnover.  
Furthermore, Ang II has also been reported to promote of macrophage mediated 
uptake of oxidised LDL via increased IL-6 production and expression of the 
scavenger receptor CD36 on macrophages (Keidar et al., 2001). Additionally, Ang 
II upregulated endothelial cell expression of the lectin-like oxidised LDL receptor 
1, which may result in increased oxidised LDL entry into the atherosclerotic 
lesion (Morawietz et al., 1999). While the exact mechanisms are unknown, these 
studies suggest that Ang II enhances the uptake of LDL and generation of foam 
cells.  
1.6.3 Vein graft failure 
Ang II is known to mediate a number of pathways involved in vein graft failure 
and through the use of animal models of vein grafting, has been directly 
implicated in its pathology. For example, administration of the ACE inhibitor 
captopril reduced neointimal formation following vein grafting in the rabbit 
(O'Donohoe et al., 1991). In a canine model, it was found that ACE activity was 
increased in grafted veins compared with control veins at 4 weeks post-
engraftment and this was associated with an increase in neointimal formation 
(Yuda et al., 2000). Furthermore, the AT1R antagonist L-158, 809, a non-peptide 
imidazopyridine derivative, significantly reduced neointimal formation and VSMC 
proliferation in comparison to control groups (Yuda et al., 2000). L158, 809 has 
also been shown to reduce neointimal formation in grafted veins in the rabbit 
when administered either systemically or directly to the vessel (Fulton et al., 
1998). Taken together, these findings suggest that local production of Ang II via 
increased ACE expression and activity enhances neointimal formation following 
vein grafting. 
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1.6.4 Restenosis 
Ang II is known to mediate a number of the cellular effects involved in 
restenosis, it has been directly implicated in the pathogenesis of restenosis and 
neointimal formation through the use of various rodent models of vascular 
injury. Increased levels of ACE have been observed in the neointimal area of 
balloon injured rat carotid arteries and in mouse femoral arteries following cuff 
induced injury, indicative of increased Ang II production within the remodelled 
vessel (Rakugi et al., 1994, Akishita et al., 2001). In line with these findings, 
ACE inhibitors have been shown to reduce neointima formation in response to 
vascular injury in several models and species, such as balloon catheter induced 
injury in rats, rabbits and guinea pig, and cuff induced injury in various strains of 
mice (Powell et al., 1989, Chen et al., 2003, Akishita et al., 2001). Increased 
expression of AT1R, indicative of increased Ang II signalling, has been observed in 
the neointimal following vascular injury of the rat carotid artery (Eto et al., 
2003). The role of the AT1R was further confirmed in this study as AT1R inhibition 
reduced neointimal thickening, associated with reduced collagen and elastin 
accumulation (Eto et al., 2003). In monkeys and rabbits, AT1R blockade also 
reduced in-stent restenosis, oxidative stress, proinflammatory factors (MCP-1, 
IL-1β, and TNF-α) and NAD(P)H oxidase expression suggesting that AT1R signaling 
is involved in neointimal formation (Ohtani et al., 2006).  
1.6.5 The counter-regulatory RAS and vascular remodelling 
While Ang II mediated effects via the AT1R are widely accepted to contribute to 
pathological remodelling of the vasculature, the components of the counter-
regulatory axis of the RAS, namely ACE2, Ang-(1-7) and Ang-(1-9) have been 
shown to exert protective effects on the vasculature.  
1.6.5.1  Vascular ACE2 
The expression and activity of ACE2 in the vasculature has beneficial effects, 
particularly in the setting of atherosclerosis, via reducing Ang II levels and 
increasing levels of Ang-(1-7). In atherosclerotic human carotid arteries, ACE2 
activity was found to be increased in early stage atherosclerosis or in unstable 
lesions in comparison to stable lesions, demonstrating differential activity of 
ACE2 at different stages of the disease (Sluimer et al., 2008). While it is 
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currently unclear how this differential activity is regulated, it may be that ACE2 
is increased in the early stages of atherosclerosis and in unstable lesions in an 
attempt to control the disease pathology and lessen injury by both reducing Ang 
II production and increasing production of Ang-(1-7) and Ang-(1-9). Additionally, 
over-expression of ACE2 using an adenoviral vector has been shown to reduce 
atherosclerotic lesion size in ApoE-/- mice (Lovren et al., 2008). Moreover, ACE2 
overexpression also stabilizes existing atherosclerotic lesions, inhibiting 
progression of lesion development at early stages of atherosclerosis, but not at 
advanced stages of the disease (Dong et al., 2009). These effects were 
associated with both reduced levels of Ang II and increased levels of Ang-(1-7), 
suggesting a key role for ACE2 in balancing the activity of both axes of the RAS in 
atherosclerosis. 
1.6.5.2 Effects of Ang-(1-7) on vascular remodelling 
To date a large proportion of the protective effects of the counter-regulatory 
axis of the RAS in the vasculature have been attributed to the production of Ang-
(1-7), and its resulting interaction with Mas (Figure 1.5). Numerous in vitro 
studies have shown that Ang-(1-7) signaling via Mas inhibits VSMC proliferation 
and migration via two main mechanisms: (1) inhibition of MAPK signaling 
pathways, for example reduced activity and expression of ERK1/2 (Tallant et al., 
1999, Zhang et al., 2010b) and (2) release of prostaglandins including 
prostacyclin (PGI2) and prostaglandin E2 (PGE2), resulting in increased cyclic 
adenosine monophosphate (cAMP) levels and inhibition of cyclo-oxygenases 
(Jaiswal et al., 1993b).  
The anti-proliferative and anti-migratory role of Ang-(1-7) is also observed in 
numerous rodent models of vascular disease. Ang-(1-7), via Mas, reduces 
neointimal formation following balloon injury (Strawn et al., 1999), stent 
implantation in rats (Langeveld et al., 2005), and angioplasty in rabbits (Zeng et 
al., 2009), and has been associated with reduced atherosclerotic lesion size in 
Apo E-/- mice (Tesanovic et al., 2010, Yang et al., 2013). Additionally, a non-
peptide agonist of Mas, AVE0991, which mimics the actions of Ang-(1-7) (Wiemer 
et al., 2002), inhibits rat VSMC proliferation in vitro (Sheng-Long et al., 2012).  
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Ang-(1-7) increases NO release, thereby acting as a vasodilator and improving 
vascular endothelial function (Brosnihan et al., 1996, Faria-Silva et al., 2005). 
Increased NO is achieved directly via Mas-mediated stimulation of eNOS and 
sustained Akt phosphorylation, or indirectly via production of bradykinin and 
receptor cross talk with the BK2R (Jackman et al., 2002, Sampaio et al., 2007a). 
Additionally, Ang-(1-7) has been shown to promote vasodilation via the AT2R in 
the SHRSP during AT1R blockade. This was shown to involve interaction between 
the AT2R and BK2R as vasodilation in response to Ang-(1-7) was prevented by 
both PD123,319 and HOE 140 (a BK2R antagonist) (Walters et al., 2005). In 
addition to promoting vasodilation, this increase in NO release was also 
demonstrated to inhibit platelet aggregation, demonstrating an anti-thrombotic 
role for Ang-(1-7) (Kucharewicz et al., 2002).  
An Ang-(1-7)-mediated increase in NO bioavailability has also been linked to 
reduced ROS production, thereby promoting improved vascular function and 
reduced atherosclerosis. In Apo E-/- knockout mice, chronic administration of 
Ang-(1-7) via osmotic mini pump restored renal endothelial function which was 
associated with increased NO bioavalibility (Stegbauer et al., 2011). To 
investigate the relationship between ROS levels and NO bioavailability in this 
setting, the ROS scavenger Tempol was used. While Tempol improved 
endothelial function in untreated Apo E-/-, it had no effect on Ang-(1-7) infused 
mice, indicating that these animals already have reduced ROS levels (Stegbauer 
et al., 2011). This was further suggested by reduced levels of H2O2 and NAD(P)H 
oxidase subunit expression in Ang-(1-7)-infused animals. In addition to reduced 
ROS activity, increased levels of eNOS were observed following treatment with 
Ang-(1-7), providing a further mechanism to support the findings of increased NO 
bioavailability (Stegbauer et al., 2011). 
In addition to Ang-(1-7)-mediated NO release from vascular endothelial cells 
(Sampaio et al., 2007a, Heitsch et al., 2001) it has recently been shown that 
Ang-(1-7) signalling mediates NO release from platelets, enhancing its anti-
thrombotic activities (Fraga-Silva et al., 2008). In vivo the anti-thrombotic 
effect of Ang-(1-7) was blocked by pharmacological Mas inhibition and is absent 
in Mas knockout (Mas-/-) mice (Fraga-Silva et al., 2008). It was not established 
whether this was due to the actions of Ang-(1-7) in endothelial cells or platelets, 
although it is likely to be a combination of both (Fraga-Silva et al., 2008). While 
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further work is required to fully dissect the mechanisms involved in the anti-
thrombotic properties, these findings have identified the Ang-(1-7)/Mas axis as a 
potential therapeutic target for the treatment of thrombotic events. The recent 
development of an orally available form of Ang-(1-7) (Ang-(1-7)-CyD), in which 
Ang-(1-7) has been incorporated into a cyclodextrin (CyD), a cyclic 
oligosaccharide that enhances drug stability, absorption across biological 
barriers and provides gastric protection (Uekama, 2004), has greatly increased 
the potential of utilising Ang-(1-7) in a therapeutic setting (Fraga-Silva et al., 
2011). This compound has been shown to be of particular use as an anti-
thrombotic intervention as it exerts antithrombotic effects in vivo, associated 
with increased plasma levels of Ang-(1-7) (Fraga-Silva et al., 2011). 
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Figure 1.5 Angiotensin-(1-7) signalling in the vasculature 
Ang-(1-7) via Mas increases NO release, thereby acting as a vasodilator and reducing thrombosis 
either 1) directly via activation of the PI3K/Akt signaling pathway resulting in increase 
phosphorylation of eNOS or 2) indirectly via cross talk with the BK2R, which increases PKA 
mediated phosphorylation of eNOS-this pathway may involve interaction with the AT2R also. Ang-
(1-7) via Mas also promotes vasodilation by stimulating PLA2 leading to increased release of AA, 
which in turn produces the prostanoids PGI2 and PGE2, both of which increase levels of cAMP. 
cAMP also reduces MAPK signaling and VSMC proliferation and migration. Ang-(1-7) via Mas also 
directly inhibits MAPK activity. AA: Arachidonic acid; AT2R: Angiotensin type 2 receptor; BK2R: 
Bradykinin 2 receptor; cAMP: Cyclic adenosine monophosphate; eNOS: endothelial nitric oxide 
synthase; NO: Nitric oxide; PI3K: Phosphoinositide 3-kinase; PGI2: Prostacyclin: PGE2: 
Prostaglandin E2; PKA: Protein kinase A. 
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1.6.5.3 Effects of Ang-(1-9) on vascular remodelling 
The role of Ang-(1-9) in the vasculature is relatively unexplored; however, as 
Ang-(1-9) can also exert biological effects, some of the previously described 
vasculoprotective effects of the counter-regulatory axis of the RAS may be 
attributed to production of both Ang-(1-9) and Ang-(1-7) (Figure 1.6). However, 
signalling via the AT2R in the vasculature is poorly defined and further work is 
required to delineate a role in this setting (Figure 1.6). Ang-(1-9) has been 
previously shown to indirectly contribute to improved vascular function through 
a number of pathways. For example, Ang-(1-9) promotes bradykinin release from 
endothelial effects and enhances the effects of bradykinin by augmenting NO 
and arachidonic acid release (Jackman et al., 2002). Additionally, inhibition of 
the RhoA/Rho-associated, coiled-coil containing protein kinase (ROCK) signaling 
pathway results in increased activity and expression of ACE2 in the aorta, and 
increased Ang-(1-9) plasma levels, associated with reduced blood pressure and 
vascular remodelling (Ocaranza et al., 2011). These effects were coupled with 
reduced ACE activity, Ang II levels and increased expression of eNOS, identifying 
that the ROCK pathway may interact with the ACE2/Ang-(1-9) axis as a novel, 
protective interaction in the vasculature.  
Ang-(1-9) has recently been demonstrated, for the first time, to have a direct 
beneficial effect on vascular function. In this study continuous infusion of Ang-
(1-9) improved aortic vasorelaxation and NO bioavailability in the SHRSP; 
importantly these effects were blocked by PD123,319, suggesting that these 
effects are due to Ang-(1-9) signalling via the AT2R (Flores-Munoz et al., 2012). 
Furthermore, Ang-(1-9) has recently been shown to induce relaxation of rat 
aortic rings in a concentration- and endothelium-dependent manner, an effect 
which was unaltered by A779 or losartan, but blocked by PD123,319 and L-NAME 
suggesting that Ang-(1-9) induces vasodilation via the AT2R and NO signalling 
(Ocaranza et al., 2014). While the mechanisms involved are currently unknown it 
is possible that Ang-(1-9) may increase NO bioavailability by stimulating 
bradykinin release, as previously documented in cardiac endothelial cells 
(Jackman et al., 2002), or by enhancing the activity of eNOS, as has been shown 
for Ang-(1-7) (Sampaio et al., 2007a).  
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Figure 1.6 Angioteinsin-(1-9) signalling in the vasculature 
Ang-(1-9) via the AT2R promotes vasodilation through increased NO either directly or via crosstalk 
with the BK2R. Ang-(1-9) mediated vasodilation is also associated with increased expression of 
NOX4. AT2R: Angiotensin type 2 receptor; BK2R: Bradykinin 2 receptor; eNOS: endothelial nitric 
oxide synthase; NO: Nitric oxide; NOX4: NADPH oxidase 4; PKA: protein kinase A. (Adapted from 
(McKinney et al., 2014)). 
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1.7 Hypothesis and aims 
Numerous studies in vitro and in vivo studies have demonstrated a 
vasculoprotective role for Ang-(1-7) signaling via Mas. The majority of this work 
has relied on the use of rodent cells and these effects have yet to be 
demonstrated in human cells. Furthermore, the cell signaling mechanisms 
involved in the effects of Ang-(1-7) have still to be fully delineated. We 
hypothesized that Ang-(1-7) also elicits protective effects in human cells 
relevant to vascular disease.  
While Ang-(1-9) has previously been demonstrated to have protective effects 
within the heart, the role of Ang-(1-9) in the vasculature remains undefined and 
the effects of this peptide in the setting of vascular remodeling have not 
previously been explored. However, as Ang-(1-9) has been demonstrated to 
antagonize the effects of Ang II, which contributes greatly to remodeling of the 
vasculature in a number of disease states, it is possible that Ang-(1-9) may also 
have protective effects within the vasculature. Furthermore, as ACE2, the 
enzyme responsible for the production of Ang-(1-9), and the AT2R, the receptor 
through which Ang-(1-9) has been demonstrated to act, have both previously 
been reported to be protective in the setting of vascular remodeling, it is 
possible that some of these previously described vasculoprotective effects of the 
counter-regulatory axis of the RAS could be attributed in part to Ang-(1-9). 
Therefore, we hypothesized that in addition to Ang-(1-7), Ang-(1-9) may also 
have protective effects in the setting of vascular remodeling.  
Therefore, the principal research aim of this thesis was to investigate and 
compare the effects of Ang-(1-7) and Ang-(1-9) in vascular remodeling. This was 
achieved through the following experimental study aims: 
 Characterise the effects of Ang-(1-7) and Ang-(1-9) on human saphenous 
vein SMC proliferation and migration, and assess the cell signalling 
pathways involved. 
 Investigate the effects of Ang-(1-7) and Ang-(1-9) on human saphenous 
vein on endothelial cell growth, migration and function. 
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 In vivo assessment of the effects of Ang-(1-7) and Ang-(1-9) on vascular 
remodelling and neointimal formation following vascular injury in mice. 
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Chapter 2 
Materials and Methods 
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2.1 Materials 
All chemicals, unless otherwise stated were purchased from Sigma-Aldrich 
(Poole, UK). Angiotensin peptides were purchased from Phoenix Pharmaceuticals 
(Karlsruhe, Germany). Receptor antagonists were purchased from Sigma-Aldrich 
(losartan and PD123,319) or Bachem (Rhein, Germany) (A779). All tissue culture 
reagents were obtained from Gibco (Paisley, UK), unless otherwise stated. All 
transfection, reverse transcription and quantitative real-time polymerase chain 
reaction (qRT-PCR) reagents were purchased from Life Technologies (Paisley, 
UK), unless otherwise stated. 
2.2 Human vascular tissue 
Saphenous veins were obtained from patients undergoing CABG surgery and 
stored in sterile saline solution by the surgical team at the Golden Jubilee 
National Hospital (Glasgow, UK). Saphenous veins were also obtained from 
patients undergoing elective varicose vein removal and were stored in the same 
way by the surgical team at Gartnavel General Hospital (Glasgow, UK). At the 
laboratory vessels were cleaned of any excess tissue under sterile tissue culture 
conditions. Endothelial cells were isolated from the vessels on the day of surgery 
and VSMC were isolated from the vessels within 24 hrs of the surgery. 
2.3 Cell and tissue culture 
All cell culture was performed under sterile conditions using class II biological 
safety vertical laminar flow cabinets (Holton Safe 2010). All cells were cultured 
in a humidified incubator at 37ºC with a constant supply of 5% carbon dioxide 
(CO2). Cells were cultured in 25cm
2, 75cm2 or 150cm2 flasks with vented lids 
(Corning, Poole, UK). CHO cells used at the Federal University of Minas Gerais 
(UFMG) were gifted by Prof Robson. A Santos and cultured in Dulbecco’s 
Modified Eagles Medium (DMEM) (Invitrogen, Paisley, UK) supplemented with 10% 
(volume/volume [v/v]) foetal calf serum (FCS), 100 international units (I.U)/mL 
penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine. 
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2.3.1 Isolation of primary endothelial cells from human 
saphenous veins 
Human saphenous vein endothelial cells (HSVEC) were isolated on the day of 
surgery by enzymatic collagenase digestion using a protocol based on the 
technique described by Jaffe et al (Jaffe et al., 1973). Briefly, saphenous veins 
were flushed of any remaining blood using wash media (DMEM supplemented 
with 100 I.U/mL penicillin, 100 µg/mL streptomycin, 2mM L-glutamine and 25mM 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). Veins were then 
filled with a solution of filter-sterilised collagenase (2 mg/mL in wash medium) 
and clamped at both ends to prevent any leakage of the solution. The vein was 
placed in a sterile petri dish and incubated in the presence of 5% CO2 for 15 
minutes at 37ºC. Endothelial cell suspensions were collected by flushing the vein 
with wash medium and collecting the eluate in a separate sterile petri dish. This 
process was repeated with fresh collagenase solution and the vein incubated for 
10 minutes at 37ºC. The cells and eluate were collected and pelleted by 
centrifugation at 12,000 g for 5 minutes at room temperature. Cells were 
resuspended in complete Large Vessel Endothelial Cell Basal Medium (TCS 
Cellworks Ltd, Botolph, Claydon, Bucks, U.K), supplemented with 20% (v/v) FCS, 
100 I.U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine, 90 µg/mL 
heparin, 1 µg/mL hydrocortisone, 1 ng/mL basic fibroblast growth factor (bFGF) 
and 0.1 ng/mL epidermal growth factor (EGF), and then incubated for 24 hours 
before a complete medium change. Cells were cultured in complete growth 
medium and used below passage 7. 
2.3.2 Isolation of primary smooth muscle cells from human 
saphenous veins 
HSVSMC were isolated within 24 hours of surgery using the explant technique as 
described by Southgate and Newby (Southgate and Newby, 1990). Briefly, the 
vein was cut longitudinally and pinned lumenal side up. Remaining endothelium 
was removed by gentle rubbing of the lumenal surface. The medial layer was 
scored with a sterile scalpel, separated from the adventitial layer and then 
chopped into 1 mm2 segments using a McIlwain Tissue Chopper (Ted Pella Inc., 
California, USA). Explants were washed with media and incubated at 37ºC in 5% 
CO2 in minimal medium until they had adhered to the bottom of the flask 
(approximately 24 hours). Explants were cultured at 37ºC in the presence of 5% 
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CO2 in 5 mL complete Smooth Muscle Cell Growth Medium 2 supplemented with 
15% (v/v) FCS, 100 I.U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-
glutamine, 0.5 ng/mL EGF, 2 ng/mL bFGF and 5 µg/mL insulin. Medium was 
changed once a week until HSVSMC migrated from the explants and then every 3 
days once passaged. Cells were cultured in complete growth medium and used 
below passage 7. 
2.3.3 Cell passage 
Cells were grown as a monolayer and media was replenished every 2-3 days. 
Cells were routinely passaged when approaching confluence to prevent 
overgrowth. To passage cells were washed twice with sterile phosphate buffered 
saline (PBS) and incubated at 37oC in 3mL trypsin-ethylenediamine tetra-acetic 
acid (trypsin-EDTA) (0.05% trypsin, 0.02% EDTA) for approximately 5 minutes or 
until the majority of the cells had detached from the flask. The action of 
trypsin-EDTA was neutralised by the addition of an equal volume of complete 
growth media. Cells were harvested by centrifugation at 1,500 g for 5 minutes 
and resuspended in complete growth media for passaging or plating. Before 
plating cells were counted using a haemocytometer to ensure the required 
seeding density was met. 
2.3.4 Cryopreservation 
Cells were harvested as described in section 2.3.3. Following centrifugation cells 
were resuspended in 1mL of complete growth media supplemented with 10% 
dimethyl sulphoxide (DMSO) per culture flask of cells. Cell suspensions were 
collected in cryo-preservation vials and cooled at -80ºC in a freezer storage box 
containing isopropanol for 24 hours. Vials were then stored in the vapour phase 
of liquid nitrogen. Cryo-preserved cells were recovered by thawing at 37ºC and 
then adding drop wise to 15 mL of complete growth media. Cell suspensions 
containing primary cells were transferred directly to a 75cm2 flask. Cell 
suspensions from cell lines were harvested by centrifugation at 1,500 g for 5 
minutes and resuspended in complete growth media before being added to the 
relevant sized cell culture flask. Cells were incubated overnight at 37ºC in the 
presence of 5% CO2 and the media changed the following day. 
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2.4 Stimulation of HSVSMC and HSVEC 
In all in vitro experiments using HSVSMC or HSVEC cells were stimulated with 
Ang II, Ang-(1-7) or Ang-(1-9) at 200 nM, unless otherwise stated. Cells were 
incubated with Ang-(1-7) and Ang-(1-9) 30 minutes prior to the addition of Ang 
II. In experiments where receptor antagonists were used, cells were incubated 
with the AT1R antagonist losartan at 10 μM, the AT2R antagonist PD123,319  at 
500 nM or the Mas antagonist A779 at 100 μM for 15 minutes prior to the addition 
of Ang-(1-7) or Ang-(1-9). The concentrations of peptides and antagonists, and 
stimulation protocol were chosen based on previous experiments within our 
group and from the literature (Flores-Munoz et al., 2011, Sampaio et al., 2007a, 
Sampaio et al., 2007b, Zhang et al., 2010b, Freeman et al., 1996, Tallant and 
Clark, 2003, Zhu et al., 2002). 
2.5 Proliferation assay 
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega, 
Southampton, UK), also known as the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) assay 
was used to measure cell proliferation. The MTS assay is a colorimetric method 
for determining the number of viable cells and is based on the conversion of the 
novel tetrazolium compound MTS to a soluble formazan product by viable cells. 
The absorbance of the formazan product can be measured and this is directly 
proportional to the number of viable cells.  
HSVEC or HSVSMC were seeded at 5x103 cells/well in 96 well plates and 
incubated overnight at 37ºC in the presence of 5% CO2. The cells were then 
rendered quiescent by incubation in serum free medium (HSVEC: 24 hours in 
DMEM, 100 I.U/mL penicillin and 100 µg/mL streptomycin; HSVSMC 48 hours in 
DMEM GlutaMAX, 100 I.U/mL penicillin and 100 µg/mL streptomycin). To induce 
proliferation, cells were then exposed to fresh media containing different 
concentrations of FCS (0%-20% (v/v) FCS in quiescing media) for 24 hours (HSVEC) 
or 48 hours (HSVSMC) at 37ºC in the presence of 5% CO2. A working solution 
containing MTS and phenazine sulphate (PMS, an electron coupling reagent) was 
prepared at a ratio of 20:1, respectively, and added to the cells in 100 µL media. 
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Cells were then incubated at 37ºC for 3 hours. Finally, absorbance was read at 
490 nm using the Wallac 1420 Victor2 plate reader (Wallac, Turku, Finland). 
To assess the effect of Ang II, Ang-(1-7) and Ang-(1-9) (all 200 nM) on cell 
proliferation, cells were incubated in either serum free medium or 5% FCS 
containing medium for 24 hours (HSVEC) or 48 hours (HSVSMC). To assess the role 
of angiotensin receptors in HSVSMC were incubated with losartan, PD123,319 or 
A779 as decribed in Section 2.4. Proliferation was then assessed as described 
above. 
2.6 Migration assay 
Cell migration was assessed in the form of a scratch assay as described by Liang 
et al (Liang et al 2007). Briefly, cells were seeded in 6 well plates at a density of 
3x105 cells per well and grown in complete culture medium at 37ºC in the 
presence of 5% CO2 until fully confluent. The cells were rendered quiescent by 
incubating in serum free medium as described in section 2.5. Horizontal lines 
were drawn on the outside bottom surface of each well to act as a guide for 
measurements. Three straight, vertical scratches were induced in the cell 
monolayer of each well using a sterile 200 μL pipette tip. Cellular debris was 
removed by gently washing cells once with 1 mL of PBS. Cells were incubated in 
serum free media with Ang II at 200nM to induce cell migration. To assess the 
effects of Ang-(1-7) and Ang-(1-9) on cell migration, cells were incubated in 
serum free media with Ang-(1-7) or Ang-(1-9) (200nM) alone for the duration of 
the experiment and 30 minutes before stimulation with Ang II. To assess the role 
of AT1R, AT2R and Mas, cells were incubated with losartan (10 μM), PD123, 319, 
500 nM or A779 (100 μM) for 15 minutes before Ang-(1-7) or Ang-(1-9), and 45 
minutes before Ang II. Cells in serum free media alone or complete growth 
medium were used as control samples. Images of the scratch were taken directly 
above the guide line using a Nikon Eclipse TS1000 microscope and imaged on 
QICAM Fast1394 camera (QImaging, Maidenhead, UK) at various time points 
between 0-30 hours post scratch. Image analysis was performed using Image J 
software where, to ensure unbiased measurements were made, a grid composed 
of 12 horizontal lines were placed over the image. The distance between the 
edges of the wound were measured along the grid lines and migration was 
expressed as a percentage of the original scratch width (0 hour).  
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In experiments which were performed to assess changes in gene and miRNA 
expression and protein activity, cells were subject to 8 scratches per well in 
order in increase the proportion of migrating cells and lysed as described in 
section 2.8 for RNA extraction or section 2.12 for protein extraction at 24 hours 
post scratch. 
2.6.1  Real time analysis of HSVSMC migration 
HSVSMC migration was also assessed in real-time using the xCELLigence system 
(Roche, Mannheim, Germany). The xCELLigence system monitors cellular events 
in a label free environment and provides quantitative information about the 
biological status of cells in real time (Atienza et al., 2006). This is achieved by 
measuring cellular impedance using specialised micro-titre plates, E-Plates, 
which have integrated gold electrodes covering 80% of the bottom of each well 
that measure impedence; changes in cellular impedance can be correlated to 
changes in cell morphology or growth (Atienza et al., 2006). In the absence of 
cells, background impedance is determined by the ionic environment of the 
culture media at the electrode-media interface and the media itself. When cells 
attach to the electrodes this alters the ionic environment at the electrode-
media interface resulting in an increase in impedance (Yu et al., 2006). As the 
cells begin to spread and proliferate, the impedance further increases. Short 
term changes in cell impedance can be correlated to changes in cell morphology 
while longer term changes in cell impedance are indicative of growth and 
movement (Atienza et al., 2006, Yu et al., 2006). Impedance measurements are 
expressed as an arbitrary unit, Cell Index (CI). CI is defined as (Rn-Rb)/15Ω, 
where Rn is the cell-electrode impedance of the well when it contains cells and 
Rb is the background impedance of the media alone (Atienza et al., 2006).  
To assess migration, HSVSMC were seeded at a density of 1x104 cells/well in an 
E-plate to create a confluent monolayer and incubated at 37ºC overnight to 
allow cells to adhere to the electrodes, resulting in a gradual increase in CI. 
Cells were rendered quiescent in serum free medium for 48 hours causing the CI 
to reach a stable plateau, indicating the cells had changed from a proliferative 
to a quiescent state. A scratch was induced in the cell monolayer as described in 
section 2.6 causing a rapid drop in CI due to the reduced electrode coverage. As 
changes in temperature can affect CI readings the cells were allowed to 
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equilibrate for 30 minutes then stimulated in serum free media as described in 
section 2.4. CI was measured every 15 minutes for 24 hours. CI was normalised 
at the time of stimulation with Ang II (referred to as 0 hour) and migration 
quantified as the fold change in normalised CI relative to 0 hour.  
2.7 Transfection of HSVSMC 
RNA interference (RNAi) techniques were used to assess the involvement of 
miRNA in HSVSMC migration. HSVSMC were transfected with a short interfering 
RNA (siRNA) designed to target human DICER or a specific miRNA-132 inhibitor 
(both Life Technologies). A siRNA designed to target GAPDH was used as a 
positive control and assess transfection efficiency. A non targeting Cy3 labelled 
siRNA or miR-inhibitor was used as a negative control. A list of all RNAi assays 
used can be found in Table 2.1. 
Table 2.1 List of RNAi assays used in HSVSMC  
 
RNA i Assay ID 
Silencer® Select DICER1 antisense RNA 1 n269596 
Silencer® Select GAPDH siRNA 4404024 
Silencer® Cy™3 Labeled Negative Control No. 1 siRNA AM4621 
Cy3™ Labeled Anti-miR™ Negative Control AM17011 
mirVana™ miRNA Inhibitor, Negative Control 4464076 
mirVana™ miR-132 Inhibitor MH10166 
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2.7.1 Transfection efficiency 
Cells were transfected using siPORTTM neoFXTM (Life Technologies) according to 
manufacturer’s instructions. Briefly, cells were plated at 3x105 cells/well in 6 
well plates and cultured in complete media at 37ºC in the presence of 5% CO2 
until 90% confluent.   For each well, 5 µL siPORTTM neoFXTM was diluted in 100 µL 
Opti-MEM® and incubated at room temperature for 10 minutes. SiRNA or miR 
inhibitors were diluted to 10, 30 or 60 nM in 100 µL Opti-MEM® and then 
combined with the diluted siPORTTM neoFXTM and incubated for a further 10 
minutes. The RNA/siPORTTM neoFXTM transfection complexes were added to 
culture media to a total volume of 2.0 mL, which was then added to the cells. A 
mock transfection control was also included where cells were treated with 
siPORTTM neoFXTM but not exposed to any RNA. The cells were incubated with the 
transfection reagents at 37ºC in the presence of 5% CO2 for 10 hours, after which 
cells were washed then incubated for a further 48 hours in serum free media. 
The media was changed to fresh serum free media and cells were incubated at 
37ºC in the presence of 5% CO2 for a further 24 hours. Transfection efficiency 
was first confirmed by visualisation of the Cy3 labelled control transfected well 
using a fluorescence microscope and then cells were lysed for RNA extraction as 
described in section 2.9 to allow for subsequent inhibition of target gene 
expression using q-RT-PCR as described in section 2.11. 
2.7.2 RNA interference in HSVSMC migration 
Cells were transfected as described with the optimal concentration of siRNA or 
miR-132 inhibitor as determined in section 2.7.1. Following a 48 hours 
quiescence period outlined cells were subject to the migration assay protocol as 
described in section 2.6. RNA was isolated at 24 hours post induction of scratch 
and stimulation as described in section 2.8. 
2.8 RNA and miRNA extraction from HSVEC and HSVSMC 
Total and miRNA was extracted using the miRNeasy mini kit (Qiagen, 
Manchester, UK), including on-column DNAse treatment to remove any DNA 
contamination, as per manufacturer’s instructions. Briefly, cells were washed in 
PBS to remove any residual media and lysed using 700 µL QIAzol lysis reagent. 
Lysates were briefly vortexed to homogenize prior to the addition of 140 µL of 
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chloroform to facilitate separation of the sample. Protein remains in the lower 
organic phase and DNA partitions to the interphase while the RNA partitions to 
the upper aqueous phase. The sample was partitioned fully by centrifugation at 
12,000 g for 15 minutes at 4ºC. The RNA containing aqueous phase was 
transferred to a fresh RNAse free microcentrifuge tube (Applied Biosystems) and 
1.5 volumes of 100 % ethanol added to facilitate binding to the RNeasy mini spin 
column. Samples were immediately added to the spin column and subjected to 
ultracentrifugation at 8000 g for 15 sec to bind the RNA to the spin column. To 
remove any contamination, columns were washed with 350 µL of buffer RWT for 
15 sec and 8000 g and the flow through discarded. Digestion of residual DNA was 
performed by incubating the spin columns with DNAse for 15 minutes at room 
temperature. The column was further washed with 350 µL buffer RWT, followed 
by two washes of 500 µL buffer RPE by centrifugation at 8000 g for 15 sec to 
remove any traces of salts from the sample. To dry, spin columns were 
subjected to centrifugation at 13,100 g for 1 minute. RNeasy spin columns were 
transferred to RNAse free microcentrifuge tubes and RNA was eluted using 50 µL 
of RNAse free water by centrifugation at 8000 g for 1 minute. This elution step 
was repeated using the original volume of RNAse free water to maximise the RNA 
yield. RNA samples were stored at -80ºC. 
2.9 Quantification of RNA 
Total RNA was quantified using a NanoDrop 1000 Spectrophotometer 
(ThermoScientific, Loughborough, UK). The NanoDrop measures the 
concentration of nucleic acid in solution by exposing the sample to a pulse of 
light at 260 nm and then measuring absorption. The relationship between the 
absorbance and the concentration of the sample is based on the Beer-Lambert 
law: 
c=A/(Θ x l) 
Where: 
c= nucleic acid concentration (ng/µL) 
A= absorbance 
Θ= molar absorptivity (constant for given solution) 
l= path length of light passing through (constant for given instrument 
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The purity of the sample was assessed by calculating the ratio of absorbance at 
260 and 280 nm. A 260/280 ratio of <2.0 was accepted as pure. 
 
2.10 Complementary deoxyribonucleic acid (cDNA) 
synthesis 
mRNA extracted from cells was reverse transcribed to cDNA to allow for analysis 
of gene or miRNA expression via qRT-PCR. For both gene expression and miRNA 
cDNA synthesis two negative control reactions were prepared: one containing 
water instead of mRNA and the other containing no reverse transcriptase, the 
enzyme responsible for cDNA synthesis.  
2.10.1 Gene expression 
mRNA extracted from cells was reverse transcribed to cDNA for gene expression 
analysis using the Taqman Reverse Transcription Reagents (Applied Biosystems, 
Warrington, UK) as per manufacturer’s instruction. A maximum of 1 µg (the 
same concentration of RNA used in each experimental repeat) was reversed 
transcribed in a reaction containing: 5.5 mM MgCl2, 2mM deoxyribonucleotide 
triphosphate (dNTP) mix (0.5 mM each), 2.5 µM random hexamers, 1x RT buffer, 
0.4 U/µL RNAse inhibitor and 1.25 U/µL multiscribe reverse transcriptase. 
Cycling conditions used were as follows: 25ºC for 10 minutes to allow annealing, 
48ºC for 30 minutes to allow for reverse transcription, followed by 95ºC for 5 
minutes to inactivate the reverse transcriptase. cDNA was stored at -20ºC. 
2.10.2 miRNA expression 
mRNA was reverse transcribed to cDNA for the detection of miRNA using specific 
stem-loop reverse transcription primers as per the Taqman miRNA Reverse 
Transcription kit (Applied Biosystems, Paisley, UK). Briefly, a 7.5 µL reaction was 
prepared containing: 1 mM dNTP mix (0.25 mM each), 1x RT buffer, 1x RT 
primer, 0.25 U/µL RNase inhibitor, 3.3 U/µL multiscribe reverse transcriptase 
and 2.5 µL of total RNA diluted to 2 ng/µL. The cycling conditions used were as 
follows: 16ºC for 30 minutes to anneal, 42ºC for 30 minutes to allow for reverse 
transcription to occur, followed by 95ºC for 5 minutes to inactivate the reverse 
transcriptase. cDNA was stored at -20ºC. 
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2.11 TaqMan
®
 quantitative real-time polymerase chain 
reaction (qRT-PCR) 
TaqMan® qRT-PCR was used to quantify relative expression levels of genes or 
miRNAs of interest. TaqMan® assays contain forward and reverse primers specific 
to the target DNA sequence between which a probe can anneal. The probe is 
labelled with a reporter fluorophore at the 5’ end and a non fluorescent 
quencher at the 3’ end, and when intact the quencher suppresses any 
fluorescence emitted by the reporter. In the presence of the target sequence 
the probe anneals and is then cleaved upon amplification of the target sequence 
via forward and reverse primers. This results in separation of the quencher from 
the reporter and therefore a detectable increase in fluorescence. Further 
reporter dye molecules are cleaved from their respective probes with each 
cycle, resulting in an increase in fluorescence intensity proportional to the 
concentration of the target product produced. Data is acquired whilst PCR is in 
the exponential phase and is measured when the reporter dye emission reaches 
a threshold, known as the cycle threshold (Ct). In all experiments a 
housekeeping gene is used, the expression of which remains stable to correct for 
any errors in RNA content. Results are shown relative quantification (RQ) to the 
experimental control using the -2∆∆Ct method as described by Livak and 
Schmittgen (Livak and Schmittgen, 2001). 
2.11.1 Gene expression 
For gene expression, q-RT-PCR was performed using inventoried TaqMan gene 
expression assays (Table 2.2). Expression of each gene was normalised to the 
housekeeping gene GAPDH (in experiments where GAPDH was the gene of 
interest, GAPDH expression was normalised to the housekeeping gene 18s). A 
reaction mixture of 12.5 µL was prepared for each sample containing 6.25 µL 
TaqMan Universal MasterMix II, 0.625 µL probe, 3.125 µL RNAse free water and 
2.5 µL cDNA, and then added in technical duplicate to a 384 well plate. For each 
probe tested the negative reverse transcription control was run in addition to a 
water only control. qRT-PCR was performed in simplex using the 7900HT 
sequence detection system (Applied Biosystems) using the following cycling 
conditions: 10 minutes at 95ºC for enzyme activation, 40 cycles of 15 seconds at 
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95ºC for denaturing of cDNA and then 60 sec at 60ºC for primer and probe 
annealing, and primer extension. 
2.11.2 miRNA expression 
For miRNA expression, qRT-PCR was performed using miR probes complementary 
to the mature miRNA sequence (Table 2.3). Expression of each miRNA was 
normalised to the housekeeper RNU48. A reaction mix of 10 µL was prepared for 
each sample containing 5 µL of TaqMan Universal MasterMix II, 0.5 µL probe, 
3.835 µL RNAse free water and 0.67 µL of miRNA RT product, and then added to 
a 384 well plate in technical duplicate. Controls were performed as above and 
the experiment performed using the 79000HT sequence detection system as in 
section 2.11.1. 
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Table 2.2 List of TaqMan Gene Expression Assays used in qRT-PCR 
 
Gene Assay ID RefSeq Gene ID 
AT1R Hs00258938_m1 NM_004835.4 
AT2R Hs01564134_g1 NM_000686.4 
Mas Hs00267157_s1 NM_002377.2 
PTEN Hs02621230_s1 NM_000314.4 
MCP-1 Hs00234140_m1 NM_002982.3 
RASA1 Hs00243115_m1 NM_002890.2 
MMP2 Hs01548727_m1 NM_001127891.1 
MMP9 Hs00234579_m1 NM_004994.2 
DICER1 Hs01651834_g1 NR_015415.1 
GAPDH Hs02758991_g1 NM_001256799.1 
18s Hs03003631_g1 
 
 
 
 
Table 2.3 List of TaqMan miRNA Expression Assays used in qRT-PCR 
 
miRNA Assay ID 
MIRBASE 
ID 
hsa-miR-132 000457 hsa-miR-132-3p 
hsa-miR-212 000515 hsa-miR-212-3p 
RNU48 001006 
NR_002745 
(NCBI accession) 
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2.12 Protein extraction 
To investigate early changes in protein activity or expression in response to 
peptide stimulation, HSVSMC were plated at 3x105 cells/well in 6 well plates and 
incubated at 37ºC in the presence of 5% CO2 overnight. Cells were then serum 
starved as described in section 2.5. The media was then changed to fresh serum 
free media and cells stimulated with Ang II alone or in combination with Ang-(1-
7) or Ang-(1-9) (all peptides 200 nM) for 5, 15, 30 or 60 minutes. Cells in serum 
free media alone or complete growth medium were used as control samples. 
Following stimulation, cells were washed using PBS and lysed for protein 
extraction. 
Total protein was extracted from cells grown in 6 well plates using 300 µL 
radioimmunoprecipitation assay (RIPA) lysis buffer (150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 50mM Tris pH 8) containing a 1x dilution of 
commercially available Complete Protease Inhibitor Cocktail (Roche Diagnostics, 
West Sussex, UK) and Phosphatase Inhibitor Cocktail (Sigma, Poole, UK). Cells 
were scraped using a cell scraper and frozen at -20°C overnight. The following 
day cells were thawed and then agitated on ice for 45 minutes at 4°C. Cell 
lysates were collected in a sterile microcentrifure tube and centrifuged at 
maximum speed at 4°C for 10 minutes. The supernatant containing protein was 
then transferred to a fresh microcentrifuge tube and stored at -20°C for short-
term storage or -80°C for long-term storage. 
2.12.1 Protein quantification 
Protein concentration was determined using bicinchoninic acid (BCA) Protein 
Assay Kit (Pierce, Rockford, USA), according to manufacturer’s instructions. This 
assay relies on a temperature dependent reduction of Cu2+ ions by protein 
peptide bonds, which then is chelated by the BCA to generate a purple coloured 
product. The absorbance of the developed colour is proportional to the protein 
content of the sample.  
Briefly, a standard curve was generated using the following bovine serum 
albumin (BSA) dilutions: 2000 µg/mL, 1500 µg/mL, 2000 µg/mL, 750 µg/mL, 500 
µg/mL, 250 µg/mL, 125 µg/mL and 25 µg/mL. Working reagent, which contains 
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copper sulphate and BCA, was prepared by mixing reagent A and reagent B at a 
ratio of 50:1, respectively. In a clear well 96 well plate, 200 µL of working 
reagent was added to 25 µL of each standard or sample in duplicate and the 
plate was covered to protect from light and incubated at 37ºC for 30 minutes. 
Absorbance was measured at 560 nm using the Wallac 1420 Victor2 plate reader 
(Wallac). Protein concentration was calculated using the linear equation based 
on the standard curve generated from the BCA protein standards. 
2.13 Western immunoblotting 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
western immunoblotting was performed to detect phosphorylation and 
expression of specific proteins.  
First, 15 µg of protein lysate was mixed with 4x LDS Sample Loading buffer 
(Pierce) supplemented with 2% (v/v) β-mercaptoethanol, and then heated at 
95°C to denature the protein. Samples were fractioned via SDS-PAGE using 10% 
polyacrylamide gels which were either purchased precast (10% Mini-PROTEAN® 
TGX™ Precast Gel; BioRAD, Hemel Hempstead, UK) or prepared within the 
laboratory (consisting of a non-restrictive 4% stacking gel containing 13.3% (v/v) 
N,N’-methylene-bis-acrylamide (polyacrylamide 30%), 25% 
tris(hydroxymethyl)aminomethane) (Tris) pH 6.8 (3.75 mM), 0.1% (v/v) SDS, 1% 
ammonium persulphate (APS) and 0.1% Tetramethylethylenediamine (TEMED) 
and a 10% resolving gel containing 33.3% (v/v) of polyacrylamide 30%, 25% of Tris 
pH 8.8 (11.25 mM), 0.1% (v/v) SDS, 1% APS and 0.1% TEMED). Samples and 10 µL 
of rainbow ladder (RPE 800 NE Amersham Bioscience UK Ltd, Buckingham, UK), a 
marker of protein size, were loaded to each well. 
Gels were electrophoresed in running buffer (25 mM Tris, 0.2 M glycine, 0.1% 
(v/v) SDS) at 80 V till samples left the well (and stacking gel of manually 
prepared gels), then switched to 120 V until the dye front was at the bottom of 
the gel.  
Proteins were transferred onto methanol charged Hybond-P membrane (GE Life 
Sciences, Buckingham, UK) overnight at 4°C at 90 mA in transfer buffer (25mM 
Tris, 0.2 M glycine, 0.1% (v/v) SDS, 20% (v/v) methanol). Membranes were then 
70 
 
blocked in 5% (w/v) BSA in TBS-T (150 mM w/v NaCl, 50 mM w/vTris, 0.1% v/v 
Tween-20) (blocking buffer) for at least 2 hours at room temperature with 
constant shaking. Membranes were then incubated with the primary antibody 
diluted in blocking buffer as outlined in Table 2.4, overnight with shaking at 
4°C. The following day membranes were washed 3 times in blocking buffer, 5 
minutes each wash, at room temperature prior to incubation with the secondary 
antibody. Swine anti-rabbit horse radish peroxidase (HRP) secondary antibody 
(DAKO, Cambridge, UK) was used at a 1:1000 dilution in blocking buffer and 
incubated with membranes for 1 hour at room temperature, with shaking. 
Membranes were then washed 3 times in blocking buffer, followed by 3 washes 
in TBS-T; all washes 15 minutes at room temperature. Protein bands were 
visualised using Amersham Enhanced Chemiluminescence (ECL) western blotting 
detection reagents (GE Life Sciences) as per manufacturer’s instructions. Briefly 
equal volumes of reagent A and reagent B were mixed, added to the membranes 
and incubated for 5 minutes at room temperature. Excess ECL was removed from 
the membranes and Kodak general purpose medical X-ray film was exposed for 
varying lengths of time and then developed using a Kodak X-Omat 1000 
developer.  
In all cases the membrane was incubated with a primary antibody to detect the 
phosphorylated protein first, and then stripped by incubation at 50°C for 30 
minutes in stripping buffer (62.5 mM Tris pH 6.8, 2% (v/v) SDS, 100mM 2-
mercaptoethanol). Membranes were washed 3 times, 10 minutes each wash, 
then incubated in blocking buffer for at least 2 hours and re-probed using a 
primary antibody for GAPDH for normalisation purposes. 
Films were scanned using Molecular Imager Chemidoc XRS+ System and the band 
intensity quantified using densitometry with Quantity One software. Bands were 
normalised to GAPDH loading control signal and presented as a ratio of the 
protein:GAPDH signal. 
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Table 2.4 List of primary antibodies used for Western Blotting 
 
Protein 
Host 
species 
Molecular 
Weight (kDa) 
Dilution 
Company 
(Catalogue number) 
(clone ID) 
Phospho 
ERK1/2 
Rabbit 42, 44 1:1000 
CST 
(9101s) 
Akt Rabbit 60 1:1000 
CST 
(4691) (C67E7) 
GAPDH Rabbit 37 1:1000 
CST 
(2118s) (14c10) 
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2.14 Detection of cellular nitric oxide release 
Release of NO was detected from cells using 4-amino-5-methylamino- 2’,7’-
difluorofluorescein diacetate (DAF-FM diacetate, Life Technologies), a non 
fluorescent compound that reacts with NO to form a fluorescent benzotriazole 
which is detectable upon excitation at 488nm.  DAF-FM diacetate enters the cell 
via passive diffusion and is then deacetylated by intracellular esterases to 
become DAF-FM, the compound that reacts with NO. 
2.14.1 NO release from HSVEC 
HSVEC were seeded at 3x105 cells/well in 6 well plates containing glass  
coverslips (22 mm diameter, #0 thickness) coated with Poly-l-lysine and 
incubated at 37ºC with 5% CO2 overnight. To diminish basal NO signalling cells 
were starved in phenol free, serum free medium (DMEM No Phenol Red, 100 
I.U/mL penicillin and 100 µg/mL streptomycin) for 2 hours at 37ºC. Cells were 
then incubated for 30 minutes at 37ºC in serum free, phenol free medium 
containing 5 µM DAF-FM diacetate. The media was then refreshed and cells 
stimulated with Ang-(1-9) (0.2 µM or 1 µM) or PD123, 319 (500 nM), alone or in 
combination for 15 minutes. When Ang-(1-9) and PD213,319 were used in 
combination, PD123,319 was was incubated with cells for 5 minutes prior to Ang-
(1-9) stimulation. Flourescent images were obtained using a Nikon TE2000-E 
inverted microscope (Nikon Instruments, Melville, NY) excited at 488 nm which 
was equipped with 63x oil immersion Plan Fluor lens and a cooled digital 
CoolSNAPHQ charge-coupled device camera (Photometrics, Tucson AZ, USA). 
Images were taken of at least 5 fields of view per coverslip and exported into 
Metamorph (version 7.7), then Image J for final image processing. 
2.14.2 NO release from transfected CHO cells 
CHO cells were cultured as described in section 2.3, and seeded at 3x105 
cells/well in 6 well plates containing glass coverslips (22mm diameter, #0 
thickness) coated with Poly-l-lysine, then incubated at 37ºC with 5% CO2 
overnight. To assess the involvement of the AT2R in Ang-(1-9) mediated NO 
release, cells were transfected with plasmid containing the human AT2R gene 
(generated by Daniel C. Villela, Federal University of Minas Gerais, Brazil) using 
Lipofectamine 2000 as per manufacturer’s instructions. Briefly, for each well, 10 
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µL lipofectamine 2000 was diluted in 250 µL Opti-MEM® and incubated for 5 
minutes at room temperature. Plasmid DNA (2 µg) was then diluted in 250 µL 
Opti-MEM®, mixed with the diluted Lipofectamine 2000 reagent and incubated 
for 20 minutes at room temperature. The DNA/Lipofectamine 2000 complexes 
were then added to 1.5 mL cell culture media and the total volume added to the 
cells. Untransfected cells were used as a control and were incubated with 5 µL 
Opti-MEM®, 500 µL Opti-MEM® and 1.5 mL culture media. Following 24 hours 
incubation cells were washed in PBS and incubated with 5 µM DAF-FM diacetate 
as described in section 2.14.1. Cells were then stimulated with Ang-(1-9), 
PD123,319 (as described in section 2.14.1) or the AT2R agonist compound 21 (1 
µM). Fluorescent images were then obtained using a Zeiss LSM 510 Meta laser-
scanning confocal microscope excited at 488 nm with an argon-ion laser (63x oil-
immersion lens; Carl Zeiss, Oberkochen, Germany). Images were taken of at 
least 4 fields of view per coverslip and exported to Image J software for image 
processing. 
2.15 Small vessel wire myography 
Wire myography experiments using vessels isolated from AT2R
-/- mice were 
performed at the Federal University of Minas Gerais. Krebs-Henseleit buffer 
(Krebs buffer) containing 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 25 mM 
NaHCO3, 1.03 mM KH2PO4, 11 mM glucose and 2.5 mM CaCl2 was prepared and 
gassed continuously through the experiment with 95% O2. Male AT2R
-/- mice of 8-
10 weeks old were sacrificed by decapitation, and the aorta and mesenteric 
arteries immediately excised and placed in ice cold Krebs buffer. All vessels 
were cleaned of any fat and connective tissue, and if required, denuded of the 
endothelial layer by gentle rubbing. The vessels were then cut into 2 mm 
segments and mounted on two stainless steel 40 µm stainless steel wires in a 4 
channel small vessel wire myograph (Danish Myo Technology, Aarhus, Denmark), 
with one of the wires connected to a force transducer and the other an 
adjustable jaw (Figure 2.1).  
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Figure 2.1 Schematic overview of a vessel segment mounted in a small vessel wire 
myograph 
Vessel segments were mounted on two 40 µm stainless steel wires with one connected to a force 
transducer to record changes in tension of exerted by the artery. The other wire was connected to 
an adjustable jaw to allow for application of tension to the vessel. 
Vessels were gradually warmed to 37ºC in Krebs buffer at resting tension. Due to 
the small diameter of mesenteric arteries a normalization step was then 
performed to calculate the internal circumference of the vessel and thereby 
determine the optimal active tension required. The internal circumference of 
the vessel was calculated based on the tension exerted by the vessel at rest and 
under transmural pressure of 100 mmHg; only vessels found to have an internal 
circumference of >150 µm were used. The optimal active tension required was 
calculated as the tension required to stretch the vessel to 90% of its internal 
circumference. A predetermined active tension of 0.6 g was applied to aortic 
rings. Active tension was applied to all vessels for 30 minutes.  To establish the 
viability of each segment and to sensitise the vessel prior to further 
pharmacological stimulation, the contractile response to 0.6 mM KCl was 
assessed. Once a stable plateau was reached the vessels were washed in Krebs 
buffer till the tension returned to the applied active tension. This was then 
repeated twice, with 30 minutes between each repeat. To assess the presence 
of functional endothelium vessels were contracted to 0.1 µM phenylephrine 
(Phe) until a stable plateau was reached and then treated with 10 µM 
acetylcholine. Endothelium was deemed viable if a relaxation of at least 70% was 
observed in response to acetylcholine. Vessels were then washed at least 3 times 
in fresh Krebs buffer till the applied active tension was achieved and incubated 
for 30 minutes prior to beginning each experimental protocol. 
To assess the effects of Ang-(1-9) on vascular tone, vessels were first contracted 
to 0.1 µM Phe until a stable plateau was achieved. Cumulative concentration 
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response curves were then performed to Ang-(1-9) using a range of 
concentrations (1x10-10 M to 1x10-6 M). This concentration range was chosen 
based on previous experiments conducted in Prof. Robson Santos laboratory and 
published reports (Ocaranza et al., 2014). In experiments where antagonists 
were used, 1x10-6M A779 or PD123, 319 was added to the organ bath 5 minutes 
prior to the first stimulation with Ang-(1-9). Lab ChartTM 5 Pro software 
(ADInstruments, Chalgrove, UK) was used to record and measure all responses. 
Data were expressed as a percentage of relaxation of the Phe induced 
contraction. 
2.16 In vivo experimentation 
All animal experiments were performed in accordance with the Animals 
Scientific Procedure Act 1986 under the project license, 60/4114, held by Dr 
Simon Kennedy (University of Glasgow, UK) and the personal license, 60/12207. 
Mice were housed at the Central Research Facility at the University of Glasgow 
and maintained on 12 hour cycles of light and dark, at ambient temperature. 
Mice were fed a standard chow diet and water provided ab libitum. 
2.16.1 Mouse carotid artery injury model 
Prior to surgery, 8-10 week old male C57BL/6 mice (Harlan, Oxon, UK) received 
an intraperitoneal injection of the analgesic buprenorphine (0.1 mg/kg) and 2.5 
mg of the antiplatelet therapy dipyridamole (Persantin). Sterile saline (0.5 mL, 
subcutaneous injection) was administered to prevent dehydration during the 
surgical procedure. General anaesthesia was induced by 3% (v/v) isoflurane 
supplemented with oxygen (0.5 L/minute) and maintained at 1.5% (v/v) 
isoflurane via a face mask throughout the procedure. Depth of anaesthesia was 
monitored throughout the surgery by assessment of hind limb reflex. Carotid 
artery injury was performed following an adapted method described by Lindner 
et al (Lindner et al., 1993). An incision was made in the ventral side of the neck 
and blunt dissection of the muscle and connective tissue was performed to 
expose the left common carotid artery. The vagus nerve was detached from the 
artery and two silk ligatures (size 6.0, Fine Science Tools, Heidelberg, Germany) 
were positioned at the proximal and distal ends of the vessel. The distal ligature 
was tightly tied and an arterial clip (Fine Science Tools, Heidelberg, Germany) 
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was positioned at the most proximal end to temporarily occlude blood flow. A 
small incision was made in the artery and a piece of modified flexible nylon 
wire, adapted by melting the end to create a blunt spherical tip, was inserted 
into the incision site and held loosely in place by tightening of the proximal 
ligature. The arterial clip was removed and the wire was advanced, while 
rotating, down the carotid artery into the thoracic aorta. This was repeated 3 
times to ensure the removal of the endothelium. The nylon wire was removed, 
the artery clip reapplied and the proximal ligature was tied and secured just 
below the incision site. Sham operated mice were used as controls, these 
animals were subjected to the same procedure except the ligatures were not 
tied, only secured in place, and blood flow occluded for 5 minutes (the 
approximate time required to perform the wire injury) using the distal ligature 
and an artery clip at the proximal end. No incision was made in the artery and 
the wire was not inserted. The ligatures were removed prior to wound closure. A 
continuous line of subcutaneous sutures (size 5.0, Vircyl, Ethicon, Edinburgh, 
UK) was used to close the skin incision. For post-operative care the mice were 
transferred to a heating mat and maintained at 37oC overnight.  
2.16.2 Osmotic mini pump implantation 
Ang-(1-7) and Ang-(1-9), alone or alongside A779 or PD123,319 (Ang-(1-9) only) 
were delivered subcutaneously via osmotic mini pump (Model 2004, Alzet, CA, 
USA) and the effects on neointimal formation assessed. Mini pumps filled with 
water were implanted into control animals. Osmotic mini pumps operate due to 
a difference in osmotic pressure between a compartment within the pump 
known as the salt sleeve and the tissue where the pump has been implanted. 
The salt sleeve has a high molarity and this causes water to enter the pump via a 
semipermeable membrane which forms the outer surface of the pump. As the 
water enters the salt sleeve, it compresses the reservoir containing the peptide, 
causing it to be released at a controlled rate predetermined by the water 
permeability of the pumps outer membrane (Theeuwes and Yum, 1976).  
Osmotic mini pumps secreted Ang-(1-7), Ang-(1-9) and A779 at a concentration 
of 48 μg/kg/hour and PD123,319 at a concentration of 200 ng/kg/minute, at a 
rate of 0.25 μL/hour for 4 weeks following implantation. Minipumps were primed 
by incubation in an isotonic solution at 37oC for 48 hours to ensure immediate 
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delivery of the peptides following vascular injury. Prior to implantation, the 
prepared mini pumps were assigned a code by an independent researcher to 
blind the study. To implant mini pumps a small incision was made in the flank 
and a subcutaneous pocket created to allow insertion of the pump. The wound 
site was closed using a continuous line of sutures (size 5.0, Vircyl, Ethicon, 
Edinburgh, UK).  
2.16.3 Pluronic gel studies 
To assess the effectiveness of local delivery of Ang-(1-7) or Ang-(1-9), the 
peptides were applied directly to the carotid artery immediately following injury 
using Pluronic F127 gel (BASF, Ludwigshafen, Germany). Pluronic F127 is a 
copolymer that when dissolved in aqueous solution displays the unique 
characteristic of reverse thermal gelation, as at room temperature Pluronic F127 
solution is a viscous liquid which is transformed to a semisolid gel at body 
temperature (Schmolka, 1972).  Therapies can therefore be dissolved in the 
Pluronic F127 solution when aqueous then be delivered locally to the animal to 
form a gel based depot of the therapeutic at the site of administration. 
Pluronic F127 was made to 22% (w/v) in sterile PBS and stored at 4°C at a liquid 
state. Immediately before administration, peptides were added to the gel to 
create a solution of 2.5 µg/µL and kept on ice. Gel only was used as a control. 
Following completion of wire injury, 100 µL of the pluronic gel was applied to 
the carotid artery using a pipette. Once it was observed that the pluronic 
solution had changed from a liquid state to gel state the wound was closed as 
described in section 2.5.1.  
Prior to assessing therapeutic effects of local delivery of Ang-(1-7) or Ang-(1-9), 
a pilot study was performed to confirm delivery of the peptides to the vessels. 
To do this, 9 animals received either gel only, Ang-(1-7) or a custom made 
biotinylated Ang-(1-9) as described above. Three animals per group were 
sacrificed as described in section 2.16.4 at 7, 14 and 28 days following injury and 
peptide application.  Peptide delivery to the vessel was assessed via 
immunohistochemistry (IHC), using a specific antibody for Ang-(1-7) and 
streptavidin for the biotinylated Ang-(1-9) as described in sections 2.17.4 and 
2.17.4.2, respectively.  
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Following this a blinded study was performed to assess the effects of local 
delivery of Ang-(1-7) and Ang-(1-9) on neointimal formation with 8 animals per 
group. 
2.16.4 Termination of procedure and tissue harvesting 
Mice were sacrificed 28 days and transcardially perfused by gravity flow with 
0.9% saline to exsanguinate. To ensure that no damage was done to the wire 
injured vessels, mice were perfused at 120 mmHg to represent physiological 
conditions. This was achieved by placing the perfusate 1.63 m above the animal, 
based on the fact that 1 mmHg equals 13.6 mm H20. For perfusion, animals were 
firstly deeply anaethetised using 4-5% isoflurane supplemented with oxygen (0.5 
L/minute) via face mask. A vertical midline incision was made through the skin 
and peritoneal cavity to expose the rib cage and internal organs, which were 
moved to expose the femoral artery of the left leg. The diaphragm was incised 
and the heart exposed.  To begin perfusion, a butterfly needle (23 g) connected 
to the perfusate was inserted into the left ventricle and held in position using 
mosquito clips and the left femoral artery cut to allow the blood to drain from 
the animal. Once the perfusate ran clear the heart was excised to confirm 
termination of the procedure. Tissues and vessels were collected and stored in 
10% (v/v) formalin for 24 hours followed by transfer to 70% ethanol. 
2.17 Histology 
2.17.1 Tissue fixation 
Tissue samples were dehydrated through an ethanol gradient to xylene and 
finally to paraffin wax using the Shandon Excelsior tissue processor (Thermo 
Scientific, Leicestershire, UK) in the sequence outlined in Table 2.5. 
Following the tissue processing sequence, vessels were held vertically in biopsy 
cassettes and embedded in paraffin wax using a Shandon Histocenter 3 
(ThermoFisher Scientific, Leicestershire, UK). Paraffin blocks were cut at 4 µm 
using a Leica microtome (ThermoFisher Scientific, Leicestershire, UK) to expose 
transverse sections of the embedded vessel and transferred to a 45oC water bath 
where they were mounted onto slides and then baked overnight at 60oC. 
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Table 2.5- Tissue processing sequence for embedding tissues in paraffin 
 
Solution Incubation Period
70% Ethanol 30 min
95% Ethanol 30 min
100% Ethanol 30 min
100% Ethanol 30 min
100% Ethanol 45 min
100% Ethanol 45 min
100% Ethanol 60 min
Xylene 30 min
Xylene 30 min
Xylene 30 min
Paraffin wax 30 min
Paraffin wax 45 min
Paraffin wax 45 min
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2.17.2 Elastin staining 
Elastin van Gieson (EVG) staining was performed to visualize the elastic lamina 
and facilitate neointimal measurements. Briefly, paraffin was removed from the 
tissue sections by immersion in HistoClear (Fisher Scientific Ltd, Leicestershire, 
UK) for 10 minutes (changed to fresh HistoClear after 5 minutes) and rehydrated 
through an alcohol gradient of 100%, 95% and 70% ethanol for 5 minutes each 
and washed in distilled water for 5 minutes. Tissue sections were oxidized by 
incubation with 0.5% (w/v) potassium permanganate for 10 minutes, washed in 
running tap water for 3 minutes followed by rinsing in dH2O for 30 sec. Sections 
were decolourised by placing in 1% (w/v) oxalic acid for 10 minutes, running tap 
water for 2 minutes and dH2O for 30 sec. Next, sections were immersed in 70% 
ethanol, and incubated for 3 hours with Miller’s elastin stain (VWR Chemicals, 
Leicestershire, UK) which stains elastin fibres black. To remove excess stain 
from the slide, sections were washed by dipping 7 times in 70% ethanol then 
dH2O for 5 minutes. Sections were counterstained with Van Gieson solution (0.1% 
acid fuchsin in saturated picric acid), which stains collagen red and muscle and 
cytoplasm yellow, for 10 minutes. Slides were dried at 60oC for 30 minutes and 
then rinsed in 100% ethanol for 10 minutes (changed to fresh ethanol after 5 
minutes). Slides were immersed in HistoClear for 10 minutes (changed to fresh 
HistoClear after 5 minutes) before being mounted with glass cover slips using 
DPX non-aqueous mounting medium. Sections were photographed using QCapture 
Pro 6.0 software and analysed using Image-Pro® Analyser 7.0 software (Media 
Cybernetics, Marlow, UK).  
2.17.3 Picrosirius red staining 
Picrosirius red staining was performed in order to visualise the collagen content 
of the injured vessels. Tissue sections were deparaffinised and rehydrated as 
described in section 2.17.2 and then placed in distilled water for 5 minutes. 
Weigert’s Haematoxylin was prepared by mixing equal parts Solution A (1% (v/v) 
haematoxylin I ethanol) and Solution B (ferric chloride 1.2% (w/v) and 1% (v/v) 
hydrochloric acid) and used to stain the nuclei for 10 minutes at room 
temperature. Slides were washed in running tap water for 10 minutes and 
incubated in 0.1% picrosirius red solution (0.1% (w/v) Sirius red F3B in saturated 
picric acid) for 90 minutes under dark conditions at room temperature. Slides 
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were then washed in acidified water (0.01N HCL (v/v) in distilled water) twice 
for 5 minutes each wash. Any remaining moisture was removed by vigorous 
shaking and then slides were dehydrated through an alcohol gradient of 70%, 90% 
and 100% ethanol for 5 minutes each. Slides were then immersed in Histoclear 
for 5 minutes and mounted as described in section 2.17.3.  
2.17.4 Immunohistochemistry 
Tissue sections were deparaffinised and rehydrated as described in section 
2.17.2 and then washed in running tap water for 5 minutes. Following 
rehydration heat induced antigen retrieval was performed by incubating sections 
in boiling 10 mM sodium citrate buffer pH 6.0 for 20 minutes. Sections were 
cooled by incubation at room temperature for 30 minutes followed by immersion 
in running tap water for 10 minutes. To block endogenous peroxidase activity 
slides were incubated in 20% (v/v) H2O2 in methanol for 30 minutes. Slides were 
then washed twice, 5 minutes each, in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.4). To reduce non-specific background staining 
sections were blocked using 20% (v/v) of the appropriate serum (all Vector Labs, 
Peterborough, UK) (Table 2.6) in PBS for 30 minutes at room temperature in a 
humidified chamber. Sections were then incubated in a humidified chamber with 
the primary antibody or with an equal concentration of isotype matched IgG non 
immune control (for primary antibodies whose host species is rabbit, normal 
rabbit IgG (Invitrogen, product number 10500c) was used, and for antibodies 
whose host species is rat, normal rat IgG (Invitrogen, product number 10700) was 
used) diluted in 2% blocking serum for 1 hour at room temperature or 4ºC 
overnight (Table 2.6).  This was the case for all antibodies outlined in Table 2.6 
with the exception of the Ang-(1-7) antibody as the concentration of this 
antibody was not provided by the manufacturer; therefore the correct 
concentration of IgG could not be calculated. In place of an IgG control, sections 
were incubated with PBS. Following incubation with the primary antibody 
sections were washed three times, 5 minutes each, in PBS. Sections were then 
incubated with the appropriate biotinylated secondary antibody diluted in 2% 
blocking buffer for 1 hour at room temperature in a humidified chamber as 
outlined in Table 2.7. Sections were then washed three times, 5 minutes each, 
in PBS followed by incubation with 1:200 (v/v) ExtraVadin®-peroxidase (Sigma) 
to facilitate binding of avidin (contained within the ExtraAvadin®-peroxidase) to 
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the biotinylated secondary antibody. Sections were then washed three times, 5 
minutes each, in PBS and the antigen detected using 3, 3’-diaminobenzidine 
(DAB) chomagen (Vector Laboratories) which produces a brown precipitate in the 
presence of peroxidase enzyme. Sections were incubated with DAB for 2-5 
minutes and placed in distilled water to neutralise the reaction. The nuclei were 
then counterstained with Mayer’s haematoxylin for 1 minute. Slides were then 
washed in running water for 5 minutes and then dehydrated and mounted as 
described in section 2.17.2. Sections were photographed using QCapture Pro 6.0 
software and analysed using Image J software. 
2.17.4.1 α-SMA 
Detection of α-SMA was performed using the VECTASTAIN® Elite ABC Kit 
(Universal) (Vector Labs) according to manufacturer’s instructions. Sections were 
deparaffinised and rehydrated as described in section 2.17.2 and then washed in 
distilled water for 5 minutes. Endogenous peroxidase activity was quenched by 
incubating slides in 20% hydrogen peroxidase for 30 minutes at room 
temperature. The sections were then blocked for 1 hr at room temperature in a 
humidified chamber with 1% (v/v) blocking serum (normal horse serum) in PBS. 
The sections were then incubated with primary antibody (Table 2.6) or an equal 
concentration of isotype matched rabbit IgG non immune control (Invitrogen) 
diluted in PBS 2% normal horse serum, for 1 hour at room temperature in a 
humidified chamber. Sections were washed three times, 5 minutes each, to 
remove any residual unbound primary antibody. Biotinylated horse anti-rabbit 
secondary antibody diluted 1 in 50 in 2% blocking serum was incubated with 
sections for 30 minutes at room temperature. VECTASTAIN® Elite avidin 
biotinylated enzyme complex (ABC), which binds to the biotin of the secondary 
antibody, was prepared by adding 2 drops reagent A and 2 drops reagent B to 5 
mL PBS and incubated for 30 minutes. Sections were washed three times, 5 
minutes each, and then incubated with the ABC complex for 30 minutes at room 
temperature. DAB detection and counterstaining of nuclei was performed as 
described in section 2.17.4 and then tissue sections were rehydrated and 
mounted as described in sections 2.17.2. 
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2.17.4.2 Detection of biotinylated Ang-(1-9) 
A custom made biotinylated version of Ang-(1-9) was used to confirm delivery of 
the peptides to the vessel via Pluronic Gel. As the biotin was already bound to 
the peptide no primary or secondary antibodies were required to detect peptide 
expression. To visualise biotin-labelled Ang-(1-9) sections were first 
deparaffinised and rehydrated as described in section 2.16.2. Heat induced 
antigen retrieval and quenching of endogenous peroxidase was performed as 
described in section 2.16.4. Sections were then incubated with ExtrAvadin 
peroxidase, the peptide detected using DAB and nuclei counterstained as 
described in section 2.17.4. Finally, tissue sections were then rehydrated and 
mounted as described in section 2.17.2. 
2.18 Statistical analysis 
Data are shown as mean ± standard error of the mean (S.E.M) and qRT-PCR data 
expressed as RQ ± RQmax of experiments which were repeated on at least 3 
seperate occasions using cells isolated from different patient samples, unless 
otherwise stated. Within each experimental repeat, migration assays included 9 
technical replicates, proliferation assays included 5 technical replicates, and 
western immunoblotting included 2 technical replicates. For each experiment 
the mean of the technical replicates was calculated and this value was used to 
generate the mean and S.E.M of the biological replicates. Within each 
experimental repeat, qRT-PCR included 3 technical replicates. The mean dCT of 
the technical replicates was calculated for each experiment and this value was 
used to generate the RQ and RQmax of the biological replicates. 
A power calculation was performed to assess the required group size for the in 
vivo studies. Using data with analogous experimental protocols, 8 mice per group 
gives 80% power at 5% significance level to detect a difference in neointimal 
area of at least 7.2 x 103 µm2 assuming a within group standard deviation of 3.55 
x 103 µm2 (Zimmerman et al, 2004). Therefore, with the exception of 
optimisation of peptide delivery via Pluronic gel, all in vivo experiments were 
performed with 8 animals per group and studies were blinded in advance by an 
independent researcher.  
84 
 
Statistical analysis was performed using GraphPad Prism software (California, 
USA). Unpaired students t-test was used when comparing two experimental 
groups. When more than two groups were compared, one way ANOVA (analysis of 
variance) was performed with Tukeys post-hoc correction for multiple 
comparisons applied. In all cases a p value of <0.05 was accepted as statistical 
significance. 
  
85 
 
Table 2.6 List of primary antibodies used in immunohistochemistry 
 
Protein 
Host 
species 
Concentration Dilution 
Incubation 
Period 
Company 
(Catalogue 
number, clone 
ID) 
Blocking 
Serum 
α-SMA Rabbit 0. 2 mg/mL 1:75 
1 hr at room 
temperature 
Abcam 
(ab5694) 
Normal 
Horse 
CD31 Rat 0.2 mg/mL 1:20 
Overnight at 
4°C 
Dianova 
(DIA-310, 
SZ31) 
Normal 
rabbit 
MAC-2 Rat 1 mg/mL 1:5000 
Overnight at 
4°C 
Cedarlane 
(CL8942AP, 
M3/38) 
Normal 
rabbit 
PCNA Rabbit 0.2 mg/mL 1:200 
Overnight at 
4°C 
Abcam, 
(Ab2426) 
Normal 
goat 
Active 
caspase 
Rabbit 0.2 mg/mL 1:50 
Overnight at 
4°C 
Abcam 
(ab2302) 
Normal 
goat 
Ang-(1-7) Rabbit n/a 1:100 
1 hr at room 
temperature 
Phoenix 
(H-002-24) 
Normal 
goat 
 
 
Table 2.7Secondary antibodies used in immunohistochemistry 
 
Protein Secondary  Antibody Concentration Dilution 
Company(Catalogue 
number) 
α-SMA 
Biotinylated Universal 
Antibody Horse anti 
rabbit IgG 
1.05 mg/mL 1:50 
Vector Labs 
(BA-1400) 
CD31 
Biotinylated rabbit 
anti rat IgG 
1.5 mg/mL 1:200 
Vector Labs 
(BA-4001) 
MAC-2 
Biotinylated rabbit 
anti rat IgG 
1.5 mg/mL 1:200 
Vector Labs 
(BA-4001) 
PCNA 
Biotinylated goat anti 
rabbit IgG 
1.5 mg/mL 1:200 
Vector Labs 
(BA-1000) 
Active 
caspase 
Biotinylated goat anti 
rabbit IgG 
1.5 mg/mL 1:200 
Vector Labs 
(BA-1000) 
Ang-(1-7) 
Biotinylated goat anti 
rabbit IgG 
1.5 mg/mL 1:200 
Vector Labs 
(BA-1000) 
 
 
 
 
 
 
 
 
 
Chapter 3 
The effects of Ang-(1-7) and Ang-(1-9) on 
HSVSMC proliferation and migration 
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3.1 Introduction 
Within the vasculature, VSMC in the medial layer normally exist in a quiescent 
contractile state, responding to various vasoactive substances such as Ang II, 
endothelin-1 and NO to regulate vascular tone. However, during states of 
vascular disease or injury, medial VSMC undergo phenotypic switching from the 
quiescent state to a synthetic state (Campbell and Campbell, 1994). This occurs 
in response to numerous stimuli involved in the pathogenesis of vascular 
remodelling, including growth factors such as Ang II and PDGF and pro-
inflammatory cytokines such as IL-1, IL-6, and TNF-α (reviewed by (Schwartz et 
al., 1990, Touyz and Schiffrin, 2000, Ross, 1993). The synthetic VSMC largely 
contribute to the progression and development of atherosclerosis and neointimal 
formation following stent implantation and vein grafting due to their ability to 
migrate and proliferate more readily than their quiescent counterparts. 
Proliferation of synthetic VSMC occurs through a regulated series of cell-cycle 
events (Pardee, 1989, Sherr, 1994a, Elledge, 1996). Under normal conditions 
quiescent VSMC are maintained in G0. After vessel injury, VSMC enter a gap 
phase (G1) in the cell cycle, leading to the production of various factors 
necessary for DNA replication in the subsequent synthetic phase (S). After S 
phase, the cells enter another gap phase (G2), when proteins are synthesized for 
mitosis (M phase). Restriction points at the G1-to-S and G2-to-M junctions ensure 
orderly progression through the cell cycle (Pardee, 1989, Sherr, 1994a, Elledge, 
1996). Growth factors, such as Ang II, PDGF, and basic fibroblast growth factor 
(bFGF), stimulate cells to enter the cell cycle and propel them to reach the 
restriction point in the late G1 phase. Cell cycle progression from the G2 phase 
to the M phase does not require further growth factor stimulation. On binding to 
their respective cell surface tyrosine kinase receptors, growth factors trigger 
cell cycle entry by transactivating nuclear factors such as c-fos and c-myc (Marx 
et al., 2011). These nuclear factors act as transcriptional factors which 
coordinate the expression and activity of a range regulatory proteins, including 
cyclins and cyclin-dependent kinases (CDK) (Sherr et al., 1994). Cyclins and their 
respective CDK form distinct complexes and are positive regulators of cell cycle 
progression. For example, CDK phosphorylation of the retinoblastoma gene 
product (Rb) at the R point at G1-S junction is an important step in the 
progression through the cell cycle to enable Rb to bind and inactivate the 
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transcription factor E2F to maintaining the cell in a quiescent state (Sherr, 
1994b). Phosphorylation of Rb in late G1 releases E2F, which in turn enhances 
the expression of genes encoding regulatory proteins necessary for cell cycle 
progression through S, G2, and M phases (DeGregori et al., 1995).  
Similarly, the process of VSMC migration is well defined and has been reviewed 
extensively (Gerthoffer, 2007, Schwartz, 1997, Abedi and Zachary, 1995). In the 
non-injured vessel, VSMC are non-migratory because of a combination of several 
factors including the relative absence of stimulatory factors, their quiescence 
from a proliferative standpoint, and because the matrix is highly adhesive 
(Gerthoffer, 2007). There are many pro-migratory molecules, including peptide 
growth factors, [such as Ang II, bFGF, and PDGF (Sato et al., 1991, Grotendorst 
et al., 1981, Jackson et al., 1993, Bell and Madri, 1990)], cytokines (such as IL-
1β, IL-6 and TNF-α), and ECM components, [such as collagen, fibronectin and 
osteopontin (Sibinga et al., 1997, Nelson et al., 1996, Liaw et al., 1994)]. Blood 
flow, sheer stress, and matrix stiffness can also affect the migration of VSMC 
(Ward et al., 2001, Li et al., 2003, Peyton and Putnam, 2005). VSMC migration 
begins with the stimulation of cell surface receptors that activate signal 
transduction pathways, triggering remodelling of the cytoskeleton, changes in 
their adhesiveness to the matrix, and activation of the motor proteins 
(Gerthoffer, 2007). VSMC extend lamellipodia toward the stimulus through actin 
polymerization (Gerthoffer, 2007). Focal contacts form just behind the leading 
edge to increase adhesion of the cell membrane to the matrix, and degradation 
of these focal contacts at the trailing edge is necessary for release of the cell 
from the matrix and therefore cell migration. The actin cytoskeleton is 
regulated by numerous signalling pathways and molecules, including trimeric G 
proteins, small G proteins, lipid kinases, Ca2+-dependent kinases, Rho kinase, 
and MAPK (Gerthoffer, 2007, Graf et al., 1997, Noma et al., 2006).  
Ang II is a powerful mitogen and is known to play an important role in VSMC 
proliferation and migration in vascular remodelling. One of the most well 
documented pathways involved in Ang II mediated VSMC migration and 
proliferation is activation of MAPK signalling, partly due to the fact that Ang II 
activates the MAPK signalling pathway at various intracellular levels. For 
example, Ang II directly stimulates tyrosine and threonine phosphorylation of 
ERK1/2, JNK and p38 MAPK in cultured VSMC from rat, mouse, rabbit and human 
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(Schieffer et al., 1996, Epstein et al., 1997, Touyz et al., 1999a, Xu et al., 1996, 
Lee et al., 2007, Kyaw et al., 2004, Yang et al., 2005, Mugabe et al., 2010). 
Furthermore, Ang II stimulates phosphorylation of various signalling molecules 
upstream from ERK1/2 such as Ras, Raf, Shc, Src and Pyk2, and it increases 
activity of MEK kinase (Eguchi et al., 1996, Liao et al., 1996, Griendling et al., 
1997, Touyz et al., 1999d). Ang II has also been shown to promote VSMC 
proliferation and migration through expression of various early response genes 
such as c-fos, c-jun and c-myc (Naftilan et al., 1989b, Lyall et al., 1992). 
Expression of these early response genes leads to the production of growth 
factors including PDGF, EGF, TGF-β and bFGF that are involved in Ang II 
mediated-VSMC proliferation and migration [reviewed in (Touyz and Berry, 
2002)].  
In addition to activation of MAPK signalling, Ang II has also been demonstrated to 
promote VSMC migration through activation of the FAK-dependent signalling 
pathway (Leduc and Meloche, 1995). In VSMC, FAK associates with paxillin and 
talin, and both FAK and paxillin can bind to the cytoplasmic tail of integrins, key 
molecules involved in attachment of the cell to the ECM (Leduc and Meloche, 
1995, Chen et al., 1995). Ang II induced activation of FAK results in its 
translocation to sites of focal adhesion within the ECM and phosphorylation of 
paxillin and talin, resulting in VSMC migration (Leduc and Meloche, 1995, Chen 
et al., 1995). While the upstream signalling pathways involved in Ang II mediated 
FAK activation are unknown, it has been suggested that Rho GTPases may play 
an important role (Rozengurt, 1995, Aspenstrom, 1999). Another tyrosine kinase 
involved in Ang II mediated VSMC migration is Pyk2 (Murasawa et al., 1998). Ang 
II-mediated stimulation of the AT1R results in an increase in intracellular calcium 
concentration, which in turn activates c-Src, leading to activation of Pyk2, which 
then promotes increased ERK activity, a key process in both VSMC migration and 
proliferation (Murasawa et al., 1998, Eguchi et al., 1999).  
Ang-(1-7) signalling via Mas is widely accepted to oppose the effects of Ang II via 
the AT1R, and this is also the case in VSMC proliferation (Freeman et al., 1996, 
Tallant et al., 1999, Tallant and Clark, 2003, Zhang et al., 2010b). Ang-(1-7) has 
been shown to exert anti-proliferative effects in VSMC via two main pathways; 
the first being through inhibition of MAPK signalling pathways (Zhang et al., 
2010b, Tallant and Clark, 2003) and the second through release of prostaglandins 
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such as prostacyclin (PGI2), resulting in increased cAMP levels (Jaiswal et al., 
1993b). The first study to identify a direct anti-proliferative role of Ang-(1-7) 
reported inhibition of proliferation of rat aortic SMC induced by Ang II, FCS or 
PDGF (Freeman et al., 1996). This anti-proliferative effect was unaltered by 
antagonism of either the AT1R or AT2R and, in the absence of identification of 
Mas at the time, it was concluded that an unknown receptor was responsible 
(Freeman et al., 1996). These findings were confirmed in a later study however, 
it was also established that the effect of Ang-(1-7) was blocked by D-Ala7-Ang-
(1-7) (A779), now widely accepted to be a Mas antagonist, suggesting Ang-(1-7) 
inhibits VSMC proliferation via Mas (Tallant et al., 1999).  
Further studies provided a detailed outline of various signalling pathways 
involved in the anti-proliferative effects of Ang-(1-7) in rat VSMC (Tallant and 
Clark, 2003). First, Ang-(1-7) blocked Ang II- and PDGF-induced activation of 
ERK1/2 signalling (Tallant and Clark, 2003). Inhibition of ERK1/2 signalling has 
also been demonstrated to be important in the anti-proliferative effects of Ang-
(1-7) in response to Ang II in mouse VSMC (Zhang et al., 2010b). However, the 
upstream mechanisms of Ang-(1-7) mediated inhibition of ERK1/2 have still to be 
established.  
Ang-(1-7) has been demonstrated to stimulate PGI2 release from VSMC (Jaiswal 
et al., 1993a, Jaiswal et al., 1993b, Muthalif et al., 1998, Tallant and Clark, 
2003), a prostaglandin which is widely accepted to prevent VSMC proliferation 
(Uehara et al., 1988, Morisaki et al., 1988). The anti-proliferative effect of Ang-
(1-7) in response to Ang II and PDGF was blocked by indomethacin, a cyclo-
oxygenase (COX) inhibitor that blocks prostaglandin production, suggesting that 
COX mediated production of prostaglandins is an important signalling cascade 
involved in the anti-proliferative effects of Ang-(1-7) in VSMC (Tallant and Clark, 
2003, Muthalif et al., 1998). 
Furthermore, Ang-(1-7) has been demonstrated to increase the VSMC content of 
cAMP to block serum-induced VSMC proliferation, an effect blocked by Rp-
cAMPS, an inhibitor of the cAMP-dependent protein kinase (Tallant and Clark, 
2003). Activated PGI2 receptors on VSMC stimulate adenylate cyclase to increase 
intracellular cAMP levels (Garg and Hassid, 1989), and as Ang-(1-7) results in an 
increase in both PGI2 and intracellular cAMP it is possible that these two 
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signalling events are part of the same pathway. For example, Ang-(1-7) 
mediated upregulation of PGI2 leads to activation of PGI2 receptors and thereby 
increased production of cAMP (Tallant and Clark, 2003). 
In comparison to its effects on VSMC proliferation, there is less known about the 
effects of Ang-(1-7) in VSMC migration and the signalling mechanisms involved. 
An anti-migratory effect for Ang-(1-7) has been demonstrated in rat aortic VSMC, 
where Ang-(1-7) directly inhibits Ang-II induced VSMC migration (Zhang et al., 
2010b). Through the use of the pharmacological antagonists losartan and A779, 
which block the AT1R and Mas, respectively, it was confirmed that the anti-
migratory effects of Ang-(1-7) were mediated via Mas (Zhang et al., 2010b). 
Furthermore, it was shown that Ang-(1-7) inhibits Ang II induced ERK1/2 
phosphorylation, providing evidence of a potential signalling pathway involved in 
the effects of Ang-(1-7) in VSMC migration (Zhang et al., 2010b).  
Comparatively, there is little known about the role of Ang-(1-9) in the vascular 
function or remodelling. Ang-(1-9) has been reported to signal via the AT2R, and 
while the signalling mechanisms employed by this receptor are currently poorly 
defined, the AT2R has been linked to reduced VSMC proliferation in vitro. For 
example, adenoviral-mediated over expression of the AT2R in rat VSMC resulted 
in a reduction in Ang II mediated VSMC proliferation via the AT1R, an effect 
which was linked to reduced MAPK activity (Nakajima et al., 1995, Stoll et al., 
1995). While further work is required to assess the Ang-(1-9)/AT2R interaction, 
these findings indicate that the AT2R may oppose the effects of Ang II in the 
VSMC. 
3.1.1 The role of microRNAs in Ang II-induced VSMC proliferation 
and migration 
In recent years it has also been suggested that Ang II may mediate a number of 
effects in the cardiovascular system through changes in expression levels of 
microRNAs (miRNA) (Zhu et al., 2011, Jin et al., 2012, Eskildsen et al., 2013). 
miRNAs are small non-coding RNA molecules 20~22 nucleotides in length that 
target the 3′-untranslated region (UTR) of mRNA to negatively regulate gene 
expression through inhibition of mRNA translation and/or mRNA degradation (van 
Rooij and Olson, 2007, Bartel, 2009). miRNA biosynthesis and maturation begins 
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with transcription of the primary miRNA (pri-miRNA) by RNA polymerase II (van 
Rooij and Olson, 2007). The pri-miRNA is then processed by the Rnase III enzyme 
Drosha to form the precursor miRNA (pre-miRNA), a ~60-nucleotide stem loop 
molecule (van Rooij and Olson, 2007, Bartel, 2009). Pre-miRNAs are then 
transported from the cell nucleus to the cytoplasm via exportin5, and once in 
the cytoplasm they are cleaved by the endonuclease DICER to produce a miRNA 
duplex (van Rooij and Olson, 2007, Bartel, 2009). This duplex is then bound to 
argonaute 2 (Ago 2) and the mature miRNA formed (Meister et al., 2004, Liu et 
al., 2004b). The mature miRNA is then incorporated into the RNA-induced 
silencing complex (RISC) leading to interaction with target mRNAs, resulting in 
regulation of a number of genes under a diverse range of patho/physiological 
conditions (Bartel, 2009). Importantly, various miRNAs have been implicated in 
the pathogenesis of vascular disease (Robinson and Baker, 2012). For example, 
miR-143 and miR-145 have been demonstrated to regulate VSMC differentiation 
and contractility and have been linked to reduced neointimal formation 
following vascular injury (Cordes et al., 2009, Boettger et al., 2009). 
Furthermore, miR-21 plays an important role in vascular remodelling and has 
been demonstrated to be elevated in human, pig and mouse models of vein graft 
failure (McDonald et al., 2013). Additionally, miR-133 has been shown to 
negatively regulate VSMC proliferation both in vitro and in vivo (Torella et al., 
2011).  
Recently, a role for miRNAs in vascular Ang II signalling has been identified. 
Through the use of small RNA deep sequencing it was demonstrated that Ang II 
stimulation of rat aortic VSMC led to increased expression of miR-132 and miR-
212 in a time and concentration dependent manner via the AT1R (Jin et al., 
2012). miR-132 and miR-212 have been shown to exist in a ‘cluster’, 
characterised by their close proximity to each other in the genome and the fact 
that they are transcribed together under the regulation of cAMP response 
element binding protein (CREB), a protein which is itself regulated by Ang II 
(Neyses et al., 1993, Jeppesen et al., 2011).The miR-132/-212 cluster has 
additionally been shown to be important in the development of blood vessels, 
mammary glands and neurons (Anand et al., 2010, Ucar et al., 2010, Wanet et 
al., 2012). Through the use of various target prediction software packages it was 
revealed that a number of predicted targets of Ang II-regulated miRNAs within 
93 
 
rat aortic VSMC were involved in proliferation and migration, including 
phosphatase and tensin homologue (PTEN), MCP-1, p120 Ras GTPase-activating 
protein 1(RASA1) (Jin et al., 2012). These targets were validated by Jin et al in 
the rat VSMC and it was found that Ang II mediated increase in mirR-132/-212 
resulted in decreased expression in PTEN and RASA1, leading to an increase in 
MCP-1 and phosphorylation of CREB, respectively (Jin et al., 2012). PTEN is a 
lipid and protein phosphatase which primarily acts to dephosphorylate 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), thereby inhibiting the actions of 
PI3K (Carracedo and Pandolfi, 2008). This second messenger is important for Akt 
activation, which promotes cell survival and growth, therefore PTEN activity 
reduces activation of this pathway leading to reduced cell proliferation (Huang 
and Kontos, 2002). Overexpression of PTEN has previously been reported to 
prevent proliferation and migration of VSMC (Huang and Kontos, 2002). MCP-1 is 
a pro-inflammatory cytokine with a key role in the progression and development 
of atherosclerosis, largely through promoting migration of sub-endothelial 
monocytes to the vessel wall and VSMC migration from the media to the 
neointima (Nelken et al., 1991, Yu et al., 1992, Sung et al., 2001).  MCP-1 has 
also been demonstrated to induce proliferation and migration of both human and 
rabbit VSMC (Viedt et al., 2002, Ma et al., 2007). RASA1 functions to increase 
the GTPase activity of Ras, which is active when guanosine triphosphate (GTP) is 
bound, resulting in reduced activity of Ras and inhibition of various downstream 
signal transduction pathways that have been reported to promote VSMC 
migration and proliferation, including MAPK signalling (Pamonsinlapatham et al., 
2009).  
Furthermore, in Ang II-induced hypertension in the rat, miR-132 and miR-212 
were upregulated in the heart, aorta and kidney in an AT1R dependent manner 
(Eskildsen et al., 2013). Additionally, miR-132 and miR-212 expression has been 
reported to be reduced in mammary arteries from patients who have undergone 
coronary artery bypass surgery and treated with AT1R antagonists (Eskildsen et 
al., 2013).  
In comparison to Ang II, there is very little known about the counter-regulatory 
axis of the RAS and regulation of miRNAs, and a role for Ang-(1-9) in particular 
has yet to be identified. Ang-(1-7) has been demonstrated to exert protective 
effects in vascular endothelial cells through interaction with miR-146a (Wang et 
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al., 2013). The presence of plasma glycated albumin has been associated with 
vascular dysfunction in diabetes, partly through increased IL-6 expression on 
endothelial cells (Lu et al., 2009). In human coronary artery endothelial cells, 
Ang-(1-7) blocked glycated albumin-stimulated miR-146a down-regulation and 
the resultant increase in IL-6 expression, identifying a novel protective 
mechanism for Ang-(1-7) in diabetes (Wang et al., 2013).  
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3.2 Aims 
The aims of this chapter were: 
 To establish the optimal conditions for proliferation of HSVSMC and assess 
the effect of Ang II, Ang-(1-7) and Ang-(1-9), and the involvement of the 
AT1R, AT2R and Mas, in this setting. 
 To assess the effect of Ang II, Ang-(1-7) and Ang-(1-9), and the 
involvement of the AT1R, AT2R and Mas, on HSVSMC migration. 
 To investigate the mechanisms involved in Ang-(1-7) and Ang-(1-9)-
mediated inhibition of Ang II-induced migration. 
 To assess the involvement of Ang II mediated regulation of microRNA-
132/-212 in HSVSMC migration. 
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3.3 Results 
3.3.1 AT1R, AT2R and Mas expression in primary HSVSMC 
Prior to investigating the effects of Ang II, Ang-(1-7) and Ang-(1-9) in HSVSMC, it 
was first confirmed that the AT1R, AT2R and Mas were expressed in HSVSMC via 
qRT-PCR (Figure 3.1 A). Results were expressed as the average delta Ct (dCt) ± 
S.E.M, relative to the endogenous housekeeping gene GAPDH, therefore a 
smaller dCt value was indicative of increased expression. The AT1R was the most 
highly expressed in HSVSMC (dCt 8.6 ± 0.6), followed by Mas (dCt 9.15 ± 0.4) and 
then the AT2R (dCt 10.6 ±0.4). 
Next, it was established whether angiotensin peptides alter receptor expression 
as this may contribute any functional effect observed downstream. Stimulation 
of HSVSMC with Ang II, Ang-(1-7) or Ang-(1-9), alone or in combination, had no 
effect on AT1R, AT2R or Mas expression in comparison to unstimulated control 
HSVSMC (Figure 3.1 B-D), suggesting that the effects of the peptides in HSVSMC 
in this study were not due to alterations in receptor expression levels. 
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Figure 3.1 Expression of AT1R, AT2R and Mas in HSVSMC 
Expression levels of AT1R, AT2R and Mas in HSVSMC was assessed via qRT-PCR using specific 
Taqman probes for each receptor. (A) Receptor expression was confirmed in unstimulated 
HSVSMC and results are expressed as average dCt ±S.E.M, relative to the endogenous 
housekeeping gene GAPDH. The effect of the RAS peptides on (B) AT1R, (C), AT2R and (D) Mas 
was also assessed and results are expressed as RQ to unstimulated control cells. N=3.  
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3.3.2 Assessing the effects of Ang II, Ang-(1-7) and Ang-(1-9) on 
HSVSMC proliferation 
To establish the optimal conditions for HSVSMC proliferation, cells were 
quiesced for 48 hours to arrest them in the resting phase of the cell cycle (Go) 
and then exposed to fresh media containing increasing concentrations of FCS 
(from 0 to 20 % v/v) for 48 hours. HSVSMC proliferation was then assessed using a 
MTS assay. FCS induced HSVSMC proliferation in a concentration dependent 
manner, with concentrations of 5% FCS and above producing a significant 
increase in proliferation in comparison to unstimulated, serum free control cells 
(P<0.05) (Figure 3.2 A). For subsequent proliferation experiments 5% FCS was 
used to induce cell proliferation as this concentration significantly increased 
HSVSMC growth in comparison to control cells without causing over-growth 
within the well. 
To assess whether Ang-(1-7) or Ang-(1-9) blocked HSVSMC proliferation, 
quiescent cells were co-incubated with either Ang-(1-7) or Ang-(1-9) (both 200 
nM) and 5% FCS for 48 hours. As expected, 5% FCS caused a significant increase 
in HSVSMC proliferation in comparison to control cells (Figure 3.2 B). 
Interestingly, Ang-(1-7) and Ang-(1-9) significantly blocked 5% FCS induced 
HSVSMC proliferation to similar levels as control, unstimulated cells (P<0.05 vs. 
5% FCS).  
To investigate if Ang II, Ang-(1-7) or Ang-(1-9) stimulation alone were able to 
induce quiescent HSVSMC to proliferate, each peptide was added individually to 
quiescent HSVSMC in serum free media for 48 hours and then cell proliferation 
assessed. While 5% FCS induced a significant increase in cell proliferation in 
comparison to control cells (P<0.05), no significant difference was observed 
between control cells and cells stimulated with either Ang II, Ang-(1-7) or Ang-
(1-9) (Figure 3.2 C). 
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Figure 3.2 Assessment of the effects of Ang II, Ang-(1-7) and Ang-(1-9) on HSVSMC 
proliferation 
Proliferation of HSVSMC was assessed using the MTS assay. (A)To assess the concentration of 
FCS required to stimulated proliferation, HSVSMC were exposed to media containing increasing 
concentrations of FCS for 48 hours. (B) HSVSMC were incubated with Ang-(1-7) or Ang-(1-9) (200 
nM) and stimulated with 5% FCS for 48 hours to assess the effect of these peptides on 
proliferation. (C) To assess if Ang II, Ang-(1-7) or Ang-(1-9) (200 nM) induce proliferation of 
HSVSMC in the absence of serum, cells were exposed to the peptides in serum free media for 48 
hours; 5% FCS was used as a positive control. N=6. *P<0.05, **P<0.01 vs. control. 
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As both Ang-(1-7) and Ang-(1-9) were found to inhibit serum induced 
proliferation, next the involvement of the AT1R, AT2R and Mas was assessed. 
Cells were incubated with the pharmacological antagonists losartan, PD123,319 
or A779, which block the AT1R, AT2R and Mas, respectively, for 15 minutes prior 
to incubation with either Ang-(1-7) or Ang-(1-9). Cells were then stimulated with 
5% FCS and proliferation assessed at 48 hours. As expected, 5% FCS caused a 
significant increase in HSVSMC proliferation in comparison to control non 
stimulated cells (P<0.05) (Figure 3.3). However, neither losartan, A779 nor 
PD123,319 had any effect on basal non-serum stimulated HSVSMC proliferation 
(P>0.05 vs. control) (Figure 3.3 A).  
Next, the receptor through which Ang-(1-9) elicits its effects was assessed. As 
expected, Ang-(1-9) significantly reduced 5% FCS induced HSVSMC proliferation 
to similar levels as control (Figure 3.3 B). Importantly, this anti-proliferative 
effect was not altered by pre-incubation with losartan or A779 (P>0.05 vs. Ang-
(1-9) + 5% FCS), but was blocked by PD123,319 (P<0.05 vs. Ang-(1-9) + 5% FCS) 
(Figure 3.3 B), suggesting that in this setting Ang-(1-9) acts via the AT2R. Ang-(1-
7) significantly reduced 5% FCS induced HSVSMC proliferation, resulting in a 
similar level of proliferation as control cells (Figure 3.3 C). This anti-
proliferative effect was un-altered by pre-incubation with losartan or PD123,319 
(P>0.05 vs. Ang-(1-7) + 5% FCS), but was inhibited by A779 (P<0.05 vs. Ang-(1-7) 
+ 5% FCS), indicating that Ang-(1-7) acts via Mas (Figure 3.3 C). 
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Figure 3.3 The role of AT1R, AT2R and Mas in the anti-proliferative effects of Ang-(1-9) and 
Ang-(1-7) in HSVSMC.  
HSVSMC proliferation was assessed at 48 hours post stimulation with 5% FCS using the MTS 
assay. To assess the role of the RAS receptors in HSVSMC proliferation, cells were incubated with 
the pharmacological antagonists losartan (10µM), PD123,319 (500 nM) or A779 (100 µM) for 15 
minutes prior to stimulation with Ang-(1-9) or Ang-(1-7) (200nM), and then 5% FCS . (A) It was first 
established if the antagonists influence HSVSMC proliferation. The effect of losartan, PD123,319 
and A779 on the anti-proliferate effects of (B) Ang-(1-9) and (C) Ang-(1-7) was then assessed. All 
experimental conditions were included in replicate experiments and data has been separated into 3 
panels due to the large number of groups; therefore, the values for control and 5% FCS are the 
same in all three panels. N=3. *P<0.05, **P<0.01 vs control; 
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3.3.3 Assessing the effects of Ang II, Ang-(1-7) and Ang-(1-9) in 
HSVSMC migration.  
As VSMC migration is also largely involved in vascular remodelling, the effect of 
the RAS peptides on HSVSMC migration was assessed using a scratch assay. A 
confluent monolayer of cells was generated and then quiesced in serum free 
media for 48 hours. A wound in the cell monolayer was created with a pipette 
tip and cells were stimulated, in serum free media, with Ang II, Ang-(1-7) or 
Ang-(1-9) alone or in combination (200 nM each peptide). As a positive control 
for migration, cells were exposed to complete cell culture media containing 15% 
FCS for the duration of the experiment. Images of the scratches were taken at 
various time points, up to 30 hours so as to avoid induction of proliferation at 
later time points, and the reduction in scratch size was measured over time as a 
measure of cell migration (Figure 3.4 A).  
Migration of HSVSMC over the full time course was quantified as a percentage 
reduction in scratch width at each time point relative to the 0 hours 
measurements (Figure 3.4 B). There was an increase in control cell migration 
over time resulting in a 53.2 ± 4.7% reduction in scratch size by 30 hours. In 
serum stimulated cells, 15% FCS induced a significant increase in HSVSMC 
migration in comparison to control cells at each time point measured and by 24 
hours the wound had completely closed (P<0.01 vs. control) (Figure 3.4 B). 
Similarly, Ang II (200nM) induced a significant increase in VSMC migration from 
12 hours post scratch in comparison to control cells and at each time point 
thereafter (P<0.01); by 24 hours the wound had closed (98.23 ± 1.2% reduction in 
scratch size) (Figure 3.4 B). Ang-(1-9) and Ang-(1-7) (200nM) resulted in an 
increase in migration of HSVSMC over time at a rate similar to control cells and 
resulted in a 52.3 ± 3.5% and 53.2 ± 5.3% reduction in scratch size by 30 hours, 
respectively (Figure 3.4 B). Ang-(1-9) and Ang-(1-7) both significantly inhibited 
Ang II-induced HSVSMC migration, producing similar levels of migration as 
control cells, resulting in a 51.4 ± 4.7% and 49.6 ± 5.5% reduction in scratch size, 
respectively (P>0.05 vs control) (Figure 3.4 B). 
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Figure 3.4 The effect of Ang II, Ang-(1-7) and Ang-(1-9) on HSVSMC migration. 
HSVSMC migration was assessed using a scratch assay. Following a 48 hours quiescent period in serum free media, 3 scratches were induced in the cell monolayer 
in each well. Cells were stimulated with Ang II, Ang-(1-9) or Ang-(1-7) (200nM) alone or in combination in serum free media. Cells stimulated with 15% FCS were used 
as a positive control. Images of the scratch were taken at 0, 6, 12, 24 and 30 hours post scratch and the reduction in scratch size measured over time, as indicated by 
the red arrows. (A) Representative images of scratch at 0 hour and 24 hours. Scale bar = 40 µm. Magnification x10; (B) Migration was quantified as a reduction in 
scratch size (%) relative to 0 hour measurement. N=5.  **P<0.01 vs. control. 
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Based on the finding that Ang-(1-7) and Ang-(1-9) block Ang II induced HSVSMC 
migration, a subsequent set of experiments was performed to investigate the 
involvement of the AT1R, AT2R and Mas. HSVSMC were incubated with losartan 
(10 µM), PD123,319 (500 nM) or A779 (100 µM) for 15 minutes prior to incubation 
with either Ang-(1-7) or Ang-(1-9). Migration was assessed at 24 hours post-
stimulation (Figure 3.5) 
First, it was established if the antagonists themselves had an effect on HSVSMC 
migration by incubating the cells with each antagonist in serum free media. 
While 15% FCS resulted in wound closure at 24 hours (P<0.01 vs control), it was 
found that neither losartan, A779 nor PD123,319 had any effect on HSVSMC 
migration in comparison to control cells (P>0.05 vs. control) (Figure 3.5 A).  
Next the receptor through which Ang II induced migration occurs was assessed. 
Ang II caused a significant increase in HSVSMC migration at 24 hours in 
comparison to control cells (93.8 ± 8.0% vs. 52.8 ± 9.0% migration; P<0.05) which 
was significantly inhibited by losartan (53.3 ± 9.9% migration; P<0.05 vs. Ang II) 
but not PD123, 319 (92.4 ± 10.1% migration) nor A779 (93.2 ± 6.3% migration), 
indicating that Ang II induced migration is achieved via activation of the AT1R 
(Figure 3.5 B).  
As before, Ang–(1-9) significantly inhibited Ang II induced migration to similar 
levels as control cells (47.7 ± 8.9% migration; P<0.05 vs. Ang II) (Figure 3.5 C). 
While losartan and A779 did not alter the anti-migratory effect of Ang-(1-9) 
(52.7 ± 8.1% and 45.4 ± 12.7% migration respectively), PD123,319 blocked the 
inhibitory effects of Ang-(1-9), resulting in near complete wound closure (89.4 ± 
9.3% migration), indicating that Ang-(1-9) mediated inhibition of Ang II-induced 
HSVSMC migration is via the AT2R (Figure 3.5 C).  
Similarly, Ang-(1-7) significantly inhibited Ang II-induced migration to an 
equivalent level to control cells (53.6 ± 10.1% migration; P<0.05 vs. Ang II) 
(Figure 3.5 D). However, the receptor through which Ang-(1-7) acts was found to 
be different to Ang-(1-9) as A779 blocked the anti-migratory effects of Ang-(1-7), 
resulting in near complete wound closure (92.6 ± 5.3% migration), while losartan 
and PD123,319 had no effect (43.4 ± 10.1% and 44.2 ± 9.6% migration 
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respectively), indicating that Ang-(1-7) mediated inhibition of Ang II induced 
HSVSMC migration is via the Mas receptor (Figure 3.5 D). 
 
Figure 3.5 The role of the AT1R, AT2R and Mas in the effects of Ang II, Ang-(1-7) and Ang-(1-
9) on HSVSMC migration 
HSVSMC migration was assessed using a scratch assay. To assess the role of the RAS receptors 
in HSVSMC migration, cells were incubated with the pharmacological antagonists losartan (10µM), 
PD123,319 (500 nM) or A779 (100 µM) for 15 minutes prior to stimulation with Ang-(1-9) or Ang-(1-
7) (200nM). Cells stimulated with 15% FCS were used as a positive control. Images of the scratch 
were taken at 0 and 24 hours post stimulation and migration was quantified as a reduction in 
scratch size (%) relative to 0 hour measurement.  (A) It was first established if the antagonists 
influence HSVSMC migration. The effect of losartan, PD123,319 and A779 on the effects mediated 
by (B) Ang II, (C) Ang-(1-7) and (D) Ang-(1-9) was then assessed. All experimental conditions were 
included in replicate experiments and data has been separated into 4 panels due to the large 
number of groups. N=3. *P<0.05, **P<0.01 vs. control; 
†
P<0.05 vs. Ang II.  
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HSVSMC migration was also assessed using the xCELLigence system to allow for 
real time, automated analysis of migration, and corroboration of the results 
obtained using a traditional scratch assay. HSVSMC were seeded in specialised 
micro-titre plates (E-plates), allowed to adhere to the electrodes and establish a 
confluent monolayer overnight, and then quiesced for 48 hours. A scratch was 
induced in the cell monolayer causing a rapid drop in CI due to the reduced 
electrode coverage and cell migration measured as a change in CI due to 
movement of cells to the wounded area. Cells were stimulated with Ang II alone 
or in combination with Ang-(1-7) or Ang-(1-9) and cells in serum free media 
alone or complete growth medium (15% FCS) were used as control samples. CI 
was normalised at the time of stimulation with Ang II and is expressed relative to 
control cells; this time will hereafter be referred to as 0 hour. 
CI of unstimulated control cells remained constant until 8 hours post stimulation 
and then gradually reduced at a steady rate; however, this reduction in CI is 
minimal and may represent a small degree of cell movement over the 
electrodes. Following stimulation with Ang II or 15% FCS there was an initial 
increase in CI followed by a small dip, then a gradual, steady increase in CI over 
time, indicative of increased cell migration (Figure 3.6 A). Cells exposed to Ang-
(1-7) or Ang-(1-9) prior to stimulation with Ang II produced a similar level and 
pattern of migration to control cells, however, the reduction in CI from 8 hours 
post stimulation was less than that in control cells under these conditions (Figure 
3.6 A). 
The data was quantified as a fold change in normalised CI relative to control 
cells at 24 hours. A significant increase in CI in comparison to control cells was 
observed following stimulation with Ang II (1.9 ± 0.1 fold change in CI) or 15% 
FCS (2.0 ± 0.1 fold change in CI) (P<0.001 vs. control), indicative of enhanced 
HSVSMC migration (Figure 3.6 B). Ang II induced increased CI was significantly 
inhibited by Ang-(1-7) and Ang-(1-9), where a fold change in CI of 1.1 ± 0.1 and 
1.0 ± 0.1 was observed, respectively (Figure 3.6 B).  
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Figure 3.6 Analysis of the effects of Ang II, Ang-(1-7) and Ang-(1-9) on HSVSMC migration 
using the xCELLigence system 
HSVSMC migration was assessed in real time using the xCELLigence system. A scratch assay 
was performed as described in Section 2.5.1. Cells pretreated with Ang-(1-7) or Ang-(1-9) for 30 
minutes prior to stimulation with Ang II (all peptides 200nM). (A) Representative CI trace. Cell index 
(CI) was normalised to control following addition of Ang II and changes in CI monitored over time. 
(B) Migration was quantified as a fold change in normalised CI at 24 hours relative to control. N=3. 
***P<0.01 vs control, 
###
P<0.001 vs Ang II. 
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As in the traditional scratch assay, the involvement of the AT1R, AT2R and Mas in 
HSVSMC migration was also assessed using the xCELLigence system. The scratch 
assay was performed and analysed as described above, except cells were 
incubated with losartan (10 µM), PD123,319 (500 nM) or A779 (100 µM) for 15 
minutes prior to incubation with either Ang-(1-7) or Ang-(1-9).  
The findings from the scratch assay performed on the xCELLigence system were 
in line with the findings from the traditional scratch assay. While 15% FCS 
resulted in increased HSVSMC migration (P<0.001 vs. Control), stimulation of 
cells with losartan, PD123,319 or A779 resulted in a similar pattern and level of 
migration as control cells (losartan 1.0 ± 0.1; PD123,319 1.0 ± 0.1; A779 1.0 ± 
0.1 fold change in CI; P>0.05 vs. control) (Figure 3.7 A). 
Ang II caused a significant increase CI in comparison to control (2.0 ± 0.1 fold 
change in CI; P<0.001 vs. control) and this was significantly inhibited by Ang-(1-
9) (1.30 ± 0.02 fold change in CI; P<0.001 vs. Ang II) (Figure 3.7 B). The effects 
of Ang-(1-9) were unaltered by A779 [1.2 ± 0.1 fold change in CI; P>0.05 vs. Ang 
II + Ang-(1-9)] (Figure 3.7 B). The effects of Ang-(1-9) were blocked by 
PD123,319, resulting in a similar pattern and level of migration as cells 
stimulated with Ang II (1.8 ± 0.1 fold change in CI; P>0.05 vs. Ang II) (Figure 3.7 
B). Together, these findings confirm that Ang-(1-9) acts via the AT2R and not Mas 
to prevent Ang II induced HSVSMC migration.  
Conversely, while Ang-(1-7) significantly inhibited the Ang II induced increase in 
CI (2.0 ± 0.1 vs. 1.1 ± 0.1 fold change in CI; P<0.001 vs. Ang II) its effects were 
unaltered by PD123,319 [1.20 ± 0.1 fold change in CI; P>0.05 vs. Ang II + Ang-(1-
7)] but effectively blocked by A779, resulting in a similar pattern and level of 
migration as cells stimulated with Ang II alone (1.9 ± 0.1 fold change in CI; 
P>0.05 vs Ang II) (Figure 3.7 C). Together these findings corroborated those from 
the traditional scratch assay and demonstrated that Ang-(1-7) acts via Mas to 
block Ang II-induced HSVSMC migration. 
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Figure 3.7 Analysis of the role of the AT1R, AT2R and Mas in the effects of Ang II, Ang-(1-9) 
and Ang-(1-7) on HSVSMC migration using the xCELLigence system. 
HSVSMC migration was assessed in real time using the xCELLigence system. A scratch assay 
was performed as described in Section 2.5.1. To assess the role of the RAS receptors in HSVSMC 
migration cells were incubated with losartan (10 µM), PD123.319 (500 nM) or A779 (100 µM) for 15 
minutes prior to stimulation with Ang-(1-7) or Ang-(1-9) (200 nM). Cells were then stimulated with 
Ang II 30 minutes later (200nM). Representative traces of CI measurements over time. Migration 
was quantified as a fold change in normalised CI at 24 hours relative to control. All experimental 
conditions were included in replicate experiments and data has been separated into 3 panels due 
to the large number of groups; therefore, the values for control and Ang II are the same in all 
panels. N=3.  ***P<0.001 vs control; 
###
P<0.001 vs. Ang II. 
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3.3.4 Assessment of mechanisms involved in Ang-(1-7) and Ang-
(1-9) inhibition of Ang II induced HSVSMC migration 
In the current data set Ang-(1-7) and Ang-(1-9) have been demonstrated to 
prevent both HSVSMC proliferation and migration in response to FCS and Ang II, 
respectively. As one of the main aims of this thesis is to investigate the 
interaction of Ang II and the counter-regulatory peptides Ang-(1-7) and Ang-(1-9) 
in HSVSMC, it was decided that a more detailed assessment of the mechanisms 
involved in the effects of these peptides in HSVSMC migration would be 
performed, as there is clear modulation of the effects of Ang II by Ang-(1-7) and 
Ang-(1-9) in this setting. 
3.3.4.1 Effect of Ang II, Ang-(1-7) and Ang-(1-9) on ERK phosphorylation in 
HSVSMC 
Ang II via the AT1R activates a number of intracellular signal transduction 
pathways that are linked to long term regulation of VSMC function, such as cell 
growth and migration (reviewed by [(Touyz and Schiffrin, 2000)]). These 
processes are initiated within minutes and involve phosphorylation of a number 
of protein kinases, including MAPK, such as ERK1/2, JNK and p38 MAPK (Xi et al., 
1999, Ohtsu et al., 2005, Lee et al., 2007). Ang II mediated phosphorylation of 
ERK1/2 in particular has been demonstrated to be an important mechanism 
involved in VSMC growth and migration (Xi et al., 1999, Ohtsu et al., 2005, Jiang 
et al., 2008, Shen et al., 2014) and importantly Ang-(1-7) has been 
demonstrated to prevent Ang II induced migration of rat VSMC via inhibition of 
Ang II-mediated phosphorylation of ERK1/2 (Zhang et al., 2010b). However, as a 
role for Ang-(1-7) has yet to be defined in human VSMC migration and the effects 
of Ang-(1-9) on VSMC migration has yet to be explored it was first assessed if 
these peptides block Ang II induced HSVSMC migration through interaction with 
the ERK1/2 pathway.  
To investigate ERK1/2 phosphorylation, quiescent HSVSMC were stimulated with 
Ang II, Ang-(1-7) or Ang-(1-9), alone or in combination (all peptides 200nM) for 5, 
30 or 60 minutes; these time points were chosen as Ang II mediated ERK1/2 
phosphorylation has been demonstrated to be transient, with a peak at 5 
minutes (Eguchi et al., 1996, Touyz et al., 1999b). For ERK1/2, two bands were 
predicted at 42 and 44 kilodalton (kDa) and for GAPDH 1 band of 37kDa. 
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However, on the 30 minutes GAPDH representative blots 3 bands were present; 
this is due to residual detection of ERK1/2 following stripping of the membrane 
as opposed to non specific binding of the GAPDH antibody (Figure 3.8). 
Stimulation of HSVSMC with Ang II for 5 minutes resulted in a significant increase 
in ERK1/2 phosphorylation in comparison to control cells (P<0.05 vs. control) 
(Figure 3.8). This effect of Ang II was transient as no differences in ERK1/2 
phosphorylation were observed at the later time points (30 or 60 minutes). The 
transient Ang II mediated-increase in phosphorylation of ERK1/2 was blocked by 
Ang-(1-9) and Ang-(1-7), as in cells exposed to Ang II alongside either of these 
peptides ERK1/2 phosphorylation was similar to control levels (Figure 3.8). Ang-
(1-7) and Ang-(1-9) alone had no effect on ERK1/2 phosphorylation at 5 minutes, 
indicating that the inhibitory effect on Ang II was not due to Ang-(1-7) or Ang-(1-
9) directly reducing ERK1/2 phosphorylation but due to inhibition of Ang II 
signalling (Figure 3.8). At 30 minutes post stimulation, the RAS peptides, alone 
or in combination had no effect on phosphorylation of ERK1/2, as levels were 
comparable to control cells under all conditions, with the exception of the 
positive control 15% FCS, which was significantly increased in comparison to 
control (P<0.01) (Figure 3.8). In cells stimulated for 60 minutes with Ang II and 
Ang-(1-7), alone or in combination, no difference in ERK1/2 phosphorylation was 
observed in comparison to control (Figure 3.8). However, for Ang-(1-9), ERK1/2 
phosphorylation was significantly elevated in cells stimulated with Ang-(1-9) 
alone and in combination with Ang II for 60 minutes in comparison to control 
cells (P<0.05 vs. control). As ERK1/2 was elevated in cells stimulated with Ang-
(1-9) alone and alongside Ang II, but not in cells stimulated with Ang II alone this 
suggests that the increased ERK1/2 phosphorylation is induced by Ang-(1-9) 
(Figure 3.8). Cells were stimulated with FCS as a positive control and ERK1/2 
phosphorylation was increased at 30 and 60 minutes, but not at 5 minutes, post 
stimulation with FCS (P<0.01 vs control cells) (Figure 3.8). 
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Figure 3.8 Effect of Ang II, Ang-(1-7) and Ang-(1-9) on ERK phosphorylation in HSVSMC. 
Quiescent HSVSMC were stimulated with Ang II, Ang-(1-7) or Ang-(1-9), alone or in combination (all peptides 200nM) for 5, 30 or 60 minutes. Cells in serum free 
media alone or complete growth medium (15% FCS) were used as control samples.  Cells were lysed for protein extraction and then Western immunoblotting 
performed. Expression of phosphorylated ERK1/2 was normalised to expression of the protein loading control GAPDH and quantified as a fold change relative to 
control at each time point. Representative blots shown. N=3. *P<0.05, **P<0.01 vs. control.
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3.3.4.2 Effects of Ang II, Ang-(1-7) and Ang-(1-9) on matrix metalloproteinase 
expression in HSVSMC 
It has been well documented that MMP2 and MMP9 are key endopeptidases 
involved in VSMC migration (Southgate et al., 1996) therefore it was assessed if 
changes in MMP2 and MMP9 were involved. HSVSMC were subjected to a scratch 
assay and cells collected at 24 hours post-stimulation for RNA extraction and 
subsequent cDNA synthesis. Expression of MMP2 and MMP9 was assessed via qRT-
PCR. 
Ang II caused a significant reduction in MMP2 expression (P<0.05 vs. control), an 
effect significantly inhibited by Ang-(1-9) (P<0.01 vs. Ang II) but not Ang-(1-7) 
(Figure 3.9 A). The effect of Ang II was inhibited by losartan (P<0.05 vs. Ang II), 
resulting in similar expression levels to that observed in control cells, suggesting 
that Ang II acts via the AT1R to down-regulate MMP2 expression. Co-incubation of 
PD123,319 partially attenuated the effect of Ang-(1-9) however, while MMP2 
expression was lower than in both unstimulated cells and cells co-stimulated 
with Ang II and Ang-(1-9), this did not reach significance. Cells co-stimulated 
with Ang II and Ang-(1-7) and A779 had similar levels of MMP2 as cells stimulated 
with Ang II alone or alongside Ang-(1-7). 
MMP9 was not detected in control, unstimulated cells and for this reason MMP9 
expression is represented as average dCt and no statistical analysis has been 
performed (Figure 3.9 B). Stimulation of HSVSMC with Ang II results in induction 
of MMP9 expression, an effect blocked by Ang-(1-7) or Ang-(1-9). Similarly, Ang 
II-induced MMP9 expression was prevented by losartan, suggesting that this 
effect was dependent on interaction with the AT1R. The effect of Ang-(1-9) and 
Ang-(1-7) on Ang II induced MMP9 expression was blocked by PD123,319 and 
A779, respectively, as under these conditions MMP9 was detected at similar 
levels to those produced in response to Ang II, suggesting that Ang-(1-9) acts via 
the AT2R while Ang-(1-7) acts via Mas to prevent the effects of Ang II. 
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Figure 3.9 Differential regulation of MMP2 and MMP9 expression by Ang II, Ang-(1-7) and 
Ang-(1-9) in HSVSMC migration. 
A scratch assay was performed in quiescent HSVSMC with 10 scratches induced per well to 
increase the population of migrating cells. Cells exposed to Ang II and Ang-(1-7) or Ang-(1-9) 
(200nM) for 24 hours and then cells were isolated for RNA extraction and subsequent cDNA 
synthesis. MMP2 and MMP9 expression was analysed by qRT-PCR using Taqman assays and 
normalised to GAPDH expression. (A) MMP2 expression is quantified as RQ to unstimulated cells. 
(B) MMP9 was not detected in control cells therefore expression is quantified as average dCt ± 
S.E.M. N=3. *P<0.05 vs. control; 
†
P<0.05, 
††
P<0.01 vs. Ang II. 
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3.3.4.3 Effects of Ang II, Ang-(1-7) and Ang-(1-9) on miR-132/miR-212 
expression and its downstream target genes in HSVSMC migration. 
Ang II has previously been reported to regulate expression of the miR-132/-212 
cluster in rat VSMC, resulting in down-regulation of various target genes that 
have been linked to VSMC proliferation and migration, including PTEN, RASA-1 
and MCP-1 (Jin et al., 2012). Therefore, regulation of the mir-132/212 cluster 
and its downstream targets was assessed. HSVSMC underwent the scratch assay 
protocol, except multiple scratches were induced in the cell monolayer to 
increase the proportion of migrating cells. HSVSMC were then stimulated with 
Ang II alone or in combination with Ang-(1-7) or Ang-(1-9). Unstimulated cells 
and cells stimulated with complete culture media (15% FCS) were used as a 
control. Cells were lysed for miRNA and RNA extraction at 24 hours post 
stimulation, and then miRNA and mRNA levels were analysed using q-RT PCR.  
Both Ang II and 15% FCS induced a significant increase in miR-132 expression in 
comparison to control cells (P<0.001), suggesting miR-132 expression is increased 
during HSVSMC migration (Figure 3.10). Ang-(1-7) and Ang-(1-9) significantly 
reduced Ang II mediated increased miR-132 expression to similar levels as 
control cells (Ang II + Ang-(1-9) P<0.01; Ang II + Ang-(1-7) P<0.001 vs. Ang II) 
(Figure 3.10 A). 
No changes in miR-212 expression were observed in cells stimulated with Ang II 
alone or alongside Ang-(1-7) or Ang-(1-9), suggesting that RAS peptides do not 
influence miR-212 expression under these conditions (Figure 3.10 B). While miR-
212 expression in cells stimulated with 15% FCS appeared to be increased in 
comparison to control cells, this did not reach significance (Figure 3.10 B). This 
is unexpected as miR-132 and miR-212 have been reported to exist in a highly 
conserved cluster. However, the lack of regulation of miR-212 in comparison to 
miR-132 may be due to differences in basal expression of these miRNA’s in 
HSVSMC, as in unstimulated cells miR-132 (average Ct 29.5 ± 0.5) is expressed at 
significantly higher levels than miR-212 (average Ct 33.6 ± 0.4). 
Next, changes in miR-132 target gene expression; PTEN, RASA-1 and MCP1 was 
assessed (Figure 3.10 C-E). In line with increased miR-132 expression, HSVSMC 
stimulated with Ang II or 15% FCS displayed significantly lower expression of 
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PTEN in comparison to control cells (P<0.01 vs. control). Similarly, Ang-(1-7) and 
Ang-(1-9) blocked the effects of Ang II (P<0.01 vs Ang II) (Figure 3.11 C). 
Conversely, Ang II alone or in combination with Ang-(1-7) or Ang-(1-9) had no 
effect on either RASA-1 or MCP-1 expression in HSVSMC (Figure 3.10 D-E).  
  
117 
 
 
Figure 3.10 Effects of Ang II, Ang-(1-7) and Ang-(1-9) on miR-132/miR-212 expression and its 
downstream target genes during HSVSMC migration. 
Quiescent HSVSMC were subjected to a scratch assay where multiple scratches were induced in 
the cell monolayer to increase the proportion of migrating cells. HSVSMC were then stimulated with 
Ang II alone or in combination with Ang-(1-7) or Ang-(1-9) (200nM). Unstimulated cells and cells 
stimulated with complete culture media (15% FCS) were used as a control. Cells were lysed for 
miRNA and RNA extraction at 24 hours post stimulation, and then miRNA and mRNA levels were 
analysed using q-RT PCR. Expression of (A) miR-132, (B) miR-212, (C) PTEN, (D) RASA1 and (E) 
MCP-1 was normalised endogenous housekeeper (RNU48 in A and B; GAPDH in C-E) and 
expression is expressed as RQ to control. N=6. *P<0.05, **P<0.01  ***P<0.001 vs control; 
†
P<0.05, 
††
P<0.01, 
†††
P<0.001 vs 5% Ang II.  
PTEN
0.00
0.25
0.50
0.75
1.00
1.25
R
Q
 t
o
 G
A
P
D
H
C
o
n
tr
o
l
A
n
g
 II
A
n
g
 II
 +
 A
n
g
-(
1
-9
)
A
n
g
 II
 +
 A
n
g
-(
1
-7
)
1
5
%
 F
C
S
C D
C
o
n
tr
o
l
A
n
g
 II
A
n
g
 II
 +
 A
n
g
-(
1
-9
)
A
n
g
 II
 +
 A
n
g
-(
1
-7
)
1
5
%
 F
C
S
E
C
o
n
tr
o
l
A
n
g
 II
A
n
g
 II
 +
 A
n
g
-(
1
-9
)
A
n
g
 II
 +
 A
n
g
-(
1
-7
)
1
5
%
 F
C
S
MCP1
0.0
0.5
1.0
1.5
R
Q
 t
o
 G
A
P
D
H
RASA1
0.0
0.5
1.0
1.5
2.0
R
Q
 t
o
 G
A
P
D
H
††
††
A B
C
o
n
tr
o
l
A
n
g
 II
A
n
g
 II
 +
 A
n
g
-(
1
-9
)
A
n
g
 II
 +
 A
n
g
-(
1
-7
)
1
5
%
 F
C
S
C
o
n
tr
o
l
A
n
g
 II
A
n
g
 II
 +
 A
n
g
-(
1
-9
)
A
n
g
 II
 +
 A
n
g
-(
1
-7
)
1
5
%
 F
C
S
miR-212
0
1
2
3
R
Q
 t
o
 R
N
U
4
8
miR-132
0
1
2
3
R
Q
 t
o
 R
N
U
4
8
††
†††
***
***
***
** †
118 
 
The effect of Ang II on miR-132 expression at 24 hours post stimulation in 
comparison to control cells (P<0.001 vs control), was significantly inhibited by 
losartan, suggesting that Ang II mediated increase in miR-132 expression was via 
the AT1R (Figure 3.11 A). The Ang II mediated increase in miR-132 expression 
was also blocked by Ang-(1-9) and Ang-(1-7) (Ang II + Ang-(1-9) P<0.01; Ang II + 
Ang-(1-7) P<0.001 vs Ang II) and similar levels of miR-132 were observed in cells 
stimulated with Ang II co-incubated with either Ang-(1-7) or Ang-(1-9) compared 
to control (Figure 3.12 A). The inhibitory effect of Ang-(1-9) was attenuated by 
PD123,319 (P<0.05 vs control, P>0.05 vs Ang II), and the effect of Ang-(1-7) was 
attenuated by A779 (P<0.01 vs control, P>0.05 vs Ang II), suggesting Ang-(1-9) 
may act via the AT2R and Ang-(1-7) via Mas (Figure 3.11 A). 
Ang II caused a significant reduction in PTEN expression in comparison to control 
cells, an effect blocked by losartan (P<0.05 vs Ang II) (Figure 3.11 B). Ang-(1-7) 
and Ang-(1-9) also prevented Ang II mediated reduction in PTEN expression, and 
cells stimulated with Ang II alongside either Ang-(1-7) or Ang-(1-9) displayed 
similar expression levels of PTEN as control (Figure 3.12 B). Again, the inhibitory 
effects of Ang-(1-7) and Ang-(1-9) were blocked by A779 and PD123,319, 
respectively (P<0.05 vs Ang II) (Figure 3.11 B). 
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Figure 3.11 The role of the AT1R, AT2R and Mas in the effects of Ang II, Ang-(1-7) and Ang-(1-
9) on miR-132 and PTEN expression in HSVSMC. 
Quiescent HSVSMC were subjected to a scratch assay where multiple scratches were induced in 
the cell monolayer to increase the proportion of migrating cells. To assess the role of the RAS 
receptors in regulation of miR-132 and PTEN expression cells were incubated with losartan (10 
µM), PD123.319 (PD) (500 nM) or A779 (100 µM) for 15 minutes prior to stimulation with Ang-(1-7) 
or Ang-(1-9) (200 nM). Cells were lysed for miRNA and RNA extraction at 24 hours post 
stimulation, and then miRNA and mRNA levels were analysed using q-RT PCR. Expression of (A) 
miR-132 and (B) PTEN was normalised endogenous housekeeper (RNU48 in A; GAPDH in B) and 
expression is expressed as RQ to control. N=3. *P<0.05, **P<0.01, ***P<0.001 vs control; 
†
P<0.05, 
††
P<0.01, 
†††
P<0.001 vs Ang II.  
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It was next assessed if Ang II induced reduction in PTEN protein levels and 
changes in downsteam targets including Akt (Huang and Kontos, 2002). Confluent 
HSVSMC were quiesced for 48 hours and then multiple scratches were induced in 
the monolayer followed by stimulation with Ang II alone or co-stimulated with 
Ang-(1-7) or Ang-(1-9) for 24 hours. Cells in serum free media or stimulated with 
15% FCS were used as a control. At 24 hours post stimulation cells were lysed for 
protein extraction and Western immunoblotting performed using specific 
antibodies for PTEN and Akt. Protein expression was quantified as a ratio of the 
total protein (PTEN or Akt) to GAPDH, the loading control.  No changes were 
observed in PTEN or Akt expression in HSVSMC stimulated with Ang II, alone or in 
combination with Ang-(1-7) or Ang-(1-9), or 15% FCS at 24 hours post stimulation 
in comparison to control cells (P>0.05 vs control) (Figure 3.12), indicating that 
the changes in PTEN expression observed at mRNA level were not apparent in 
protein levels at this time point.  
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Figure 3.12 Effects of Ang II, Ang-(1-7) and Ang-(1-9) on PTEN and Akt protein expression in 
HSVSMC migration 
Quiescent HSVSMC underwent a scratch assay with multiple scratches in the cell monolayer to 
increase the proportion of migrating HSVSMC. Cells were then stimulated with Ang II alone or 
alongside Ang-(1-7) or Ang-(1-9) for 24 hours. Cells in serum free media or stimulated with 
complete growth media (15% FCS) were used as a control. At 24 hours post stimulation cells were 
lysed for protein extraction and Western immunoblotting was then performed using speficic 
antibodies for PTEN and AKT. Protein expression was quantified as a ratio of the total protein 
expression of  (B) PTEN or (C) Akt, to the loading control GAPDH. Representative immunoblots of 
PTEN, Akt and GAPDH expression. N=2.  
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To assess the role of miR-132 in Ang II mediated HSVSMC migration, a specific 
miR-132 inhibitor was used. miRNA inhibitors are small, chemically modified 
single-stranded RNA molecules designed to specifically bind to and inhibit miRNA 
activity (Stenvang et al., 2008, Weiler et al., 2006). Therefore, these molecules 
are not designed to alter expression levels of the miRNA but prevent changes in 
target gene expression.  
First the transfection efficiency of the miRNA inhibitor was assessed in HSVSMC 
using a Cy3 labelled negative control. As expected, no fluorescence was 
observed in nontransfected, control HSVSMC (NTC). No Cy3 positive cells were 
observed in HSVSMC transfected with 10nM or 30nM of the labelled non targeting 
molecule and only a small proportion of cells transfected at 60nM were positive 
for Cy3, suggesting a low transfection efficiency (Figure 3.13 A). As cells 
transfected with 60nM of the Cy3 control displayed the highest positive cell 
number, this concentration was used for all subsequent experiments.  
Expression of PTEN was used to assess efficiency of the miR-132 inhibitor. In 
nontransfected cells, Ang II and 15% FCS induced a significant reduction in PTEN 
expression in comparison to control (Ang II P<0.01; 15% FCS P<0.05 vs control) 
(Figure 3.13 B). In cells transfected with the non targeting negative control 
(scramble), stimulation with either Ang II resulted in a significant reduction in 
PTEN expression (P<0.05), and while 15% FCS also reduced this was not 
significantly different to control (Figure 3.13 B). A similar effect was observed in 
cells transfected with the miR-132 inhibitor, with both Ang II and 15% FCS 
significantly reduced PTEN expression in comparison to control, suggesting that 
the transfection efficiency attained was possibly not high enough. (Figure 3.13 
B).  
Conversely, in nontransfected cells, Ang II and 15% FCS induced a significant 
increase in miR-132 expression in comparison to control (P<0.05) (Figure 3.13 C). 
In cells transfected with the non targeting negative control (scramble), 
stimulation with either Ang II resulted in a significant increase in miR-132 
expression (P<0.01), and while 15% FCS also increased miR-131 expression this 
was not significantly different to control (Figure 3.13 C). A similar pattern in 
response to Ang II and FCS was observed in cells transfected with the miR-132 
inhibitor, however, these changes were not significantly different to 
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unstimulated cells and miR-132 expression was lower under all stimulation 
conditions compared to non transfected cells and cells transfected with the non 
tragetting miRNA inhibitor (Figure 3.13 C). 
HSVSMC migration was quantified at 24 hours post stimulation, in untransfected 
cells and cells transfected with either the non targeting molecule or miR-132 
inhibitor. Under all conditions, both Ang II and 15% FCS caused a significant 
increase in HSVSMC migration at 24 hours post stimulation in comparison to 
control (P<0.001) (Figure 3.13 D). However, in unstimulated cells transfected 
with the miR-132 inhibitor, there was a significant increase in HSVSMC migration 
in comparison to unstimulated, untransfected cells (P<0.01). In both 
untransfected cells and cells transfected with scramble miR inhibitor basal 
HSVSMC migration at 24 hours was comparable at 52.8 ± 7.4 % and 52.2 ± 7.8 % 
migration, respectively (Figure 3.13 D). However, in unstimulated cells 
transfected with the miR-132 inhibitor, basal HSVSMC migration at 24 hours was 
significantly higher at 71.1 ± 12.1 % migration, suggesting that the miR-132 
inhibitor influenced basal HSVSMC migration (Figure 3.13 D).  
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Figure 3.13 Effect of mir-132 inhibition on PTEN expression and HSVSMC migration. 
HSVSMC were transfected with either a Cy3 labelled non targeting miRNA inhibitor or a miR-132 
inhibitor as described in section 2.7. (A) Transfection efficiency was assessed by visualisation of 
fluorescent cells. (B) Cells were transfected with either a scramble miR-inhibitor or the miR-132 
inhibitor at 60 nM described, then stimulated with Ang II or 15% FCS for 24 hours. Cells were then 
lysed for RNA extraction and subsequent synthesis to cDNA. (B) PTEN and (C) miR-132 
expression was assessed using qRT-PCR and expressed as RQ to control. (D) HSVSMC migration 
was quantified as a reduction in scratch width (%) at 24 hours relative to the 0 hour measurement. 
N=3. *P<0.05, **P<0.01, ***P<0.001 vs control. 
 
10nM 30nM 60nMNTC
Cy3 labelled negative control
Control
Ang II
15% FCS
Control
Ang II
15% FCS
A
B
C
D
*** ***
NTC Scramble miR-132 
inhibitor
0
50
100
M
ig
ra
ti
o
n
 (
%
)
***
**
PTEN Expression
NTC Scramble miR-132 
inhibitor
0.0
0.5
1.0
1.5
*
**
**
*
R
Q
 t
o
 G
A
P
D
H
Control
Ang II
15% FCS
NTC Scramble miR-132
inhibitor
0.0
0.5
1.0
1.5
2.0
2.5
R
Q
 t
o
 R
N
U
4
8
miR-132 Expression
**
**
**
125 
 
3.3.4.4 The role of miRNA in Ang II induced HSVSMC migration 
Although Ang II increased miR-132 expression in HSVSMC, it was not essential for 
HSVSMC migration. Therefore, an alternative approach was taken to determine 
whether miRNA regulation essential for Ang II-mediated HSVSMC migration. To 
do this an experiment to inhibit DICER, the key enzyme involved in miRNA 
generation was undertaken. This was achieved through the use of a specific 
siRNA to knock down DICER expression within VSMC stimulated with Ang II.  
To assess the optimal concentration of siRNA required for maximal transfection 
of HSVSMC, cells were transfected with increasing concentrations (10-60 nM) of a 
Cy3 labelled control siRNA (Figure 3.14 A). In HSVSMC transfected with the Cy3 
labelled control siRNA, the number of Cy3 positive cells increased in a 
concentration-dependent manner, as indicated by increased red fluorescence 
(Figure 3.14 A). The majority of cells transfected at 60 nM were positive for Cy3. 
Next, to assess the optimal concentration of siRNA required for efficient knock 
down of gene expression in HSVSMC, cells were transfected with increasing 
concentrations of a siRNA against GAPDH. In HSVSMC transfected with the GAPDH 
siRNA, there was a reduction in GAPDH expression in a concentration dependent 
manner (Figure 3.14 B). GAPDH expression was significantly reduced in 
comparison to cells transfected with the scrambled siRNA at concentrations of 
30nM and above, however, maximal knockdown of GAPDH was observed in cells 
transfected with 60 nM siRNA (Figure 3.14 B). Cy3 labelled control siRNA 
transfection (scramble siRNA) did not lead to alterations in GAPDH expression 
(Figure 3.14 B). 
Transfection with the DICER targeting siRNA at 60 nM significantly reduced DICER 
expression in HSVSMC in comparison to untransfected cells or cells transfected 
with the non targeting siRNA (scramble) (P<0.001) (Figure 3.14 C).  
 
126 
 
 
Figure 3.14 Transfection efficiency of siRNA in HSVSMC 
The transfection efficiency of siRNAs in HSVSMC was assessed as described in section 2.7. (A) 
Cells were transfected with increasing concentration of a Cy3 labelled non targeting siRNA (10, 30, 
60 nM) and transfection efficiency assessed by visualisation of fluorescent cells. (B) To assess the 
optimal concentration for efficient gene knock down, cells were transfected with a siRNA targeting 
GAPDH (10, 30, 60 nM). GAPDH expression was normalised to 18s and expressed as RQ to the 
comparable concentration of the scrambled siRNA. (C) DICER expression following transfection of 
HSVSMC with 60 nM DICER siRNA. N=3. 
*
P<0.05, 
***
P<0.001 vs control; 
##
P<0.01 vs scramble 
siRNA. 
  
GAPDH siRNA
10nM 30nM 60nM
0.00
0.25
0.50
0.75
1.00
1.25
R
Q
 t
o
 1
8
s
10nM 30nM 60nMNTC
Cy3 labelled negative control
Cy3 Scramble siRNA
GAPDH siRNA
* ***
A
B
C DICER Expression
Control Scramble DICER siRNA
0.00
0.25
0.50
0.75
1.00
1.25
***
###R
Q
 t
o
 1
8
s
127 
 
Although it was previously demonstrated that Ang II mediated miR-132 
expression was not essential for HSVSMC migration, expression levels of this 
miRNA and its target PTEN were assessed to confirm that siRNA-mediated 
knockdown of DICER had functional biological effects on miRNA and mRNA 
expression. HSVSMC underwent a scratch assay following transfection and then 
stimulated with Ang II or 15% FCS to induce migration. Cells were lysed for RNA 
extraction at 24 hours post stimulation and miR-132 and PTEN expression 
assessed. In untransfected cells or cells transfected with a non targeting siRNA 
(scramble), there was a significant increase in miR-132 expression in HSVSMC 
stimulated with Ang II or 15% FCS in comparison to control (P<0.05 vs. control) 
(Figure 3.15 A). In cells transfected with the DICER siRNA, miR-132 expression 
was unaltered by Ang II in comparison to control, suggesting that knockdown of 
DICER blocked the Ang II mediated increase in miR-132 expression (Figure 3.15 
A). miR-132 expression was elevated in cells transfected with DICER siRNA when 
stimulated with 15% FCS in comparison unstimulated cells, however this change 
did not reach significance (Figure 3.15 A).  
Furthermore, in untransfected cells or cells transfected with the scramble siRNA 
there was a significant reduction in PTEN expression in HSVSMC stimulated with 
Ang II or 15% FCS in comparison to control (P<0.05 vs. control) (Figure 3.15 B). In 
cells transfected with the DICER siRNA, PTEN expression was unaltered in 
response to Ang II or 15% FCS, suggesting that Ang II mediated reduction in PTEN 
occurs via a mechanism dependent on DICER expression (Figure 3.15 B).  
In addition to assessing the effects of DICER siRNA on Ang II induced changes in 
miR-132 and PTEN expression, it was also established if knockdown of DICER had 
functional consequences on Ang II induced HSVSMC migration. In untransfected 
control cells, and cells transfected with a scramble siRNA or DICER siRNA, there 
was a significant increase in HSVSMC migration in response to Ang II and 15% FCS 
at 24 hours post stimulation in comparison to unstimulated cells (Figure 3.15 C). 
Under all transfection conditions, stimulation of cells with Ang II or 15% FCS 
resulted in wound closure by 24 hours. However, in cells transfected with DICER 
siRNA, there was a significant increase in basal migration of HSVSMC in 
comparison to untransfected cells and cells transfected with the scramble siRNA 
(P<0.01) (Figure 3.15 C). In both untransfected cells and cells transfected with 
scramble siRNA basal HSVSMC migration at 24 hours was comparable at 50.36 ± 
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5.3 % and 51.1 ± 4.0 % migration, respectively (Figure 3.16 C). However, in 
unstimulated cells transfected with DICER siRNA, basal HSVSMC migration at 24 
hours was significantly higher at 70.4 ± 14.4 % migration, suggesting that 
alterations in miRNA expression through reduced DICER expression promote 
HSVSMC migration in the absence of other stimuli (Figure 3.15 C). 
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Figure 3.15 Effect of DICER knockdown on Ang II-mediated regulation of miR-132 and PTEN 
expression, and HSVSMC migration. 
HSVSMC were transfected with 60nM scramble or DICER siRNA and then underwent the scratch 
assay protocol as described in section 2.7. Cells were stimulated with Ang II or 15% FCS for 24 
hours and then lysed for miRNA and RNA extraction. (A) miR-132 and (B) PTEN expression was 
assessed via qRT-PCR and expressed as RQ to control. (C) HSVSMC migration was quantified as 
a reduction in scratch width (%) at 24 hours relative to the 0 hour measurement. N=3. *P<0.05, 
**P<0.01, ***P<0.001 vs control. 
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3.4 Discussion 
This study is the first to report a role for Ang-(1-9) in human VSMC proliferation 
and migration, and to provide a direct comparison between Ang-(1-7) and Ang-
(1-9) in these processes. The data demonstrate that Ang-(1-7) and Ang-(1-9) 
inhibit serum induced proliferation of HSVSMC via Mas and AT2R, respectively. 
While Ang II was unable to induce proliferation of HSVSMC in this study, it was 
demonstrated to have potent pro-migratory effects. Ang II-induced HSVSMC 
migration via the AT1R in agreement with previous reports (Schieffer et al., 
1996, Epstein et al., 1997, Touyz et al., 1999a, Xu et al., 1996, Lee et al., 2007, 
Kyaw et al., 2004, Yang et al., 2005, Mugabe et al., 2010), and its effect was 
inhibited by both Ang-(1-7) and Ang-(1-9) via Mas and the AT2R, respectively. 
The effect of Ang-(1-7) via Mas agrees with previous reports in rat VSMC (Zhang 
et al., 2010b). Further investigation into the functional interplay of the RAS 
peptides in HSVSMC migration identified alterations in ERK1/2 activity and, 
MMP2 and MMP9 expression as potential mechanisms contributing to the 
observed results.  
Additionally, as Ang II has recently been demonstrated to regulate expression of 
the miR-132/-212 cluster in rat aortic VSMC, thereby regulating a number of 
target genes involved in VSMC migration including PTEN, MCP-1 and RASA-1 (Jin 
et al., 2012), this pathway was also assessed. Ang II-mediated HSVSMC migration 
was associated with an increase in miR-132 but not miR-212 expression, and a 
decrease in PTEN expression at the mRNA level. These changes were mediated 
via the AT1R and were inhibited by Ang-(1-7) and Ang-(1-9); the effects of Ang-
(1-7) and Ang-(1-9) were partially attenuated by antagonism of Mas and the 
AT2R, respectively, suggesting a role for these receptors in this setting. 
However, PTEN protein levels were unchanged. Similarly, there was no change in 
MCP-1 expression at mRNA or Akt at protein levels, both of which are key 
proteins involved in the downstream signalling pathways of PTEN, suggesting the 
changes in PTEN gene expression were not converted to changes in protein levels 
under these experimental conditions. Additionally, in contrast to the findings in 
rat aortic VSMC, no changes in RASA-1 were observed. While highlighting a 
potential mechanism involved in HSVSMC migration, these results also 
demonstrate key differences in the miRNA response to Ang II between rat and 
human VSMC (Jin et al., 2012).  The role of miRNA-132 in Ang II induced HSVSMC 
131 
 
migration was further investigated through the use of a miR-132 inhibitor, which 
blocks miR-132 activity and through siRNA-mediated downregulation of DICER, a 
key enzyme involved in miRNA biogenesis. It was found that Ang II mediated 
HSVSMC migration was not dependent on miR-132 or synthesis of an alternative 
miRNA. However, reduced miR-132 activity and DICER expression increased basal 
migration of unstimulated HSVSMC. 
Ang II is a potent mitogen and widely accepted to promote VSMC proliferation 
via stimulation of the AT1R [extensively reviewed by (Touyz and Schiffrin, 
2000)]. However, in the majority of the studies demonstrating a proliferative 
role for Ang II the cells used have been isolated from arteries and evidence for 
Ang II induced proliferation in human VSMC isolated from saphenous veins is 
conflicting (Mii et al., 1994, Patel et al., 1996). In the present study, Ang II had 
no effect on proliferation of quiescent HSVSMC following a 48 hours stimulation 
period. This is in line with previous findings from Mii and colleagues who 
demonstrated that Ang II (1-1000 nM) had no effect on HSVMC proliferation when 
stimulated in the presence of either 0.5 % or 10% FCS (Mii et al., 1994). In a later 
study by Patel et al, it was demonstrated that Ang II caused increased HSVSMC 
proliferation at 1 nM but not at higher concentrations (10 nM or 1 µM) and that 
this increase in proliferation was via the AT1R and associated with increased 
expression of c-fos (Patel et al., 1996).  
One possible explanation for the difference in the response to Ang II in cells 
isolated from arteries and veins may lie in their basal phenotypic differences. 
Primary VSMC cultures isolated from veins and arteries share many common 
features, including similarities in morphology and responses to mitogens and 
chemoattractants (Deng et al., 2006, Yang et al., 1998, Liu et al., 2004a). 
However, it has been demonstrated that although some responses are similar, 
VSMC from arteries and veins in culture maintain distinct cell lineage gene 
expression programmes and responses (Deng et al., 2006). For example, 
stimulation of human coronary artery smooth muscle cells (HCASMC) in culture 
with oxidised LDL led to reduced proliferation and migration, and increased 
expression of growth-inhibitory genes involved in cell cycle control such as 
cyclin-dependent inhibitors cyclin-dependent kinase inhibitor 1 (CDKN1a) and 
cyclin-dependent kinase 4 inhibitor C (CKDN2C) (Deng et al., 2006). Conversely, 
stimulation of HSVSMC under the same conditions resulted in increased 
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proliferation, partially via increase IGF-1 signalling and activation of NFkB (Deng 
et al., 2006). While this has yet to be demonstrated to be the case for Ang II, it 
may explain the differences observed in the proliferative response to Ang II 
documented in the literature.  
While Ang II had no effect on HSVSMC proliferation, stimulation with increasing 
concentrations of serum resulted in a concentration-dependent increase in 
HSVSMC proliferation. As Ang-(1-7) has previously been shown to inhibit serum 
induced proliferation (Tallant and Clark, 2003), FCS was used as the mitogen to 
assess the effects of Ang-(1-7) and Ang-(1-9) on HSVSMC proliferation. A serum 
concentration of 5% FCS was chosen as this was sufficient to induce a significant 
increase in proliferation in comparison to control, unstimulated cells but low 
enough to avoid overgrowth of the cells within the well.  
This study demonstrates for the first time an anti-proliferative role for Ang-(1-7) 
in human VSMC. In line with previously published data, Ang-(1-7) inhibits HSVSMC 
proliferation via Mas (Tallant and Clark, 2003, Tallant et al., 1999, Freeman et 
al., 1996, Zhang et al., 2010b). While in this current study the mechanisms 
involved in the anti-proliferative effects of Ang-(1-7) have not been defined, 
previous studies have identified inhibition of MAPK signalling pathways and 
release of prostacyclin as key in the anti-proliferative effects of Ang-(1-7) 
(Tallant and Clark, 2003, Zhang et al., 2010b). Ang-(1-7) blocked Ang II- and 
PDGF-induced activation of ERK1/2 signalling in rat aortic SMC and Ang II-
induced activation of ERK1/2 in mouse aortic VSMC (Tallant and Clark, 2003). 
However, the upstream mechanisms of Ang-(1-7) mediated inhibition of ERK1/2 
have still to be established. Additionally, Ang-(1-7) has been demonstrated to 
inhibit VSMC proliferation through stimulation of COX-mediated PGI2 release 
(Tallant and Clark, 2003, Jaiswal et al., 1993b, Jaiswal et al., 1993a, Muthalif et 
al., 1998).  
This study also demonstrates for the first time an anti-proliferative role for Ang-
(1-9) in human VSMC. In fact, these findings are the first to identify a direct 
effect of Ang-(1-9) in VSMC via the AT2R, and although signalling via this 
receptor is poorly defined, the AT2R has been linked to reduced VSMC 
proliferation in vitro. For example, adenoviral-mediated over expression of the 
AT2R in rat VSMC resulted in a reduction in Ang II mediated VSMC proliferation 
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via the AT2R, an effect which was linked to reduced MAPK activity (Nakajima et 
al., 1995, Stoll et al., 1995). While the mechanisms involved in the anti-
proliferative effects of Ang-(1-9) in HSVSMC proliferation have yet to be 
established, inhibition of MAPK signalling may be involved as data from this 
present study suggests that Ang-(1-9) modulates ERK1/2 phosphorylation, as 
discussed below. 
In addition to VSMC proliferation, Ang II is known to promote VSMC migration, 
another key process in vascular remodelling. The data from this study 
demonstrate that Ang II promotes HSVSMC migration via the AT1R. This finding is 
in line with previously published studies (Schieffer et al., 1996, Epstein et al., 
1997, Touyz et al., 1999a, Xu et al., 1996, Lee et al., 2007, Kyaw et al., 2004, 
Yang et al., 2005, Mugabe et al., 2010). The findings from this current study so 
far demonstrate that Ang-(1-7) and Ang-(1-9) prevent both HSVSMC proliferation 
and migration in response to FCS and Ang II, respectively. However, as one of 
the main aims of this thesis is to investigate the interaction of Ang II and the 
counter-regulatory peptides Ang-(1-7) and Ang-(1-9) in HSVSMC, it was decided 
that a more detailed assessment of the mechanisms involved in the effects of 
these peptides in HSVSMC migration would be performed, as there is clear 
modulation of the effects of Ang II by Ang-(1-7) and Ang-(1-9) in this setting. 
Ang II via the AT1R activates a number of intracellular signal transduction 
pathways that are linked to long term regulation of VSMC function, such as cell 
growth and migration. These processes are initiated within minutes and involve 
phosphorylation of a number of protein kinases, including MAPK, such as ERK1/2, 
JNK and p38 MAPK (Xi et al., 1999, Ohtsu et al., 2005, Lee et al., 2007). Ang II 
mediated phosphorylation of ERK1/2 in particular has been demonstrated to be 
an important mechanism involved in VSMC growth and migration (Xi, Graf et al. 
1999; Ohtsu, Mifune et al. 2005; Jiang, Bujo et al. 2008; Shen, Zhu et al. 2014) 
and importantly Ang-(1-7) has been demonstrated to prevent Ang II induced 
migration of rat VSMC via inhibition of Ang II-mediated phosphorylation of 
ERK1/2 (Zhang et al., 2010b). In this present study it was found that Ang II cause 
a transient increase in ERK1/2 phosphorylation at 5 minutes post-stimulation and 
ERK1/2 levels returned to similar levels as unstimulated cells by 30 minutes. This 
increase in ERK1/2 phosphorylation in the minutes following stimulation with 
Ang II is consistent with previous studies in rat VSMC where it was found that Ang 
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II induced ERK1/2 phosphorylation was maximal 3 to 10 minutes post stimulation 
(Eguchi et al., 1996, Touyz et al., 1999d, Kyaw et al., 2004, Mugabe et al., 
2010). However, in contrast with the findings from this present study, others 
have found that Ang II-induced phosphorylation of ERK1/2 remained elevated at 
both 30 at 60 minutes post stimulation (Zhang et al., 2010b, Eguchi et al., 1996, 
Touyz et al., 1999d), however, this may be due to variation between cells from 
different vascular beds and species.  
Interestingly, both Ang-(1-7) and Ang-(1-9) blocked Ang II-induced ERK1/2 
phosphorylation in HSVSMC at 5 minutes post stimulation. For Ang-(1-7) this is 
consistent with a previous study in rat VSMC using a scratch assay, where Ang-(1-
7) inhibited Ang II-induced VSMC migration via inhibition of ERK1/2 signalling 
(Zhang et al., 2010b). While the signalling mechanisms involved have yet to be 
defined, it is likely that Ang-(1-7) can activate a signalling pathway that leads to 
blockage of ERK1/2 activation or its downstream signalling and therefore can 
inhibit Ang II-induced ERK1/2 activation and Ang II-stimulated HSVSMC migration. 
For example, Ang II mediated activation of c-Src, a vital component in the 
regulation of focal contact formation, is blocked by Ang-(1-7) in human 
endothelial cells, and c-Src is upstream of ERK1/2 signalling (Sampaio et al., 
2007b). Therefore, a similar effect may occur in HSVSMC; however, further 
investigation is required to confirm this. 
Ang-(1-9) was shown to inhibit Ang II-mediated HSVSMC migration via the AT2R, 
therefore it is plausible that Ang-(1-9) also inhibits Ang II-induced ERK1/2 
phosphorylation via the AT2R. While signalling via the AT2R is poorly 
characterised, activation of various pathways that involve tyrosine or 
serine/threonine phosphatases has been suggested as potential signalling 
pathways (Horiuchi et al., 1999). Phosphatases suggested to be involved in AT2R 
signalling include mitogen-activated protein kinase phosphatase 1 (MKP-1), SH2 
domain containing phosphatase (SHP-1) and protein phosphatase 2A (PP2A) 
(Nouet and Nahmias, 2000). Interestingly, these phosphatases have been shown 
to interact with the ERK1/2 pathway, identifying them as potential regulators of 
Ang-(1-9)-mediated inhibition of ERK1/2 activation (Calo et al., 2010b). At 60 
minutes post-stimulation there was a significant increase in ERK1/2 
phosphorylation in cells stimulated with Ang-(1-9) alone or in combination with 
Ang II. As no changes were observed in ERK1/2 phosphorylation at this time point 
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in cells stimulated with Ang II alone, this increased phosphorylation is likely due 
to a direct action of Ang-(1-9). This is the first evidence of a direct effect of 
Ang-(1-9) in VSMC. ERK1/2 activation is most often associated with pro-
proliferative and pro-migratory effects in VSMC [reviewed by (Touyz and 
Schiffrin, 2000)], while Ang-(1-9) has been demonstrated to have no effect on 
HSVSMC migration alone and have anti-migratory and anti-proliferative effects in 
response to Ang II and serum, respectively. Therefore, it is unclear what the 
functional consequences of Ang-(1-9) mediated ERK1/2 phosphorylation are and 
further investigation is required. 
It has been well documented that MMP2 and MMP9 are involved in VSMC 
migration by degradation of the ECM and are upregulated in various pathologies 
involving VSMC migration (Southgate et al., 1996). The data in this current study 
suggest Ang II reduces MMP2 expression, an effect prevented by Ang-(1-9) but 
not Ang-(1-7), and AngII causes an increase in MMP9 expression, which is 
prevented by Ang-(1-9) and Ang-(1-7). While Ang II has previously been shown to 
upregulate MMP2 and MMP9 expression in cardiovascular pathology (Jung et al., 
2010), it has been shown that in the same cell type Ang II can cause a reduction 
in MMP2 expression and this effect is unaltered by Ang-(1-7), while MMP9 is 
upregulated by Ang II and this upregulation is inhibited by Ang-(1-7) (Pan et al., 
2008). This is consistent with the findings from this study. However, it is 
important to note that these changes have only been demonstrated at mRNA 
level and a further assessment of protein expression and activity would be 
required. These differential effects of Ang-(1-7) and Ang-(1-9) on MMP 
expression indicate that they may have differential mechanisms of actions, 
consistent with the use of different receptors.  
Ang II has recently been demonstrated to regulate expression of the miR-132/-
212 cluster in rat aortic VSMC, leading to alterations in various target genes 
relevant to VSMC migration, such as PTEN, MCP-1 and RASA-1 (Jin et al., 2012). 
Therefore, this was also assessed in the present study to investigate a role for 
Ang II-mediate miR-132/-212 regulation in HSVSMC migration. The data 
demonstrate that Ang II-mediated HSVSMC migration was associated with an 
increase in miR-132 but not miR-212 expression. As both miRNA’s exist in a 
cluster it would be expected that as one miRNA increases in expression the other 
would increase (van Rooij and Olson, 2007). However, this differential 
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expression of miR-132 and miR-212 in response to Ang II has also been observed 
in adult rat cardiac fibroblasts (Jiang et al., 2013). In these cells miR-132 was 
found to be increased in response to Ang II at 24 hours post stimulation, 
however, miR-212 was not found to be regulated (Jiang et al., 2013). It is 
possible that the miR-132 and miR-212 responses to Ang II differ between species 
and cell type. Based on the findings that Ang II regulated miR-132 in HSVSMC, 
expression of its validated targets PTEN and RASA-1 was assessed. While no 
changes were observed in RASA-1 expression, Ang II significantly reduced PTEN 
expression. Additionally, MMP9 and the AT1R have both been identified as 
potential targets of miR-132 in  cardiac fibroblasts and rat VSMC, respectively 
(Jiang et al., 2013, Elton, 2008), however, these findings were not replicated in 
this current data set as MMP9 expression was increased in response to Ang II 
while AT1R expression was unchanged.  
Increased PTEN levels are associated with reduced VSMC migration, due to 
inhibition of PI3K signalling (Huang and Kontos, 2002). Overexpression of PTEN 
via an adenoviral vector (AdPTEN) inhibited Ang II and PDGF mediated 
proliferation and migration of VSMCs (Huang and Kontos, 2002, Dong et al., 
2013).  Both these studies reported a reduction in phosphorylation of Akt and 
FAK as a result of PTEN expression. Interestingly, phosphorylation of Akt and FAK 
have previously been demonstrated to increase in a time dependent manner in 
response to Ang II stimulation of VSMC, highlighting the importance of Ang II 
induced reduction of PTEN expression in VSMC migration (Dong et al., 2013). 
Inhibition of Akt in VSMCs has been demonstrated to inhibit migration which is 
thought to occur due to prevention of cytoskeleton remodelling (Galaria et al., 
2005). FAK however is important for the generation of focal contacts in 
migration (Gerthoffer, 2007), therefore suggesting PTEN overexpression may also 
reduce focal contact formation. Furthermore, increased expression of PTEN has 
been linked to reduce expression of the pro-inflammatory cytokine MCP-1 
following cuff injury in rats (Koide et al., 2007). This was suggested to be linked 
to inactivation of NF-κB due to the reduced phosphorylation of inhibitor of kappa 
b-alpha (IκB-α), an inhibitory protein that dissociates from NF-κB when 
phosphorylated allowing activation, in AdPTEN transduced mice (Koide et al., 
2007). This pathway was further supported in a study using rat arterial VSMCs 
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which were deficient in PTEN, where increased cytokine production was 
inhibited by PI3K/Akt or NF-κB suppression (Furgeson et al., 2010). 
Due to the fact that Ang II stimulation of HSVSMC led to changes in PTEN at the 
mRNA level the PTEN pathway was investigated further, by assessing protein 
levels of PTEN and changes in expression levels of molecules downstream from 
PTEN in the signalling cascade. In this study, PTEN protein levels were 
unchanged at 24 hours following stimulation with Ang II. In a recent study, Ang II 
was found to reduce PTEN expression at the protein level in rat aortic VSMC at 
12 hours following stimulation. Along with the different origins of these cells, 
inconsistent PTEN regulation may be due to a greater reduction in PTEN mRNA 
levels in rat arterial VSMCs of approximately 0.4 fold after 12 hours in contrast 
to around 0.6 fold in the present study following 24 hours Ang II stimulation. The 
lack of change in PTEN protein does not however rule out the regulation of PTEN 
post-translation by Ang II. Dong et al demonstrated that Ang II increased ROS 
production in rat VSMC leading to rapid phosphorylation or oxidation of PTEN, 
resulting in its de-activation (Dong et al., 2013). However this regulation would 
be independent of miR-132 due to the temporal aspects of the reported de-
activation of PTEN; 30 minutes and 120 minutes for phosphorylation and 
oxidation respectively (Dong et al., 2013).  Similarly, there was no change in 
MCP-1 expression at mRNA or Akt at protein levels observed in the current study, 
both of which are key proteins involved in the downstream signalling pathways 
of PTEN, suggesting these changes in gene expression were not converted to 
protein within these experimental conditions. MCP-1 is known to promote VSMC 
migration (Ma et al., 2007) and mRNA levels of MCP-1 have been reported to be 
increased in a concentration-and time dependent manner in response to Ang II in 
rat arterial VSMC (Chen et al., 1998), which is inconsistent with the results from 
the present study where there was no change in MCP-1 mRNA expression 
following Ang II stimulation for 24 hours. This discrepancy may be due to the 
HSVSMC used in this study in comparison to rodent arterial VSMC used in other 
studies (Ma et al., 2007, Jin et al., 2012).  
The role of miRNA-132 in Ang II-induced HSVSMC migration was further 
investigated through the use of a miR-132 inhibitor, which blocks miR-132 
activity and through siRNA-mediated downregulation of DICER, a key enzyme 
involved in miRNA biogenesis (van Rooij and Olson, 2007, Bartel, 2009). It was 
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found that Ang II-mediated HSVSMC migration was not dependent on miR-132 or 
through synthesis of an alternative miRNA via DICER. However, this is not 
entirely unexpected as Ang II is a powerful mitogen and has been demonstrated 
to promote VSMC proliferation and migration through a cascade of various cell 
signalling pathways [reviewed by (Touyz and Schiffrin, 2000)]. Therefore, it is 
highly possible that Ang II mediate HSVSMC migration is via an alternative 
pathway independent of regulation of miRNA. However, reduced miR-132 
activity and DICER expression increased basal migration of unstimulated HSVSMC. 
There is no published evidence to support a role for alterations in miR-132 or -
212 in the absence of stimuli. However, a number of miRNAs have been 
demonstrated to be active during the phenotypic switching of VSMC from the 
synthetic to the quiescent state, and would therefore be active during serum 
starvation (Leeper et al., 2011). As HSVSMC were transfected with the DICER 
siRNA prior to being quiesced it is possible that during the 48 hours quiescent 
period, DICER levels were inhibited and as a result miRNAs involved in 
maintaining the cells in a quiescent state were not activated. However, further 
work is required to establish if this is the case and an assessment of miRNA 
levels in comparison to non-quiescent HSVSMC would be required. 
3.5 Conclusion 
In summary, the data demonstrate that Ang-(1-7) or Ang-(1-9),via Mas and the 
AT2R respectively, block FCS induced proliferation and Ang II-induced migration 
of HSVSMC. Investigation into the functional interplay of Ang II, Ang-(1-7) and 
Ang-(1-9) in HSVSMC identified regulation of ERK1/2 activity, and MMP2 and 
MMP9 as potential mechanisms contributing to the observed results. While 
further work is required to fully elucidate the signal transduction pathways of 
Ang-(1-7) and Ang-(1-9) in HSVSMC, this data demonstrates a functional role for 
of Ang-(1-9) in VSMC and is the first to directly compare the effects of Ang-(!-7) 
and Ang-(1-9) in the vasculature, identifying both peptides as potential 
therapeutic targets in acute vascular injury.  
Additionally, Ang II-mediated HSVSMC migration was demonstrated to be 
associated with an increase in miR-132 expression and downregulation of its 
target PTEN at the mRNA level, consistent with previous reports in rat VSMC (Jin 
et al., 2012). These changes were found to be via the AT1R and inhibited by Ang-
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(1-7) and Ang-(1-9). However, PTEN protein levels were unchanged and no 
changes were observed in key proteins involved in the downstream signalling 
pathways of PTEN, including Akt and MCP-1. The role of miR-132 in Ang II 
induced HSVSMC migration was further investigated through the use of a miR-132 
inhibitor and downregulation of DICER. While it was found that Ang-II mediated 
HSVSMC migration was not dependent on miR-132 or regulation of an alternative 
miRNA via DICER, it was found that inhibition of miR-132 or DICER expression 
increased basal HSVSMC migration. Together these findings demonstrate key 
differences in the miRNA response to Ang II between rat and human VSMC, and 
identify a further potential mechanism of HSVSMC migration independent of Ang 
II.  
 
 
 
 
 
 
 
 
Chapter 4 
The effects of Ang-(1-7) and Ang-(1-9) on vascular 
endothelial cell function 
  
  
141 
 
4.1 Introduction 
In the vasculature the endothelium exists as a single cell monolayer surrounding 
the lumenal surface of the vessel wall. The endothelium is able to respond to a 
large number of physical and chemical signals leading to the production of a vast 
number of factors that regulate vascular tone, cell adhesion, thrombogenicity, 
inflammation and VSMC proliferation (White et al., 1994, Furchgott and 
Zawadzki, 1980, Saye et al., 1984, Kinlay et al., 2001, Ghosh and Karin, 2002, 
Gryglewski et al., 1986, Darley-Usmar et al., 1992). With the endothelium 
playing such an important role in vascular homeostasis, it is no surprise that 
damage to the endothelial layer leads to the development and progression of 
various vascular pathologies. Reduced NO bioavailability occurs as a result of 
increased NO degradation or reduced NO production, both of which are largely 
triggered by oxidative stress and the production of ROS (White et al., 1994, 
Darley-Usmar et al., 1992, Gryglewski et al., 1986). ROS production is elevated 
by a number of CVD risk factors including hypertension, hypercholesterolaemia 
and smoking. This alteration in ROS levels leads to reduced endothelial function, 
increased VSMC growth and increased vascular inflammation, all processes which 
underlie the pathology of vascular remodelling and disease (Cai and Harrison, 
2000). 
Prolonged exposure to CVD risk factors, or physical endothelial denudation (as 
occurs during stent deployment in angioplasty procedures or surgical preparation 
of bypass grafts prior to CABG procedures), leads to reduced endothelial 
function and integrity, and untimately to remodelling of the vasculature and 
failure of revascularisation attempts (Kipshidze et al., 2004, Inoue et al., 2011, 
Van Belle et al., 1998). Importantly, the functioning and integrity of the 
endothelium not only depends on the extent of the injury but also on the 
endogenous capacity for repair (Deanfield et al., 2007). One mechanism through 
which the endothelial layer is repaired is by proliferation of adjacent mature 
endothelial cells, which can then migrate to the denuded area to replace the 
lost and damaged cells (Deanfield et al., 2007). Following vascular injury both 
endothelial cells and VSMC become activated, leading to the production and 
release of various growth factors, including bFGF and vascular endothelial 
growth factor (VEGF). These growth factors have been demonstrated to 
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contribute to enhanced endothelial cell growth (Schweigerer et al., 1987, 
Tsurumi et al., 1997, Lindner et al., 1990). 
Re-growth of the endothelial layer is essential in acute vascular injury and has 
been demonstrated to repress neointimal thickening and the occurrence of 
thrombosis. However, the new endothelial layer may also be dysfunctional, 
resulting in decreased vascular integrity, increased permeability and impaired 
vasodilation (Weidinger et al., 1990, Hamon et al., 1995, Hamon et al., 1996, 
Kipshidze et al., 2004). This impaired functioning of the neo-endothelial layer 
has been shown to be maintained for some time following the completion of re-
endothelialisation (Shimokawa et al., 1987, Weidinger et al., 1990). The 
dysfunctional neo-endothelial layer has been linked to impaired vasomotion and 
responses to both vasodilator and vasoconstrictor stimuli (Shimokawa et al., 
1989, Shimokawa et al., 1987, Mc Fadden et al., 1993, Hamon et al., 1996). For 
example, enhanced constrictor responses have been observed in human arterial 
segments previously subjected to angioplasty (Mc Fadden et al., 1993, Hamon et 
al., 1996). Furthermore, the neo-endothelial layer has also been demonstrated 
to have a reduced ability to generate NO, linking this dysfunctional re-growth to 
increased vascular remodelling, inflammation and thrombus formation 
(Weidinger et al., 1990, Saroyan et al., 1992, Hamon et al., 1995). Therefore, 
the optimal treatment strategy in acute vascular injury would not only allow 
complete re-endothelialisation but would contribute to improved functioning of 
the neo-endothelium.  
A role for Ang-(1-7) in improved endothelial function has been well established. 
Ang-(1-7) has been shown to increase NO release via two main mechanisms. 
First, directly through interaction with Mas, Ang 1-7 stimulates eNOS activation 
via reciprocal phosphorylation/dephosphorylation at Serine1177/Threonine495 
further leading to sustained Akt phosphorylation (Sampaio et al., 2007b). 
Second, Ang-(1-7) indirectly increases NO release via production of bradykinin 
and receptor cross talk with the bradykinin BK2R (Jackman et al., 2002, Sampaio 
et al., 2007a). Ang-(1-7)-mediated NO release has been linked to improved 
vascular endothelial function, vasodilation, and reduced ROS production, 
inflammation and thrombosis (Brosnihan et al., 1996, Faria-Silva et al., 2005, 
Stegbauer et al., 2011). Combined, these effects of Ang-(1-7) have been linked 
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to reduced atherosclerosis and improved endothelial function following vein 
grafting (Langeveld et al., 2008, Stegbauer et al., 2011). 
However, there is much less evidence from the literature in support of a direct 
effect of Ang-(1-9) in the endothelium. Ang-(1-9) has been shown to potentiate 
NO release indirectly via interaction with bradykinin signalling. For example, in 
human pulmonary artery endothelial cells Ang-(1-9) has been shown to stimulate 
bradykinin release and to enhance the effects of bradykinin in EC by augmenting 
NO and arachidonic acid release (Erdos et al., 2002, Jackman et al., 2002). 
Importantly, it was shown that not only was Ang-(1-9) an active peptide but that 
it is more potent than Ang-(1-7) in achieving these results (Jackman et al., 
2002). Ang-(1-9) has been demonstrated to have a direct beneficial effect in the 
vasculature by increasing NO bioavailability (Flores-Munoz et al., 2012). 
Continuous infusion of Ang-(1-9) improved aortic vasorelaxation in the SHRSP 
through increased NO bioavailability, an effect which was blocked by PD123,319, 
suggesting that these effects are due to Ang-(1-9) acting via the AT2R (Flores-
Munoz et al., 2012). More recently, Ang-(1-9) was found to induce relaxation of 
rat aortic rings in a concentration- and endothelium-dependent manner; this 
effect was inhibited by PD123,319 but not A779 or losartan, suggesting that in 
this setting Ang-(1-9) mediated vasdodilation of aortic rings via the AT2R 
(Ocaranza et al., 2014). However, the mechanisms through which Ang-(1-9) acts 
to achieve this is currently unknown and a direct effect of Ang-(1-9) on NO 
release in human endothelial cells has yet to be demonstrated.  
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4.1.1 Aims 
The aims of this chapter were to: 
 To establish the optimal conditions for proliferation of HSVEC and assess 
the effect of Ang-II, Ang-(1-7) and Ang-(1-9). 
 To assess the effect of Ang II, Ang-(1-7) and Ang-(1-9) on HSVEC 
migration. 
 To determine the effects of Ang-(1-9) on release of NO from HSVEC. 
 To investigate the effect of Ang-(1-9) on vascular tone in the aorta and 
mesenteric arteries of AT2R
-/- mice. 
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4.2 Results 
4.2.1 AT1R, AT2R and Mas expression in primary HSVEC 
Prior to investigating the effects of Ang-(1-7) and Ang-(1-9) in HSVEC, it was first 
confirmed that the AT1R, AT2R and Mas were expressed in HSVEC via qRT-PCR 
(Figure 4.1). The AT1R (dCt 12.1 ± 2.3) was the most highly expressed of the RAS 
receptors, followed by Mas (dCt 14.2 ± 0.1) and then the AT2R (dCt 16.3 ± 1.9) 
(Figure 4.1). 
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Figure 4.1 Expression of AT1R, AT2R and Mas in HSVEC. 
Expression levels of AT1R, AT2R and Mas in HSVEC was assessed via qRT-PCR using specific 
Taqman probes for each receptor. Results are expressed as average dCt ± S.E.M, relative to the 
endogenous housekeeping gene GAPDH. N=3.   
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4.2.2 Assessing the effects of Ang II, Ang-(1-7) and Ang-(1-9) on 
HSVEC proliferation 
To establish the optimal conditions for HSVEC proliferation, cells were quiesced 
for 24 hours and then exposed to fresh media containing increasing 
concentrations of FCS (0-20% v/v) for 24 hours and HSVEC proliferation assessed 
via the MTS assay. It was found that FCS induced HSVEC proliferation in a 
concentration-dependent manner, with concentrations of 5% FCS and above 
producing significantly increased proliferation in comparison to unstimulated, 
serum free control cells (P<0.05) (Figure 4.2 A). Therefore, for subsequent 
experiments 5% FCS was used to induce HSVEC proliferation.  
To assess whether Ang-(1-7) or Ang-(1-9) blocked HSVEC proliferation quiescent 
cells were incubated with either Ang-(1-7) or Ang-(1-9) (200 nM) and stimulated 
with 5% FCS for 24 hours. As expected, 5% FCS caused a significant increase in 
HSVEC proliferation in comparison to control cells (Figure 4.3 B). However, 
proliferation was unaffected by Ang-(1-9) and Ang-(1-7) and proliferation 
remained significantly increased in comparison to control cells (P<0.05 vs control 
cells) (Figure 4.2 B). 
To investigate if Ang II, Ang-(1-7) or Ang-(1-9) themselves were able to induce 
HSVEC proliferation, quiescent cells were stimulated with each peptide in serum 
free media for 24 hours and then cell proliferation was assessed. While 5% FCS 
induced a significant increase in cell proliferation in comparison to control cells 
(P<0.05), no significant difference was observed between control cells and cells 
stimulated with either Ang II, Ang-(1-7) or Ang-(1-9) (Figure 4.2 C).  
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Figure 4.2 Assessment of the effects of Ang II, Ang-(1-7) and Ang-(1-9) on HSVEC 
proliferation 
Proliferation of HSVEC was assessed using the MTS assay. (A) To assess the concentration of 
FCS required to stimulate proliferation, HSVEC were exposed to media containing increasing 
concentrations of FCS for 24 hours. (B) Cells were incubated with Ang-(1-7) or Ang-(1-9) for 24 
hours, and stimulated with 5% FCS to assess the effect of the peptides. (C) To assess if Ang II, 
Ang-(1-7) or Ang-(1-9) induced proliferation of HSVEC cells were exposed to the peptides in the 
absence of serum for 24 hours; 5% FCS was used as a positive control. N=3-4. *P<0.05, **P<0.01 
vs. control. 
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4.2.3 Effect of Ang II, Ang-(1-7) and Ang-(1-9) on HSVEC migration 
As migration of resident endothelial cells is an important process in re-
endothelialisation following vascular injury (Deanfield et al., 2007), the effects 
of Ang II, Ang-(1-7) or Ang-(1-9), alone or in combination, on HSVEC migration 
was assessed. This was achieved using a scratch assay where scratches were 
induced in the monolayer of quiescent HSVEC prior to stimulation with RAS 
peptides. HSVEC migration was quantified as a percentage reduction in scratch 
width over time. Cells in serum free media alone were used as a control and 
basal HSVEC migration over time resulted in a 43.7 ± 4.5 % reduction in scratch 
size by 30 hours (Figure 4.3). Ang II, Ang-(1-9) and Ang-(1-7), alone or in 
combination had no effect on HSVEC migration in comparison to control cells at 
any time point (P>0.05), suggesting they do not induce HSVEC migration (Figure 
4.3). HSVEC stimulated with complete HSVEC growth media containing 20% (v/v) 
FCS were included as a positive control and it was found that 20% FCS resulted in 
a significant increase in HSVEC migration in comparison to control cells at each 
time point (P<0.05) and by 24-30 hours the wound had completely closed (Figure 
4.3).  
To assess if Ang II, Ang-(1-7) or Ang-(1-9), alone or in combination, inhibited 
serum stimulated HSVEC migration, HSVEC were stimulated with 20% FCS and 
each peptide alone or in combination. The peptides alone or in combination did 
not affect FCS induced HSVEC migration, as there was an equivalent increase in 
HSVEC migration over time as 20% FCS alone and complete wound closure by 24 
hours for all combinations of peptides (Figure 4.4). 
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Figure 4.3 The effects of Ang II, Ang-(1-7) and Ang-(1-9) on HSVEC migration 
HSVEC migration was assessed using a scratch assay. Following starvation in serum free media for 24 hours, 3 scratches were induced in the cell monolayer of each 
well. Cells were then stimulated with Ang II, Ang-(1-9) or Ang-(1-7), alone or in combination (200nM each), in serum free media. Images of the scratch were taken at 0, 
6, 12, 24 and 30 hours post scratch. (A) Representative images of scratch at 0 hours and 24 hours. Scale bar = 40 µm. Magnification 10x.(B) Migration was quantified 
as a reduction in scratch size (%) relative to the 0 hour measurement (B). N=3. ***P<0.001 vs. control.   
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Figure 4.4 The effect of Ang II, Ang-(1-7) and Ang-(1-9) on serum induced migration of HSVEC 
HSVEC migration was assessed using a scratch assay. Following starvation in serum free media for 24 hours, 3 scratches were induced in the cell monolayer of each 
well. Cells were then stimulated with Ang II, Ang-(1-9) or Ang-(1-7), alone or in combination (200nM each), in the presence of 20% FCS. Images of the scratch were 
taken at 0 and 24 hours. Representative images of each condition from an individual experiment which was performed on 3 separate occasions. Scale bar = 40 µm. 
Magnification 10x.  
0 hr
24 hr
Control Ang II Ang-(1-7) Ang-(1-9)
Ang II +
Ang-(1-7)
Ang II +
Ang-(1-9)
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4.2.4 Effects of Ang-(1-9) on nitric oxide release 
In order to investigate the effect of Ang-(1-9) on NO release the cell-permeable, 
fluorescent indicator of NO, DAF-FM, was used. All cells were serum starved for 
2 hours in phenol free media to minimise basal NO release, however, some NO 
activity was maintained in control, unstimulated HSVEC as evidenced by the 
observed fluorescence signal when cells were loaded with DAF-FM (Figure 4.5). 
In control cells the fluorescence signal was most intense in the centre of the 
cells, however, further cellular staining would be required to accurately assess 
NO localisation within the cell. When stimulated with Ang-(1-9) at 200 nM or 1 
µm, there was an increase in the intensity of the fluorescence signal within 
discrete central regions of the cell and there was a change in cell morphology, 
with cells becoming smaller and losing their characteristic cobblestone 
appearance, in comparison to unstimulated control cells at 15 minutes post-
stimulation (Figure 4.5). The Ang-(1-9)-induced increase in fluorescence and 
change in cell morphology was blocked by co-incubation with PD123,319, with 
cells exposed to both peptide and antagonist being similar to control cells 
(Figure 4.5). When HSVEC were stimulated with PD123,319 alone no changes in 
fluorescence or cell morphology in comparison to unstimulated cells were 
observed (Figure 4.5). 
To further assess the involvement of the AT2R in Ang-(1-9) mediated NO release, 
CHO cells were transfected with a plasmid engineered to express the human 
AT2R and then loaded with DAF-FM before being stimulated with Ang-(1-9) 
(Figure 4.6). Untransfected cells and cells transfected with the AT2R displayed 
no basal NO release, as evidenced by the lack of fluorescence signal observed 
(Figure 4.6) While Ang-(1-9) had no effect on untransfected CHO cells, in CHO 
cells expressing the AT2R stimulation with Ang-(1-9) led to generation or release 
of NO, evidenced by increased fluorescence when treated with Ang-(1-9) (Figure 
4.6). In cells expressing the AT2R, PD123,319 blocked the response to Ang-(1-9) 
but had no effect when added alone, providing further evidence to suggest that 
Ang-(1-9) acts via the AT2R in this setting (Figure 4.6).  
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Figure 4.5 Effect of Ang-(1-9) on NO release in HSVEC 
Ang-(1-9) mediated NO release from HSVEC was assessed using DAF-FM. Cells were serum 
starved in phenol free, serum free media for 2 hours to minimise basal NO signalling and then 
loaded with 5 µM DAF-FM for 30 minutes. Cells were stimulated with Ang-(1-9) (200 nM or 1 µM) 
alone or in the presence of PD123,319 (PD123) (500nM); cells were also exposed to PD123,319 
alone. Images of the cells were taken at 15 minutes post-stimulation with peptide or antagonist of 5 
individual areas per condition. Representative images of an experiment performed on 2 separate 
occasions. Scale bar = 25 µm.  
Control Ang-(1-9) 200nM Ang-(1-9) 1μM
Ang-(1-9) 200nM
+PD123
Ang-(1-9) 1μM
+PD123
PD123
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Figure 4.6 Role of the AT2R in Ang-(1-9) induced NO release. 
CHO cells were transfected with a plasmid engineered to express the human AT2R. The following 
day cells were loaded with DAF-FM (5 µM) for 30 minutes and then stimulated with Ang-(1-9) 
(200nM) alone or in the presence of PD123,319 (500nM). Untransfected cells (NTC) control cells 
and cells stimulated with Ang-(1-9), and transfected cells unstimulated and stimulated with 
PD123,319 were used as negative controls. Images of the cells were taken at 15 minutes post 
stimulation of 5 individual areas per condition.  Representative images shown of an experiment 
performed on 2 separate occasions. Scale bar = 10 µm.  
NTC
Ang-(1-9)
AT2R
Ang-(1-9)
AT2R
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4.2.5 Effect of Ang-(1-9) on vascular reactivity in intact vessels 
Despite the data suggesting that Ang-(1-9) mediated NO release is via the AT2R, 
previous unpublished data from Prof Robson Santos’ group demonstrated that 
stimulation of pre-constricted aortic rings from AT2R
-/- mice with Ang-(1-9) 
resulted in significant vasorelaxation in an endothelium- and concentration-
dependent manner (Prof Robson Santos, Federal University of Minas Gerais, 
Brazil, personal communication). This finding was confirmed in the present study 
where it was demonstrated that Ang-(1-9) promoted vasodilation of pre-
constricted aortic rings from AT2R
-/- mice in a concentration and endothelium-
dependent manner, resulting in 19.2 ± 6.3 % relaxation of the vessel at the 
maximal concentration of 1 µM (Figure 4.7 A). As Ang-(1-9) is reported to be 
converted to Ang-(1-7) (Donoghue et al 2000), which is widely accepted to 
promote vasodilation via Mas, vessels were incubated with A779 prior to 
stimulation with Ang-(1-9). A779 blocked the response to Ang-(1-9) and a 
negligible response to Ang-(1-9) was observed both in endothelium intact and 
denuded aortic rings in the presence of A779. 
A similar set of experiments was also performed using mesenteric artery rings 
from AT2R
-/- mice to investigate if this phenotype also occurs in small resistance 
arteries. Similar to in the aorta, incubation with Ang-(1-9) mediated significant 
vasodilation of pre-constricted mesenteric artery rings in a concentration 
dependent manner (Figure 4.7 B). Importantly, this response was also found to 
be endothelium-dependent as vessels with an intact endothelium produced a 
25.8 ± 6.6 % relaxation at the maximum concentration of Ang-(1-9) (1 µM)  which 
was significantly different to the 5.7 ± 2.2 % relaxation observed when the 
endothelium was denuded. However, in contrast to the findings in aortic rings, 
A779 had no effect on the vasodilation induced by Ang-(1-9) in either 
endothelium intact or denuded vessels.  
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Figure 4.7 Effects of Ang-(1-9) on vascular tone in AT2R knockout mice 
Vasorelaxant response to increasing concentrations of Ang-(1-9) in AT2R
-/-
 (A) aortic or (B) 
mesenteric artery rings. Vessel rings were pre-contracted to phenylepherine (Phe) and 
vasorelaxant response to Ang-(1-9) assessed. Response is expressed as % relaxation of the Phe 
preconstriction. N=4-6.  
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4.3 Discussion 
In this chapter, the effect of Ang-(1-7) and Ang-(1-9) on endothelial cell growth, 
migration and function were assessed. It was found that Ang II, Ang-(1-7) or Ang-
(1-9) had no effect on growth or migration of primary, adult HSVEC. 
Furthermore, a direct effect of Ang-(1-9) on NO release from both HSVEC and a 
cell line that expressed the AT2R (CHO) was demonstrated. In vitro Ang-(1-9) 
induced NO release in an AT2R sensitive manner, however in vessels from AT2R
-/- 
mice the biological effect of Ang-(1-9) was maintained and led to vasodilation of 
both aortic and mesenteric artery rings.  
The findings from this current data set demonstrate that Ang II, Ang-(1-7) or 
Ang-(1-9) do not influence endothelial cell proliferation or migration. The 
effects of Ang II on endothelial cell growth and migration have been extensively 
studied and Ang II has been demonstrated to have both pro- and anti-
proliferative effects. For example, Ang II is a potent mediator of angiogenesis 
and has been demonstrated to promote proliferation and migration of 
endothelial cells, largely through increased VEGF expression, leading to vessel 
tube formation and neoangiogenesis (Herr et al., 2008, Zhu et al., 2013, Martini 
et al., 2010). Conversely, Ang II has been demonstrated to promote endothelial 
cell apoptosis, largely through the production of ROS and pro-inflammatory 
cytokines, leading to enhanced endothelial dysfunction and vascular remodelling 
(Dimmeler et al., 1997, Shan et al., 2008, Liu et al., 2013). These differential 
results are not entirely unexpected due to the vast array of cell signalling 
pathways induced by Ang II and are linked to differences in experimental 
protocols used to study different biological processes that occur in angiogensis 
and re-endothelialisation. There is currently no evidence from the literature to 
suggest that Ang-(1-7) or Ang-(1-9) would promote endothelial cell proliferation 
or migration and the majority of studies to date have focussed on the effects of 
these peptides on endothelial cell function (Sampaio et al., 2007a, Sampaio et 
al., 2007b, Jackman et al., 2002).  
In addition to endothelial damage, VSMC proliferation is a key process involved 
in late vein graft failure and in-stent restenosis. One therapeutic approach is 
targeting the VSMC proliferation that underlies the formation of the neointima 
through the use of cell cycle inhibitory drugs, such as rapamycin, paclitaxel or 
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cytochalasin D (Schachner et al., 2004, Murphy et al., 2007). While these drugs 
have been shown to have beneficial effects leading to reduced neointimal 
formation they have also been linked to impaired re-endothelialisation through 
inhibition of endothelial cell proliferation, leading to increased neointimal 
formation and late stage thrombosis which can have serious clinical implications 
(Karha and Topol, 2006, Murphy et al., 2007, Luscher et al., 2007, Douglas et 
al., 2013). Therefore therapies that specifically target VSMC growth and 
migration, without preventing re-endothelialisation are optimal in vein graft 
failure and in-stent restenosis (Inoue and Node, 2009). As demonstrated in 
Chapter 3, both Ang-(1-7) and Ang-(1-9) prevent VSMC proliferation and 
migration. Combined with the findings in this present study that they do not 
effect endothelial cell proliferation or migration, this data set identifies these 
two peptides as potential therapeutics in these pathologies.  
Re-growth of the endothelial layer is essential in acute vascular injury; however, 
the neo-endothelium is often dysfunctional due to an impaired ability to 
generate NO, which can lead to further vascular remodelling, increased 
inflammation and thrombosis (Kipshidze et al., 2004, Weidinger et al., 1990, 
Hamon et al., 1995). Therefore, the optimal treatment strategy would not only 
allow complete re-endothelialisation but would also contribute to improved 
functioning of the neo-endothelium through increased NO production.  
As discussed, Ang-(1-7) via Mas is known to increase NO production directly via 
increased eNOS activity and indirectly via interaction with the bradykinin system 
(Sampaio et al., 2007b, Jackman et al., 2002). This increased NO production has 
been linked to improved vascular endothelial function, vasodilation, and 
reduced ROS production, inflammation and thrombosis (Brosnihan et al., 1996, 
Faria-Silva et al., 2005, Stegbauer et al., 2011). Importantly, Ang-(1-7) has also 
been linked to improved endothelial function as well as reduced vascular 
remodelling following stent implantation in rats, identifying this peptide as an 
attractive therapeutic agent in acute vascular injury (Langeveld et al., 2008, 
Langeveld et al., 2005).  
Comparatively, there is much less known about Ang-(1-9) and for this reason the 
effect of Ang-(1-9) on NO release was assessed in this present study. Ang-(1-9) 
stimulated NO release in an AT2R sensitive manner in both primary HSVEC and in 
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cells transfected with AT2R. While this is the first in vitro evidence to suggest a 
direct effect of Ang-(1-9) signalling via the AT2R leading to production of NO, 
this has previously been demonstrated ex vivo where it was found that aortic 
rings from SHRSPs infused with Ang-(1-9) displayed improved vasorelaxation 
which was blunted by the NOS inhibitor, L-NAME (Flores-Munoz et al., 2012). 
Importantly, this effect was absent in SHRSP infused with Ang-(1-9) and 
PD123,319, suggesting Ang-(1-9) acts via the AT2R. Furthermore, Ang-(1-9) 
induced vasodilation of rat arotic rings in an concentration- and endothelium-
dependent manner, and was blocked by pre-incubation of the vessel with L-
NAME or PD123,319, suggesting that Ang-(1-9) mediated vasodilation via the 
AT2R and generation of NO (Ocaranza et al., 2014). 
In HSVEC, unstimulated cells displayed basal NO release, however, Ang-(1-9) 
stimulation led to increased NO release or generation, associated with a change 
in cell morphology and cellular location of NO. However, this change was 
difficult to quantify due to the level of basal NO activity and the lack of staining 
of different cellular structures, which would allow for a more in depth 
interpretation of the results observed. Additionally, a more thorough assessment 
of NO signalling pathways, over an extended time course, in Ang-(1-9) 
stimulated HSVEC through the use of western immunoblotting for key proteins 
involved, such as eNOS and Akt, is required to understand the mechanism of 
action of Ang-(1-9). This approach has previously been utilised to investigate the 
effects of Ang-(1-7) in primary endothelial cells and demonstrated that Ang-(1-7) 
signalling via Mas induces NO release through sustained Akt activation and 
reciprocal phosphorylation/dephosphorylation of eNOS at serine1177/threonine495 
(Sampaio et al., 2007b). Furthermore, as HSVEC express AT1R, AT2R and Mas, it 
would be worthwhile to extend these findings to include a comparison of the 
effects of Ang II, Ang-(1-7) and Ang-(1-9) on NO signalling in HSVEC to allow for 
an in depth investigation of the functional interplay between the RAS peptides 
and receptors in primary endothelial cells. 
Ang-(1-9) also stimulated release of NO from CHO cells expressing the AT2R. 
While the use of cell lines has less translational impact than the experiments 
performed in primary HSVEC, an artificial approach is beneficial to study the 
Ang-(1-9)/AT2R interaction and cell signalling pathways due to the fact that 
there are less variables. For example, there is no basal NO activity and the cells 
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only express the human form of the AT2R, while the HSVEC express AT1R, AT2R 
and Mas, allowing for interaction between receptors and potential signalling via 
receptors other than AT2R. In fact, the use of both primary cells and cell lines 
would be beneficial to investigate Ang-(1-9) signalling. This approach has 
previously been utilised to investigate the cell signalling mechanisms induced by 
Ang-(1-7) at Mas and to identify the functional effects of the novel RAS peptide 
alamandine and its receptor, MrgD (Sampaio et al., 2007b, Lautner et al., 2013). 
However, there are also some limitations of the cell line-based approach. For 
example, it is important to assess transfection efficiency of the receptor in each 
experiment. However, due to the lack of availability of specific AT2R antibodies, 
it was not possible to determine the transfection efficiency in this current data 
set. One way to overcome this would be to design a plasmid to express the AT2R 
with a fluorescent epitope tag, such as cyan fluorescent protein (CFP), which 
would allow the transfection efficiency to be determined parallel to visualisation 
of the fluorescent NO signal (Canals et al., 2006). One major limitation to 
experiments based on transiently transfected cells is the large variability in 
expression level of the gene of interest among population of cells and between 
experiments (Ward et al., 2011). Furthermore, due to differences in expression 
patterns this approach is not ideal to study receptor interactions. Therefore, it 
would be worthwhile to generate stable cell lines to express either the AT2R 
alone or co-expressed with another receptor to allow for the study of receptor 
interactions. Stable cell lines remove both the variability between populations 
and experiments as they as designed so that all cells express the receptor and 
from one parental stock of cells (Ward et al., 2011). Stable cell lines engineered 
to express the AT1R and Mas have proven utility in aiding the understanding of 
ligand-mediated signalling at each receptor as well as allowing the effects of 
receptor-receptor interaction to be assessed (Kostenis et al., 2005). 
While the data discussed above demonstrate that Ang-(1-9) stimulates NO 
release in an AT2R dependent manner in vitro, ongoing, unpublished studies 
from Prof. Robson A. Santos’ research group revealed that Ang-(1-9) induced 
vasodilation in pre-constricted aortic rings from both wild type and AT2R
-/- mice 
in an endothelium dependent manner, suggesting that at least ex vivo Ang-(1-9) 
may act on the endothelium via an alternative receptor or mechanism. These 
findings in the AT2R
-/- mice were confirmed in this present study in both aortic 
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rings and mesenteric artery rings, demonstrating that the effect is present in 
both large conduit vessels and small resistance arteries. However, it is important 
to highlight the low number of vessels/animals used in this study, therefore, 
further replicates are required. Additionally, it would be worthwhile to 
investigate differences in expression of other RAS receptors or enzymes within 
the vessels of the two strains of mice in order to gain further insight into any 
potential differences in the vasorelaxant response to Ang-(1-9) in the presence 
and absence of the AT2R. 
The fact that Ang-(1-9) elicits direct biological effect independent of the AT2R is 
somewhat unexpected as to date all previously published data suggests that Ang-
(1-9) acts via this receptor (Flores-Munoz et al., 2011, Flores-Munoz et al., 2012, 
Ocaranza et al., 2014, Cha et al., 2013). One possible explanation for this 
phenotype is that in the absence of the AT2R, Ang-(1-9) acts on an alternative 
receptor leading to vasodilation, however, further work would be required to 
investigate this fully. Another explanation is that Ang-(1-9) may be metabolised 
to an alternative peptide, such as Ang-(1-7) which also promotes vasodilation in 
an endothelium-dependent manner.  As Ang-(1-7) has been shown to promote 
vasodilation via Mas this potential mechanism of action was explored in the 
current study using the Mas antagonist A779. A779 blocked the vasodilator 
effects of Ang-(1-9) in aortic rings but not mesenteric artery rings, suggesting 
that in the aorta, but not mesenteric artery, Ang-(1-9) may be converted to Ang-
(1-7) which acts via Mas to induce vasodilation.  
It is currently unclear as to why this differential mechanism of action of Ang-(1-
9) between vascular beds occurs, one possibility is that levels of key enzymes 
involved in Ang-(1-9) metabolism, such as ACE, are differentially expressed 
within the aorta and mesenteric arteries of AT2R
-/- mice, and therefore future 
experiments should involve an assessment of ACE expression. Furthermore, the 
differential mechanism of relaxation is possibly linked to differences in the 
mechanisms of vasodilation in conduit and resistance vessels. In large conduit 
vessels such as the aorta, release of NO from the endothelium is the main 
mechanism of vasodilation, and in smaller resistance vessels, such as the 
mesenteric arteries, EDHF emerges as an important mediator of vasodilation in 
addition to NO. In fact, it has been demonstrated that the contribution of EDHF-
mediated responses as a mechanism for endothelium-dependent relaxation 
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increases as the vessel size decreases (Shimokawa et al., 1996), with the 
exception of the coronary and renal vasculature where EDHF plays a major role 
even in large conduit arteries (Feletou and Vanhoutte, 1988). In mice, EDHF-
mediated responses in resistance vessels are at least as important as NO in 
mediating endothelium-dependent vasodilatation, as demonstrated by the fact 
that neither inhibition of or genetic deletion of eNOS attenuates vasodilator 
responses both in vivo and in vitro (Waldron et al., 1999, Brandes et al., 2000). 
Therefore, it is possible that in the absence of the AT2R, in the aorta Ang–(1-9) is 
metabolised to Ang-(1-7), a peptide which has previously been demonstrated to 
promote vasodilation via NO, while in the mesenteric arteries Ang-(1-9) activates 
an alternative signalling pathway that is potentially involved in EDHF signalling. 
The findings from this data set highlight the need for accurate measurement of 
peptide levels and the use of a combination of RAS peptides and antagonists to 
fully understand the functional interplay involved. 
While the current data set suggests that neither Ang-(1-7) nor Ang-(1-9) would 
enhance regeneration of the endothelial layer through proliferation or migration 
of resident endothelial cells, it is possible that these peptides may promote re-
endothelialisation via an alternative mechanism. It has been suggested that 
while local endothelial cells would be sufficient to maintain vascular integrity 
throughout life in healthy circumstances, in the maintained presence of risk 
factors, loss of endothelial integrity would rapidly develop if local replication 
were the only repair mechanism (Op den Buijs et al., 2004). It has become clear 
that circulating endothelial progenitor cells (EPC) are an alternative mechanism 
for maintenance and repair of the endothelium (Asahara et al., 1997). These 
cells are recruited from the bone marrow, circulate in the peripheral blood, and 
can differentiate into mature cells with endothelial characteristics. In their fully 
developed state they are capable of endothelial outgrowth and tube or vascular 
sprout formation, and therefore are involved in re-endothelialisation and 
angiogenesis (Asahara et al., 1997). Although under physiological conditions EPC 
do not contribute significantly to endothelial cell turnover of blood vessels in 
normal adult tissue, there is a robust contribution of circulating EPCs to 
endothelial cells within vessels one month following vascular injury (Crosby et 
al., 2000).  Several factors, including VEGF, NO, estrogen and drugs such as 
statins can regulate the number of EPC in the circulation (Takahashi et al., 
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1999, Asahara et al., 1999, Dimmeler et al., 2001, Strehlow et al., 2003, Aicher 
et al., 2003). 
In recent years the effects of the RAS, in particular Ang II, on EPC population 
and function has been explored. Evidence from the literature suggests that Ang 
II can be both detrimental and beneficial to EPC functioning. For example, Ang II 
via the AT1R has been linked to reduced EPC population in a number of models, 
an effect which has been linked to inhibition of differentiation of bone marrow 
mononuclear cells (BM-MNC) to EPCs (Bahlmann et al., 2005, Yu et al., 2008, 
You et al., 2008). For example, in BM-MNC cultured from SHRs, AT1R inhibition 
increased the number of EPCs after a 7 day culture period (You, Cochain et al. 
2008). Additionally, chronic AT1R inhibition in vivo increased EPCs but not 
haematopoetic stem cells in diabetic patients, suggesting that the AT1R may 
inhibit their differentiation to EPCs (Bahlmann, de Groot et al. 2005). Ang II has 
also been linked to increased EPC senescence through increased ROS production 
(You et al., 2008, Imanishi et al., 2005). Stimulation of EPC senescence occurred 
due to increased activation of NADPH oxidase signalling leading to increased ROS 
and ONOO- production. Increased oxidative stress was associated with down-
regulation of the chromosomal telomere-extending enzyme telomerase, 
suggesting that Ang II may induce telomeric damage in EPC leading to 
senescence. However, in other cell types Ang II/ROS-induced senescence does 
not involve telomeres or telomerase activity, and therefore its effect could also 
be associated with global DNA damage (Herbert et al., 2008). Further 
investigation into the mechanisms of Ang II induced senescence is therefore 
required.  In contrast, it has also been demonstrated that Ang II improves EPC 
recruitment through stimulation of VEGF, which leads to increased eNOS 
signalling (Imanishi et al., 2005, Qian et al., 2009). However, while Ang II may 
have the potential to enhance the activity of EPC’s, increased Ang II is 
detrimental during vascular injury and it would therefore be unsuitable to utilise 
this peptide as a therapy. 
There is also mounting evidence to suggest a role for Ang-(1-7) in EPCs. For 
example, Ang-(1-7) has been shown to increase production of EPCs in a Mas 
dependent manner (Qian et al., 2009). Furthermore, Ang-(1-7) has recently been 
demonstrated to improve EPC migration and functioning in diabetic patients 
(Jarajapu et al., 2013). The mechanisms through which Ang-(1-7) increases EPC 
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population are still unknown; however, two potential pathways have been 
identified. First, Ang-(1-7) inhibits Ang II-induced ROS production through 
inhibition of c-Src signalling and therefore reduced NADPH oxidase activity 
(Sampaio et al., 2007a). Second, Ang-(1-7) has been demonstrated to stimulate 
eNOS activity through Akt (Sampaio et al., 2007b), and this pathway is also 
involved in VEGF signalling. Since these pathways play an important role in EPC 
senescence and angiogenic function, respectively, they may account for the 
stimulating effects of Ang-(1-7) on EPCs (Qian et al., 2009). 
An effect of Ang-(1-9) on EPC generation or function has yet to be identified, 
however, ACE2 has recently been linked to improved EPC function through 
increased eNOS expression and activity, and reduced production of ROS (Chen et 
al 2013). While the authors concluded that this was likely to be due to reduced 
Ang II and increased Ang-(1-7) production (Chen et al., 2013), as Ang-(1-9) is also 
synthesised by ACE2 it is possible that this peptide may also play a role in the 
observed results. While the involvement of EPCs in the protective effects of Ang-
(1-7) and Ang-(1-9) in acute vascular injury has not yet been explored, this novel 
interaction identifies a potential mechanism for enhanced re-endothelialisation. 
4.4 Conclusion 
In summary, the data demonstrate that Ang-(1-7) or Ang-(1-9) do not promote or 
inhibit proliferation or migration of primary HSVEC, suggesting that they would 
not limit re-endothelialisation following vascular injury. Furthermore, a direct 
role for Ang-(1-9) in production of NO has been identified, which appears to be 
mediated via the AT2R in vitro. However, studies using AT2R
-/- mice revealed 
that Ang-(1-9) retained its biological functions in the absence of the AT2R, 
suggesting that, at least in the absence of the AT2R, Ang-(1-9) can either act at 
an alternative receptor or is metabolised to an alternative peptide which 
promotes vasodilation. Importantly, in the aorta the vasodilator effect of Ang-(1-
9) was abolished by A779, indicating that in the aorta Ang-(1-9) may be 
converted to Ang-(1-7) to elicit its effects. Interestingly, this was not observed 
in the mesenteric arteries, identifying differential effects of Ang-(1-9) between 
vascular beds. While further work is required to fully elucidate the effects of 
Ang-(1-9) in the vasculature, this present study highlights both Ang-(1-7) and 
Ang-(1-9) as potential therapeutic targets in acute vascular injury. 
 
 
 
 
 
 
 
 
 
Chapter 5 
Effects of Ang-(1-7) and Ang-(1-9) on vascular 
remodelling in vivo 
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5.1 Introduction 
As atheroscelerosis develops, advanced complex plaques are formed that largely 
occlude the affected artery resulting in reduced blood flow through the vessel 
and tissue ischaemia (Ross, 1999a). Restoration of blood flow through an 
occluded blood vessel, known as revascularisation, is most commonly achieved 
through CABG surgery or PCI (Goldman et al., 2004, British Heart Foundation, 
2012, European Coronary Surgery Study Group, 1982, RITA-2 trial participants, 
1997, King, 2005). However, the long-term success of these treatments are 
significantly limited by failure of conduit grafts in CABG and restenosis of 
stented vessels in PCI, caused by neointimal formation, impaired re-
endothelialisation and thrombosis (Motwani and Topol, 1998, Mehilli et al., 
2011, Lopes et al., 2012, Schwartz et al., 1995, Mitra et al., 2006). 
Various cellular processes initiated during and immediately following 
engraftment of the vein to the arterial system underlie the pathogenesis of vein 
graft failure, both at an early and late stage. Surgical preparation of the vein 
causes significant denudation of the endothelial layer and immediately following 
engraftment to the arterial circulation the vein is exposed to a period of 
ischaemia following by reperfusion (Thatte and Khuri, 2001, Shi et al., 2001, 
West et al., 2001). Furthermore, the engrafted vein is subject to increased 
pressure and altered haemodynamic conditions within the arterial circulation 
resulting in further endothelial stress (Dobrin et al., 1989). Together, this results 
in the generation of ROS, which in turn trigger an inflammatory response within 
the graft, leading to recruitment of platelets and various inflammatory cells 
(West et al., 2001, Shi et al., 2001). Under these conditions, the remaining 
endothelial cells become activated, allowing adhesion of the circulating 
platelets and inflammatory cells. This exposes the circulating blood to a highly 
thrombogenic surface, resulting in thrombosis, the main cause of early vein graft 
failure (Bryan and Angelini, 1994).  These early events also predispose the vessel 
to neointimal formation and superimposed atherosclerosis, the main cause of 
reduced graft patency. Adherent platelets and leukocytes generate various 
growth factors and pro-inflammatory mediators which activate VSMC within the 
media, leading to VSMC migration to the intima where they proliferate and 
synthesise ECM, resulting in the formation of a large neointimal area (Lerner et 
al., 1986, Cooper and Newby, 1991, Segel et al., 2011). While VSMC migration 
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and proliferation is thought to be most prevalent within the first week following 
engraftment, these processes are key in vein graft patency and failure (Newby, 
1997). Furthermore, this neointimal area is highly susceptible to an accelerated 
form of atherosclerosis due to the infiltration of inflammatory cells, which 
creates a cytotoxic environment within the plaque encouraging the uptake of 
lipids (Schwartz et al., 1995). Adherent monocytes infiltrate the vessel wall and 
differentiate into resident macrophages which then transform into foam cells 
following lipid uptake. These resident macrophages also release various 
mediators that further enhance neointimal formation such as MMPs, growth 
factors and cytokines. The atherosclerotic plaques that form within the graft are 
diffuse and unstable due to poorly developed or absent fibrous caps, and are 
therefore more prone to rupture (Shelton et al., 1988, Virmani et al., 1988).  
Within four weeks the endothelial layer of the engrafted vein is repaired due to 
proliferation and migration of endothelial cells and recruitment of bone marrow 
derived EPCs, a process which is thought to repress VSMC growth and 
proliferation, and therefore neointimal thickening (Cross et al., 1988, Ku et al., 
1991). However, the function of the new endothelial layer is impaired, largely 
due to the increased arterial pressure and asymmetric neointimal area creating 
increased flow-induced stress, resulting in endothelial cell damage and 
enhanced platelet and leukocyte adhesion. This process ultimately leads to late 
stage thrombosis and enhanced neointimal thickening (Shimokawa et al., 1987, 
Dobrin et al., 1989, Caro et al., 2002). 
In the setting of in-stent restenosis, the neointimal growth that occurs is a 
multifactorial response to mechanical vessel injury at the time of stent 
deployment. The force required to dilate the vessel and deploy the stent results 
in denudation of the endothelium and often dissection of the medial layer of the 
arterial wall (Costa and Simon, 2005). Furthermore, the atherosclerotic plaque is 
compressed and the fibrous cap disrupted, exposing the sub-endothelial pro-
inflammatory core of the plaque to the circulating blood (Inoue and Node, 
2009). This initial damage stimulates an acute inflammatory response within the 
vessel, resulting in expression of adhesion molecules, recruitment and 
infiltration of various inflammatory cells and a cascade of cytokine and growth 
factor release (Costa and Simon, 2005, Welt and Rogers, 2002). The pro-
inflammatory environment within the vessel is sustained for several weeks 
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following injury and leads to migration and growth of VSMC, processes which 
underlie the pathogenesis of restenosis and neointimal growth (Libby et al., 
1992). While the VSMC closest to the region of injury undergo apoptosis, the 
surviving VSMC migrate from the media to the intima (Perlman et al., 1997, 
Hanke et al., 1990). Activated platelets at the site of injury and resident VSMC 
secrete growth factors promoting VSMC proliferation and migration (Walker et 
al., 1986). VSMC proliferation is thought to be maximal at 5 to 7 days after 
injury with around 10 to 20% of the total medial VSMC proliferating (Rogers et 
al., 1998). VSMC in the synthetic state are also key producers of ECM proteins, 
such as collagens and proteoglycans, resulting in increased neointimal volume 
due to the high rate of ECM synthesis which lasts for a number of months 
following injury (Inoue and Node, 2009, Lee et al., 1993).  
Re-endothelialisation of the vessel is thought to occur within three to four weeks 
following PCI with growth factors such as VEGF facilitating endothelial cell 
proliferation and migration (Brindle, 1993). While re-growth of the endothelial 
layer has been demonstrated to repress neointimal thickening and the 
occurrence of thrombosis, the new endothelial layer may also be dysfunctional, 
resulting in decreased vascular integrity, increased permeability and impaired 
vasodilation (Weidinger et al., 1990, Hamon et al., 1995, Kipshidze et al., 2004). 
One interventional approach to prevent late vein graft failure and in-stent 
restenosis is targeting the VSMC proliferation that underlies the formation of the 
neointima through the use of cell cycle inhibitory drugs, such as paclitaxel or 
sirolimus (Htay and Liu, 2005, Murphy et al., 2007). In the case of CABG surgery 
the vein graft can be incubated with these drugs prior to engraftment and 
several studies in animal models have shown that adopting this approach results 
in reduced neointimal formation, at least in the early phase of disease 
(Schachner et al., 2004, Murphy et al., 2007). For example, incubating pig 
saphenous veins for one hour with paclitaxel, sirolimus or cytochalasin D reduced 
neointimal formation at one but not three months following implantation 
(Murphy et al., 2007). Additionally, sirolimus reduced re-endothelialisation and 
increased the incidence of thrombosis (Murphy et al., 2007). In an attempt to 
circumvent the issue of restenosis following stent employment drug eluting 
stents were developed which were coated with polymers to elute the cell cycle 
inhibitory drugs (Htay and Liu, 2005). Drug eluting stents have been shown to 
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inhibit restenosis in comparison to bare metal stents, confirming that inhibition 
of VSMC proliferation is beneficial in this setting (Schampaert et al., 2006, Stone 
et al., 2009, Caixeta et al., 2009), however they do not come without 
complications of their own. Several studies have reported that drug eluting 
stents are associated with an increased risk of late stent thrombosis (Karha et 
al., 2006, Joner et al., 2007) as the drugs also inhibit endothelial cell 
proliferation, thereby inhibiting regeneration of the endothelial layer, enhancing 
neointimal formation and increasing the incidence of late in-stent thrombosis 
(Douglas et al., 2012). Therefore therapies that specifically target VSMC growth 
and migration, without preventing re-endothelialisation are optimal in vein graft 
failure and in-stent restenosis (Inoue and Node, 2009).  
As discussed in Chapter 3, Ang-(1-7) and Ang-(1-9) prevent VSMC migration and 
proliferation, via the Mas receptor and AT2R, respectively. Importantly, as shown 
in Chapter 4, these peptides did not affect endothelial cell proliferation and 
migration, indicating that they may prevent neointimal formation but not inhibit 
re-endothelialisation of the vasculature following injury in vivo, and are 
therefore attractive novel therapeutic targets in the setting of vascular 
remodelling. In this chapter the role of Ang-(1-7) and Ang-(1-9) in vivo in a 
mouse model of vascular remodelling, the carotid artery wire injury model, has 
been investigated. This model was first developed by Lindner et al in 1993 and 
involves isolation of the carotid artery and advancement of a guide wire into the 
vessel towards the aorta (Lindner et al., 1993). This causes endothelial 
denudation and in turn promotes intimal and medial VSMC proliferation and 
migration, and rapid platelet adherence to the subendothelial matrix, resulting 
in the formation of a large neointima within 2 to 4 weeks (Lindner et al., 1993). 
Repair of the endothelial layer is expected to be complete at 4 weeks following 
injury (Lindner et al., 1993). Based on the effects of Ang-(1-7) and Ang-(1-9) in 
vitro and the fact that this will be the first study to assess the role of Ang-(1-9) 
in this setting, this model was deemed to be ideal to investigate the role of Ang-
(1-7) and Ang-(1-9) in vascular remodelling.  
Additionally, this study includes an investigation into the involvement of the 
AT2R and Mas receptor in this setting. Ang-(1-7) is widely accepted to be the 
endogenous ligand at the Mas receptor (Santos et al., 2003) has been previously 
shown to exert its inhibitory effects on neointimal formation in rats by 
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interaction with Mas (Zeng et al., 2009) and therefore a group of animals were 
administered both Ang-(1-7) and A779 following vascular injury to assess this 
interaction in the mouse carotid artery injury model. The protective effects of 
Ang-(1-9) has been previously shown to be mediated via the AT2R and 
independent of conversion to Ang-(1-7) and signalling at Mas (Flores-Munoz et 
al., 2012, Flores-Munoz et al., 2011) (Chapters 3 and 4). However as very little is 
known about this peptide in the vasculature, one group of animals received Ang-
(1-9) and PD123, 319, and another Ang-(1-9) and A779 to investigate the possible 
conversion to Ang-(1-7). All peptide and antagonist combinations were delivered 
subcutaneously via osmotic mini pumps resulting in delivery of the peptide to 
the systemic circulation at a constant rate over the 28 day post-operative 
period. 
Furthermore, an additional study was performed to assess the effectiveness of 
locally delivered peptide in the mouse carotid artery wire injury model. Here 
the peptides were applied directly to the vessel immediately following injury to 
allow for local delivery through the use of Pluronic F127 gel. Pluronic F127 is a 
commercially available copolymer that when dissolved in aqueous solution 
displays the unique characteristic of reverse thermal gelation, as at room 
temperature Pluronic F127 solution is a viscous liquid which is transformed to a 
semisolid gel at body temperature (Schmolka, 1972).  Therapies can therefore 
be dissolved in the Pluronic F127 solution when aqueous then be delivered 
locally to the animal to form a gel based depot of the therapeutic at the site of 
administration. This approach has never been used to deliver Ang-(1-7) or Ang-
(1-9), and confirmation of delivery of the peptides was required prior to 
investigating their therapeutic potential. Therefore a pilot study was performed 
using an antibody against Ang-(1-7) and a biotinylated form of Ang-(1-9) to 
confirm their delivery prior to investigating the therapeutic effects of locally 
delivered peptides. 
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5.1.1 Aims 
The aims of this chapter were: 
 To determine the extent of neointimal formation and vascular 
remodelling following carotid artery injury in C57BL/6 mice. 
 To investigate the effect of subcutaneous delivery of Ang-(1-7) and Ang-
(1-9), and the role of Mas and the AT2R, on neointimal formation and 
vascular remodelling following carotid artery injury in C57BL/6 mice. 
 To assess the efficacy of Pluronic F127 gel as a method for local delivery 
of Ang-(1-7) and Ang-(1-9). 
 To determine the effects of local delivery of Ang-(1-7) and Ang-(1-9) on 
neointimal formation and vascular remodelling following carotid artery 
C57BL/6 mice. 
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5.2 Results 
5.2.1 Neointimal formation in C57BL/6 mice following vascular 
injury 
Total body weight was monitored throughout the wire injury study and no 
difference was observed between sham and injured mice (Table 5.1). Heart and 
kidney weight were assessed at 28 days and expressed a percentage of total 
body weight; no differences in heart or kidney were observed between sham and 
injured mice (Table 5.1). 
Table 5.1 Body and organ weight measurements following sham and vascular injury 
procedures. 
 
Histological analysis of EVG stained sections from carotid arteries at 28 days 
following wire injury revealed a significant increase in vascular remodelling in 
injured carotid arteries in comparison to sham operated arteries (Figure 5.1). 
This remodelling was associated with the formation of a significant neointimal 
area (23608.3 ± 5100.1 µm2 wire injury vs. 176.9 ± 136.4 µm2 sham; P<0.01), an 
increase in medial area (57300.5 ± 16051.3 µm2 wire injury vs. 23842.9 ± 1376.7 
µm2 sham; P<0.05) and neotintima/media (NI/MA) ratio (0.49 ± 0.13 wire injury 
vs.0.01 ± 0.01 sham; P<0.01) (Figure 5.1). Additionally, injured carotid arteries 
had a more disorganized elastic lamina in comparison to sham operated animals. 
The neointimal area observed in wire injured vessels appeared to have a large 
proportion of ECM as evidenced by the large proportion of elastin (black) and 
collagen (pink) staining (Figure 5.1).  
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Figure 5.1 Neointimal growth in the carotid artery 28 days after sham and vascular injury 
procedure.  
Representative histological sections of the left carotid artery from (A) sham and (B) injured mice 
using EVG staining. Elastin appears black and collagen pink. (C) Neointimal area (NI), (D) media 
area (MA), and (E) NI/MA ratio was assessed. Outer dotted line = external elastic lamina, middle 
dotted line = internal elastic lamina, inner dotted line = lumen. Scale bar =100 μm, magnification 
x20, red box = 3x zoom. ***P<0.001, **P<0.01, P<0.05 vs. sham. n=6-8. 
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5.2.2 Effects of subcutaneous delivery of Ang-(1-7) and Ang-(1-9) 
on vascular remodelling, in the absence and presence of 
Mas or AT2R inhibition,  
Total body weight was monitored throughout the study and no difference was 
observed between the experimental groups (Table 5.2). Heart and kidney weight 
was assessed at 28 days and expressed a percentage of total body weight; no 
differences in heart or kidney were observed between the experimental groups 
(Table 5.2). 
Table 5.2 Effects of subcutaneous delivery of water, Ang-(1-7) and Ang-(1-9) on body and 
organ weight measurements following vascular injury 
 
 
EVG staining was also performed to assess the extent of vascular remodelling 
following subcutaneous delivery of Ang-(1-7) and Ang-(1-9), in the absence and 
presence of Mas or AT2R inhibition (Figure 5.2). Delivery of Ang-(1-7) resulted in 
a trend towards reduced neointimal area (16538.0 ± 3487.3 µm2 Ang-(1-7) vs. 
30609.7 ± 2771.3 µm2 control) and a significant reduction in NI/MA ratio (0.40 ± 
0.07 Ang-(1-7) vs. 0.80 ± 0.07 control; P<0.05) in comparison to control vessels 
(Figure 5.2). Ang (1-7) had no effect on medial area (39178.3 ± 6051.23 µm2 Ang-
(1-7) vs. 38132.8 ± 2708.8 µm2 control) (Figure 5.2). To assess the involvement 
of Mas in the effect of Ang-(1-7), Ang-(1-7) and A779 were co-infused for 28 days 
following vascular injury. A779 abolished the effects of Ang-(1-7), resulting in a 
similar neointimal area as control vessels (28617.1 ± 3479.9 µm2 Ang-(1-7) 
+A779; P>0.05 vs control) (Figure 5.2).  
Ang-(1-9) also reduced vascular remodelling in comparison to control vessels, 
resulting in a significant reduction in neointimal area (6577.7 ± 3090.0 µm2 Ang-
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(1-9) vs. 30609.7 ± 2771.3 µm2 control; P<0.001) and NI/MA ratio (0.17 ± 0.10 
Ang-(1-9) vs. 0.80 ± 0.07 control; P<0.001), suggesting it may be more 
efficacious than Ang-(1-7) (Figure 5.2). Media area was unaltered by Ang-(1-9) 
(50664.8 ± 4847.1 µm2 Ang-(1-9) vs. 38132.8 ± 2708.8 µm2 control; P>0.05 vs 
control) (Figure 5.2).  
To assess the involvement of the AT2R in the effects of Ang-(1-9), Ang-(1-9) was 
co-infused with PD123,319 for 28 days following vascular injury. Co-infusion of 
PD123,319 with Ang-(1-9) blocked its effects, resulting in a significant increase 
in neointima area compared to Ang-(1-9) (32912.6 ± 6432.3 µm2 Ang-(1-
9)+PD123,319 vs 6577.7 ± 3090.0 µm2 Ang-(1-9); p<0.001) and NI/MA (0.58 ± 0.13 
Ang-(1-9)+PD123,319 vs 0.17 ± 0.10 Ang-(1-9);P,0.05) in comparison to animals 
who received Ang-(1-9) alone (Figure 5.2). PD123,319 blocked the effects of 
Ang-(1-9) on neointima area and NI/MA to similar levels as control vessels (Figure 
5.2). Furthermore, co-infusion of Ang-(1-9) and PD123,319 resulted in a 
significant increase in media area in comparison to control (61230.0 ± 7993.2 
µm2Ang-(1-9) + PD123,319 vs 38132.8 ± 2708.8 µm2 control; P<0.05) (Figure 5.2).  
Ang-(1-9) was also co-infused with A779 to address the possibility of conversion 
to Ang-(1-7) and/or interaction with Mas.  A779 did not alter the anti-
remodelling effects of Ang-(1-9), resulting in a comparable neointima area 
(13751.1 ± 2709.4 µm2) and NI/MA (0.34 ± 0.06) to Ang-(1-9) treated groups; 
both parameters were significantly different to control vessels (neointima area 
P<0.05 and NI/MA P<0.01 vs control). Co-infusion of Ang-(1-9) and A779 resulted 
in an equivalent medial area to control and Ang-(1-9) treated vessels [42175.2 ± 
3019.6 µm2; P>0.05 vs control or Ang-(1-9)] (Figure 5.2). 
During histological analysis of the vessels it was also observed that while co-
infusion of Ang-(1-7) with A779, and Ang-(1-9) with PD123,319 prevented the 
anti-remodelling effects elicited by the peptides alone, a large proportion of 
these two groups had increased vessel remodelling, largely within the media, in 
comparison to all other groups (Figure 5.3). This increased remodelling 
presented in the form of more complex lesions and was associated with positive 
vessel remodelling, medial hyperplasia, and stretching and often disruption of 
the elastic lamina (Figure 5.3).  
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Figure 5.2 Effects of subcutaneous delivery of Ang-(1-7) and Ang-(1-9) on neointima 
formation in the carotid artery at 28 days following vascular injury, in the absence and 
presence of Mas or AT2R inhibition. 
Representative histological sections of the injured left carotid artery from (A) control animals 
(water) and animals administered (B) Ang-(1-7), (C) Ang-(1-9), (D) Ang-(1-7)+A779, (E) Ang-(1-
9)+PD123,319 or (F) Ang-(1-9)+A779 stained using EVG staining. Elastin appears black while 
collagen is stained pink. (G) Neointima area, (H) media area and (I) NI/MA ratio was assessed. 
Scale bar =100 μm, magnification x20, red box = 3x zoom.  ***P<0.01 **P<0.01, P<0.05 vs. control 
(water); 
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Figure 5.3 Incidence of increased vessel remodelling 
Representative histological sections of the injured left carotid artery exhibiting (A) normal and (B) 
more complex vascular remodelling at 28 days post injury stained with EVG. Complex lesions 
presented with positive outward vessel remodelling and stretching of and/or disruption of the elastic 
lamia, as indicated by red arrows. (C) Number of mice per group with complex vessel remodelling 
at 28 days following vascular injury. Scale bar =100 μm, magnification x20. Red box = 3x zoom. 
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5.2.2.1 Structural composition of remodelled vessels. 
To further investigate the effects of Ang-(1-7) and Ang-(1-9) on vascular 
remodelling following injury the composition of the lesions was assessed using 
further histological analysis.  
5.2.2.1.i  Extracellular matrix 
EVG staining was performed to assess elastin content within the vessel (Figure 
5.2). At 28 days post injury, large areas of neointimal formation were present in 
control and Ang-(1-7) + A779 and Ang-(1-9) + PD123, 319 infused animals, with 
comparatively smaller neointimal area in Ang-(1-7), Ang-(1-9) and Ang-(1-9) 
+A779 treated animals. The neointima areas contained large amounts of ECM as 
indicated by the high degree of elastin staining. In control vessels, a high degree 
of elastin staining was observed within the media, this was unaltered in animals 
infused with Ang-(1-7) or Ang-(1-7)+A779, however reduced medial elastin 
content was observed in animals infused with Ang-(1-9) alone or Ang-(1-9) and 
PD123,319 or A779.  
Picrosirus red staining was used to assess collagen content within the remodelled 
vessels at 28 days post injury (Figure 5.4). Picrosirus red staining was present 
within the neointima, and a higher degree of positive staining was observed 
within the neointima compared to the media. However, positive collagen 
staining was similar in colour to the elastic lamina and much less than staining 
observed in the periadventitial connective tissue, therefore under these 
conditions it is unclear if the pink staining is truly new collagen deposition or 
whether stained elastic fibres were contributing to the observed results.  
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Figure 5.4 Picrosirus red staining of left carotid arteries at 28 days following vascular injury. 
Representative histological sections of the injured left carotid artery from (A) control animals 
(water) and animals administered (B) Ang-(1-7), (C) Ang-(1-9), (D) Ang-(1-7)+A779, (E) Ang-(1-
9)+PD123,319 or (F) Ang-(1-9)+A779 stained with picrosirus red and counterstained with Weigarts 
haemotoxylin. Collagen appears pink/red and nuclei appear purple/blue. Outer dotted line = 
external elastic lamina, middle dotted line = internal elastic lamina, inner dotted line = lumen. Scale 
bar =100 μm, magnification x20. Red box = 3x zoom. N = 6-10 animals per group.  
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5.2.2.1.ii. Vascular smooth muscle cell content 
As migration and proliferation of VSMC are key processes in neointimal 
formation, the contribution of VSMC to vascular remodelling following injury was 
assessed via the presence of α-SMA, a SMC marker (Figure 5.5). Vessels from all 
groups at 28 days displayed positive staining for α-SMA within both the media 
and neointima. Large neointimal lesions were observed in control, Ang-(1-
7)+A779 and Ang-(1-9)+PD123, 319 treated animals and these neointimal areas 
were largely composed of VSMC, as indicated by the high degree of positive 
detection of α-SMA. Overall these vessels contained a larger number of α-SMA 
positive cells due to the presence of a large neointima in comparison to vessels 
from animals infused with Ang-(1-7), Ang-(1-9) or Ang-(1-9) + A779.  
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Figure 5.5 α-SMA content of the left carotid artery at 28 days following vascular injury. 
IHC was performed using an anti-α-SMA antibody to assess VSMC expression within the injured 
vessel. DAB chromagen was used to detect α-SMA positive cells (brown), indicated by arrow head, 
and tissue sections were counterstained with haemotoxylin to visualise nuclei (blue). 
Representative histological sections of α-SMA content in the injured left carotid artery from (A) 
control animals (water) and animals administered (B) Ang-(1-7), (C) Ang-(1-9), (D) Ang-(1-
7)+A779, (E) Ang-(1-9)+PD123,319 or (F) Ang-(1-9)+A779 via osmotic minipump. (G) An isotype 
matched IgG was used as a control. Outer dotted line = external elastic lamina, middle dotted line = 
internal elastic lamina, inner dotted line = lumen Scale bar =100 μm, magnification x20, red box = 
3x zoom. n = 6-10 animals per group. 
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5.2.2.1.iii. Re-endothelialisation 
Re-endothelialisation of the vessels following vascular injury was assessed via 
immunostaining for CD31, an endothelial cell marker. At 28 days post-injury an 
intact endothelial cell layer was prevalent in all groups, as indicated by the 
brown staining surrounding the lumen (Figure 5.6).  
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Figure 5.6 CD31 content of the left carotid artery at 28 days following vascular injury. 
IHC was performed using an anti-CD31 antibody to assess endothelial cell expression within the 
injured vessel. DAB chromagen was used to detect CD31 positive cells (brown), indicated by arrow 
head, and tissue sections were counterstained with haemotoxylin to visualise nuclei (blue). 
Representative histological sections of CD31 content in the injured left carotid artery from (A) 
control animals (water) and animals administered (B) Ang-(1-7), (C) Ang-(1-9), (D) Ang-(1-
7)+A779, (E) Ang-(1-9)+PD123,319 or (F) Ang-(1-9)+A779 via osmotic minipump. (G) An isotype 
matched IgG was used as a control. Outer dotted line = external elastic lamina, inner dotted line = 
internal elastic lamina. Lumen is not outlined due to positive CD31 detection in this region. Scale 
bar =100 μm, magnification x20, red box = 3x zoom. n = 6-10 animals per group. 
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5.2.2.1.iv. Proliferation 
The degree of cell proliferation within the injured vessel at 28 days post injury 
was assessed using the proliferation marker proliferating-cell nuclear antigen 
(PCNA) (Figure 5.7). In control vessels and vessels from mice infused with Ang-
(1-7) or Ang-(1-9), few PCNA positive cells were detected, closely associated 
with the sub-endothelial cell layer. However, in vessels from animals co infused 
with Ang-(1-7) and A779 there was a significant number of PCNA positive cells 
observed in both the media and the neointimal area, however the highest 
proportion was within the neointima. A similar effect was observed in Ang-(1-9) 
+ PD123, 319 treated mice where a high proportion of PCNA positive cells was 
observed, particularly within the neointima. PCNA positive cells were also 
observed in vessels co-infused with Ang-(1-9) + A779, however this was to a 
much lesser extent than in mice co-infused with Ang-(1-9) + PD123,319 and 
where present was observed within the media.  
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Figure 5.7 PCNA content of the left carotid artery at 28 days following vascular injury. 
IHC was performed using an anti-PCNA antibody to assess cell proliferation within the injured 
vessel. DAB chromagen was used to detect PCNA positive cells (brown), indicated by arrow 
heads, and tissue sections were counterstained with haemotoxylin to visualise nuclei (blue). 
Representative histological sections of PCNA content in the injured left carotid artery from (A) 
control animals (water) and animals administered (B) Ang-(1-7), (C) Ang-(1-9), (D) Ang-(1-
7)+A779, (E) Ang-(1-9)+PD123,319 or (F) Ang-(1-9)+A779 via osmotic minipump. (G) An isotype 
matched IgG was used as a control. Outer dotted line = external elastic lamina, middle dotted line = 
internal elastic lamina, inner dotted line = lumen. Scale bar =100 μm, magnification x20, red box = 
3x zoom. n = 6-10 animals per group. 
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5.2.2.1.v. Inflammation 
To assess the presence of macrophages as a measure of inflammation within the 
remodelled vessels at 28 days post injury, immunostaining for the macrophage 
marker macrophage antigen-2 (MAC-2) was performed (Figure 5.8). In control 
vessels, a small number of MAC-2 positive cells were observed within the media 
and neointima. In Ang-(1-7) and Ang-(1-9) infused mice no significant differences 
were observed, however positive immunostaining did appear to be reduced in 
comparison to control animals. The effects of Ang-(1-7) were blocked by co-
infusion of A779 as there was a higher proportion of MAC-2 positive cells than 
both control or Ang-(1-7) infused mice. In Ang-(1-7) + A779 infused animals the 
largest proportion of MAC-2 positive cells were observed within the media, 
however, positive cells were also detected within the neointima. The effects of 
Ang-(1-9) were unaltered by co-infusion of A779 as vessels from animals infused 
with Ang-(1-9) + A779 displayed similar levels of MAC-2 positive cells to that 
observed in control or Ang-(1-9) infused mice. Conversely, co-infusion of Ang-(1-
9) + PD123,319 appeared to increase MAC-2 content within the injured vessels to 
a higher extent than control or Ang-(1-9) infused animals, as a higher number of 
MAC-2 positive cells were observed within the media and to a lesser extent in 
the neointima.  
  
187 
 
 
Figure 5.8 Mac2 content of the left carotid artery at 28 days following vascular injury. 
IHC was performed using an anti-Mac2 antibody to assess macrophage content within the injured 
vessel. DAB chromagen was used to detect Mac2 positive cells (brown), indicated by arrow head, 
and tissue sections were counterstained with haemotoxylin to visualise nuclei (blue). 
Representative histological sections of Mac2 content in the injured left carotid artery from (A) 
control animals (water) and animals administered (B) Ang-(1-7), (C) Ang-(1-9), (D) Ang-(1-
7)+A779, (E) Ang-(1-9)+PD123,319 or (F) Ang-(1-9)+A779 via osmotic minipump. (G) An isotype 
matched IgG was used as a control. Outer dotted line = external elastic lamina, middle dotted line = 
internal elastic lamina, inner dotted line = lumen. Scale bar =100 μm, magnification x20, red box = 
3x zoom. n = 6-10 animals per group. 
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5.2.2.1.vi. Apoptosis 
To assess the extent of cell apoptosis within the injured vessel, immunostaining 
was performed against the apoptosis marker active-caspase 3 (Figure 5.9). At 28 
days post injury negligible active caspase 3 activity was observed in all groups 
and no differences were apparent between any of the groups.  
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Figure 5.9 Active caspase-3 content of the left carotid artery at 28 days following vascular 
injury. 
IHC was performed using an anti-active caspase-3 antibody to assess cell apoptosis within the 
injured vessel. DAB chromagen was used to detect active caspase-3 positive cells (brown) and 
tissue sections were counterstained with haemotoxylin to visualise nuclei (blue). Representative 
histological sections of active caspase-3 content in the injured left carotid artery from (A) control 
animals (water) and animals administered (B) Ang-(1-7), (C) Ang-(1-9), (D) Ang-(1-7)+A779, (E) 
Ang-(1-9)+PD123,319 or (F) Ang-(1-9)+A779 via osmotic minipump. (G) An isotype matched IgG 
was used as a control. Outer dotted line = external elastic lamina, middle dotted line = internal 
elastic lamina, inner dotted line = lumen. Scale bar =100 μm, magnification x20, red box = 3x 
zoom. n = 6-10 animals per group. 
Control Ang-(1-7)
Ang-(1-9) Ang-(1-7) + A779
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5.2.2.2 Structural composition of complex lesions 
As detailed in section 5.2.2, it was observed that a large proportion of vessels 
from animals co-infused with Ang-(1-7) and A779, or Ang-(1-9) and PD123,319 
developed complex lesions with increased vessel remodelling, largely within the 
media, in comparison to other groups (Figure 5.3). To investigate the structural 
composition of these complex lesions the histology stains and IHC described in 
section 5.2.2.1 were employed. For all components of the vessels investigated 
there was no difference in the composition of the complex lesions observed in 
animals infused with Ang-(1-7)+A779 or Ang-(1-9)+PD123,319, therefore the 
following analysis describes the common features of the complex lesions which 
were found consistently in both groups. 
The complex lesions contained a high proportion of ECM content, as revealed by 
EVG staining for elastin and picrosirus red staining for collagen (Figure 5.10). 
Many vessels contained an intact internal elastic lamina, therefore it was clear 
to distinguish between the neointima and the media. However, even in vessels 
where the elastic lamina was disrupted the neointima could still be distinguished 
due to differences in the structural organisation. Similar to vessels without 
complex lesions, the neointima contained large amounts of elastin which 
appeared highly organised, more compact and matrix-like in structure. However, 
EVG staining within the medial area of the complex lesions was far less uniform 
in structure and composition. Picrosirus red staining revealed a similar pattern, 
with a higher degree of more organised positive staining for collagen within the 
neointima compared to the media. However, as outlined previously this staining 
was similar in colour to the elastic lamina and lighter than the periadventitial 
connective tissue, so it was unclear whether this is elastin or collagen.  
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Figure 5.10 Elastin and collagen content of the complex lesions observed in the injured 
vessels of Ang-(1-7) + A779 and Ang-(1-9) + PD123,319 infused mice. 
Representative histological sections of the complex lesions observed in the injured vessels of Ang-
(1-7) + A779 and Ang-(1-9) + PD123,319 infused mice stained with EVG and picrosirus red to 
assess elastin and collagen content within the vessel, respectively. In EVG stained sections elastin 
appears black while collagen is stained pink. In picrosirus red stained sections collagen appears 
pink/red and nuclei appear purple/blue due to counterstaining with Weigarts haemotoxylin. Outer 
dotted line = external elastic lamina, middle dotted line = internal elastic lamina, inner dotted line = 
lumen. Incomplete dotted line indicates disruption of elastic lamina. Scale bar =100 μm, 
magnification x20. n = 6-10 animals per group. 
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Immunostaining for VSMC using α-SMA revealed that the complex lesions 
contained a high proportion of VSMC within the media and neointima (Figure 
5.11).  
Re-endothelialisation of the complex lesions was confirmed by immunostaining 
for CD31 (Figure 5.11). An intact endothelial cell layer was present in all vessels, 
as indicated by the brown staining surrounding the lumen. However, CD31 
positive cells were also present within the media of the complex lesions, and 
appeared in a pattern of circular areas, indicative of small vessel formation with 
lumens, suggesting neovascularisation had occurred within the complex lesion.  
A high proportion of proliferating cells were present within the complex lesion, 
as indicated by positive immunostaining for PCNA (Figure 5.11). Most PCNA cells 
were localised within the media of the complex lesion and to a lesser extent 
within the neointima. However, the number of PCNA positive cells within the 
neointima of vessels with complex lesions was higher than in those without. 
Additionally, a number of PCNA positive cells were observed in areas of apparent 
neovascularisation. 
The complex lesions also contained a high number of cells positive for MAC-2, 
indicating increased presence of macrophages (Figure 5.11). Similar to cell 
proliferation, macrophage content was highest within the medial area and to a 
lesser extent within the neointima, and was higher in both areas than in vessels 
without complex lesions. 
Very few vessels with a complex lesion contained cells positive for active 
caspase-3 activity, and in any vessels where it was observed, the number of 
positive cells were very few and localised within the media of the lesion (Figure 
5.11).  
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Figure 5.11 Cellular composition of the complex lesions observed in the injured vessels of 
Ang-(1-7) + A779 and Ang-(1-9) + PD123,319 infused mice. 
Representative images of the IHC analysis of the cellular composition of the complex lesions 
observed in the injured vessels of Ang-(1-7) + A779 and Ang-(1-9) + PD123,319 treated mice was 
performed using anti-α-SMA, anti-CD31, anti-PCNA, anti-Mac2 and anti-active caspase-3 
antibodies to detect the expression of VSMC, VEC, proliferating cells, macrophages and cell 
apoptosis, respectively. DAB chromagen was used to detect positive antigen binding (brown), 
indicated by arrow heads, and tissue sections were counterstained with haemotoxylin to visualise 
nuclei (blue). Outer dotted line = external elastic lamina, middle dotted line = internal elastic lamina, 
inner dotted line = lumen, with the exception of CD31 images where the inner dotted line = internal 
elastic lamina and luminal outline is absent due to positive CD31 cells within this region. 
Incomplete dotted line indicates disruption of the elastic lamina. Scale bar =100 μm, magnification 
x20, red box = 3x zoom. n = 6-7 animals per group.  
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5.2.3 Local delivery of Ang-(1-7) and Ang-(1-9) via Pluronic F-127 
gel 
Prior to investigating the functional effects of local delivery of Ang-(1-7) or Ang-
(1-9) via Pluronic F-127 gel, the efficacy of delivery via this method was 
assessed.  Mice whose vessels were exposed to gel only were used as controls. 
Animals were sacrificed at 7, 14 and 28 days post-wire injury and peptide 
delivery to the vessel assessed via IHC, using a specific antibody for Ang-(1-7) 
and streptavadin for the biotin-labelled Ang-(1-9).  
Ang-(1-7) was detected in control and Ang-(1-7) treated vessels at all time 
points, as indicated by brown staining, and the level of detection was similar 
between both groups throughout the study (Figure 5.12). Detection of Ang-(1-7) 
was most prevalent in the adventitia and periadventitial connective tissue. Ang-
(1-7) was also detected in the neointimal of injured vessels, particularly in 
control vessels at 28 days post injury. Ang-(1-7) was not detected in the media 
of vessels from either group at any time point. While Ang-(1-7) was detected in 
the adventitia and neointima of vessels from all groups, the staining was diffuse 
and did not appear to be localised to specific cells. Furthermore, some positive 
staining was observed in the lumen in areas which were acellular, suggesting 
unspecific binding of the primary antibody. No positive staining was observed in 
the PBS control group.  
Positive detection of biotin-labelled Ang-(1-9), as indicated by brown staining, 
was observed at all time points; no positive staining was observed in control 
vessels (Figure 5.13). However, biotin-labelled Ang-(1-9) was only detected in 
the periadventitial connective tissue. Furthermore, detection levels declined 
over time, with the highest level of positive staining at 7 days post injury and 
application, and the lowest levels observed at 28 days.  
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Figure 5.12 Detection of Ang-(1-7) in left carotid arteries at 7, 14 and 28 days post vascular 
injury.  
IHC was performed using an anti-Ang-(1-7) antibody to assess peptide levels within the injured 
vessel following application of Ang-(1-7)-containing Pluronic F-127 gel. Tissue sections were 
incubated with PBS in place of primary antibody as a control. DAB chromagen was used to detect 
bound antigen (brown) and tissue sections were counterstained with haemotoxylin to visualise 
nuclei (blue). Representative histological sections of Ang-(1-7) in the injured left carotid artery from 
control animals and animals administered Ang-(1-7) at 7, 14 and 28 days post application via 
Pluronic F-127 gel. Outer dotted line = external elastic lamina, middle dotted line = internal elastic 
lamina, inner dotted line = lumen. Scale bar =100 μm, magnification x20. N = 3 animals per group. 
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Figure 5.13 Detection of biotinylated-Ang-(1-9) in left carotid arteries at 7, 14 and 28 days 
post vascular injury 
Delivery of biotinylated-Ang-(1-9) via Pluronic F-127 gel was assessed by incubation of tissue 
sections with ExtrAvadin peroxidase and the peptide detected using DAB chromogen (brown), 
indicated by arrow heads. Tissue sections were counterstained with haemotoxylin to visualise 
nuclei (blue). Representative histological sections of biotin-Ang-(1-9) detection in the injured left 
carotid artery from control (gel only) and peptide treated animals at 7, 14 and 28 days post 
application via Pluronic F-127 gel. Outer dotted line = external elastic lamina, middle dotted line = 
internal elastic lamina, inner dotted line = lumen. Scale bar =100 μm, magnification x20. N = 3 
animals per group. 
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5.2.4 Effects of local delivery of Ang-(1-7) and Ang-(1-9) on 
vascular remodelling 
Total body weight was monitored throughout the local peptide delivery study 
and no difference was observed between the experimental groups (Table 5.3). 
Heart and kidney weight was assessed at 28 days and expressed as a percentage 
of total body weight; no differences in heart or kidney weight were observed 
between the experimental groups (Table 5.3). 
Table 5.3 Effects of local delivery of Ang-(1-7) and Ang-(1-9) on body and organ weight 
measurements following vascular injury 
 Organ weight was taken as a percentage of the body weight, n=8.  
EVG staining was performed to assess the extent of vascular remodelling at 28 
days post vascular injury, following local delivery of Ang-(1-7) or Ang-(1-9) via 
Pluronic F-127 gel. Vessels coated in gel only were used as a control. The study 
was unblinded following morphometric analysis of the stained sections and 
revealed that there were no differences between control, Ang-(1-7) or Ang-(1-9) 
treated vessels for all parameters measured (Figure 5.14). Neointima formation 
was modest and similar in area in all experimental groups. Similarly, no 
differences were observed in medial area, and therefore NI/MA. There were no 
apparent differences in ECM deposition in the injured vessels of all three groups 
as indicated by the similar degree of elastin (black) and collagen (pink staining) 
(Figure 5.14). 
 
   
Control (gel only) Ang - (1 - 7) Ang - (1 - 9) 
Start weight (g) 24.0  ± 0.9 23.2  ± 0.2 24.0  ± 0.7 
Final weight (g) 26.8  ± 1.0 25.5  ± 0.7 26.3  ± 0.7 
Heart/Body weight (%) 0.7  ± 0.02 0.6  ± 0.03 0.7  ± 0.02 
Kidney/Body weight (%) 0.7  ± 0.01 0.7  ± 0.02 0.7  ± 0.02 
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Figure 5.14 Effects of local delivery of Ang-(1-7) and Ang-(1-9) on neointimal formation in the carotid artery at 28 days following vascular injury.    
Representative histological sections of the injured left carotid artery from (A) control animals and animals administered (B) Ang-(1-7), (C) Ang-(1-9) via Pluronic F-127 
gel stained using EVG stain. Elastin appears black while collagen is stained pink. Neointimal area (D), media area (E) and NI/MA ratio (F) was assessed. Scale bar 
=100 μm, magnification x20, red box = 3x zoom. n= 7-8 animals per group. 
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5.3 Discussion 
Prior to assessing the effects of Ang-(1-7) and Ang-(1-9) in vascular remodelling, 
a carotid artery wire injury model in mice was established. This is a commonly 
used model of acute vascular injury, where a nylon wire is inserted into the 
vessel causing endothelial denudation and mechanical stretching of the vessel 
wall, resulting in the formation of a neointima within 2 to 4 weeks (Lindner et 
al., 1993). Consistent with previous findings it was demonstrated that at 28 days 
post injury there was a significant increase in vascular remodelling in injured 
vessels compared to non-injured vessels (Lindner et al., 1993). This remodelling 
was associated with an increase in medial area and formation of a large 
neointimal area which was highly composed of ECM.  
In this present study it was found that Ang-(1-7) infusion reduced vascular injury 
in comparison to control vessels, as evidenced by the reduction in neointimal 
formation and NI/MA ratio. Ang-(1-7) had no effect on the medial area. 
Importantly, blockade of Mas using the pharmacological inhibitor A779 abolished 
the anti-remodelling effects of Ang-(1-7), resulting in a similar neointimal area 
and NI/MA ratio as control vessels. These findings are consistent with previous 
studies in various rodent models of vascular injury where Ang-(1-7) was shown to 
inhibit neointimal growth (Strawn et al., 1999, Langeveld et al., 2005, Langeveld 
et al., 2008, Zeng et al., 2009, Wu et al., 2011). For example, in a rat model of 
carotid artery injury induced by balloon embolectomy catheter, Ang-(1-7) 
infusion via osmotic mini pump was proven to reduce neointimal area without 
affecting medial area (Strawn et al., 1999). Furthermore, it was demonstrated 
that these effects were independent of the AT1R or AT2R (Strawn et al., 1999). 
In another study, where vascular injury in rabbits was induced by aortic 
angioplasty, Ang-(1-7) infusion, again via osmotic mini pump, resulted in 
inhibition of neointimal formation but no change in media area (Zeng et al., 
2009). Importantly, these effects were blocked by A779, indicating that Ang-(1-
7) acted via Mas. More recently, using the rat autologous jugular vein graft 
model it was demonstrated that Ang-(1-7) reduced vascular remodelling and 
neointimal formation within the vein graft (Wu et al., 2011).  
The findings from this study show for the first time a direct action of Ang-(1-9) 
in vascular remodelling. Here we show that Ang-(1-9) reduced neointimal 
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formation and NI/MA ratio following wire injury to the mouse carotid artery. 
Importantly, the effects of Ang-(1-9) were demonstrated to be via the AT2R, as 
PD123,319 blocked the effects of Ang-(1-9), resulting in a significant increase in 
neointima area, media area and NI/MA in comparison to animals who received 
Ang-(1-9) alone. Conversely, co infusion of A779 with Ang-(1-9) produced similar 
results to those observed with Ang-(1-9) alone, indicating that the Ang-(1-9) 
mediated inhibition of neointimal formation was achieved via a direct effect of 
Ang-(1-9), as opposed to conversion to Ang-(1-7) and signalling via Mas. No 
previous studies have been performed to assess the role of Ang-(1-9) in acute 
vascular injury, however, Ang-(1-9) has recently been shown to indirectly 
contribute to reduced aortic remodelling associated with hypertension (Ocaranza 
et al., 2011). In hypertensive deoxycorticosterone acetate (DOCA)-salt rats, it 
was demonstrated that inhibition of the RhoA/Rho-associated, coiled-coil 
containing protein kinase (ROCK) signalling pathway using Fausidil resulted in 
increased activity and expression of ACE2 in the aorta, and increased Ang-(1-9) 
plasma levels, as well as reduced blood pressure and reduced expression of key 
genes related to vascular remodelling, such as TGF-1, PAI-1 and MCP-1 
(Ocaranza et al., 2011). While this study identifies a potential novel pathway of 
Ang-(1-9) in the vasculature and an avenue for exploration in the current study it 
is worthwhile to highlight that the vascular remodelling observed in the study by 
Ocaranza et al was very mild as it was induced by hypertension as opposed to 
direct vessel injury (Ocaranza et al., 2011).  
The results from this present study indicate that the effects of Ang-(1-9) are 
mediated via the AT2R. While further work is required to fully understand the 
vasculoprotective effects of the Ang-(1-9)/AT2R interaction and corroborate 
these findings, there is evidence in the literature which supports a protective 
role for the AT2R in vascular injury. For example, over-expression of the AT2R 
following balloon injury in the rat results in attenuation of neointimal formation 
(Nakajima et al., 1995). Similarly, in an alternative model of vascular injury 
where a cuff is placed around the femoral artery to induce neointima formation, 
absence of the AT2R resulted in increased neointimal formation (Akishita et al., 
2000, Wu et al., 2001). Furthermore, following cuff placement AT2R
-/- mice have 
reduced apoptosis within the neointima, consistent with increased neointimal 
area (Suzuki et al., 2002). The AT2R has also been linked to reduced 
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atherosclerosis as deletion of the AT2R from Apo E
-/- mice results in a worsened 
atherosclerotic phenotype associated with increased VSMC content within the 
lesion (Sales et al., 2005). Taken together these results demonstrate that the 
AT2R is important in the development of atherosclerosis and vascular 
remodelling following injury. 
Remodelling of the ECM and deposition of ECM proteins such as elastin and 
collagen occurs during the remodelling process and largely contributes to 
neointimal formation. This has been shown to be the case in the present study 
where large areas of neointimal formation containing a high proportion of ECM 
following vascular injury were observed. While Ang-(1-7) reduced neointimal 
formation there were no differences in the organization of the ECM within the 
media or small neointimal area present. The effects of Ang-(1-7) were shown to 
be achieved via Mas and these findings were consistent with previously published 
results suggesting that Ang-(1-7) reduces vascular remodelling in part through 
inhibition of ECM synthesis and deposition (Strawn et al., 1999, Langeveld et al., 
2005, Zeng et al., 2009). Similarly, Ang-(1-9) reduced neointimal formation and 
therefore ECM synthesis, an effect which was shown to be via the AT2R and 
independent of conversion to Ang-(1-7) and signalling via Mas. However, Ang-(1-
9) also reduced medial elastin content in comparison to control vessels, an 
effect which was unaffected by either AT2R or Mas inhibition. Although there is 
no information in the literature to suggest Ang-(1-9) can reduce ECM synthesis 
and deposition in the vessel in response to injury, it has been shown that Ang-(1-
9) can inhibit collagen expression in the heart in an Ang II infusion model of 
hypertension (Flores Munoz et al, unpublished) and in the SHRSP (Flores-Munoz 
et al., 2012). In the studies by Flores Munoz et al, these effects were 
demonstrated to be via the AT2R. Currently little is known about the cell 
signalling mechanisms employed by Ang-(1-9) and it is possible that in the 
vasculature this peptide reduces ECM deposition via an alternative receptor to 
the AT2R or can be metabolised to an alternative peptide that may lead to this 
reduced ECM content within the media following vascular injury.  
VSMC migration and proliferation is largely involved in the development of 
neointimal formation following vascular injury (Costa and Simon, 2005). The 
results from this current study confirm that vessels from all groups are largely 
composed of VSMC. Vascular injury results in the formation of a large neointimal 
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area, highly composed of VSMC, this neointimal formation is blocked by both 
Ang-(1-7) and Ang-(1-9) and therefore reduced VSMC content is observed within 
the total vessel. The effects of Ang-(1-7) were shown to be via Mas while the 
effects of Ang-(1-9) appeared to be via the AT2R and independent of conversion 
to Ang-(1-7) and signalling through Mas. While this anti-vascular remodelling 
effect of Ang-(1-9) has not previously been demonstrated, the anti-proliferative 
and anti-migratory role of Ang-(1-7) has been observed in numerous rodent 
models of vascular disease. Ang-(1-7), via Mas, reduces neointimal formation 
following balloon injury (Strawn et al., 1999), stent implantation in rats 
(Langeveld et al., 2005), and angioplasty in rabbits (Zeng et al., 2009) and has 
been associated with reduced atherosclerotic lesion size in Apo E-/- mice (Jawien 
et al., 2012). 
VSMC proliferation is one of the most important processes involved in the 
development of neointimal formation. In this present study, very little cell 
proliferation was observed at 28 days following vascular injury in control, Ang-
(1-7) and Ang-(1-9) groups. However, this is consistent with previous findings and 
likely to be linked to the 28 day time point studied. Cell proliferation is thought 
to be maximal within the first 5 to 14 days following vascular injury and then 
decline as the vessel becomes re-endothelialised, findings which are in line with 
this current study (Lindner et al., 1993). While no differences were observed in 
cell proliferation between control or Ang-(1-7) treated vessels at 28 days post 
injury, this may not have been the case at earlier time points where VSMC 
proliferation has been shown to be maximal, such as 5 to 14 days post-injury, 
and further investigation of these times would be required to assess the anti-
proliferative effects of Ang-(1-7). It has previously been demonstrated that Ang-
(1-7) infusion reduced VSMC proliferation within both the media and neointimal 
of normotensive Sprague-Dawley rats in comparison to saline infused animals at 
12 days following vascular injury (Strawn et al., 1999). However, in contrast to 
the findings of this present study, VSMC proliferation following rat autologous 
vein graft surgery was present at 28 days following vascular injury. The number 
of proliferating cells was reduced in comparision to control vessels and this was 
demonstrated to be via inhibition of the ERK1/2 and p38 MAPK pathways (Wu et 
al., 2011).  
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Increased cell proliferation was observed in vessels from animals co-infused with 
Ang-(1-7) + A779 or Ang-(1-9) + PD123, 319, and to a lesser extent Ang-(1-9)+ 
A779, in comparison to control vessels. It is unclear as to the reason for this as 
there were no differences in reendothelialisation however, a similar trend is 
observed in macrophage content of the vessels suggesting a link between the 
two. This is plausible since macrophages secrete a number of growth factors and 
cytokines which would in turn act on the VSMC causing cell proliferation (Assoian 
et al., 1987). Ang-(1-7) signalling via Mas has previously been linked to reduced 
macrophage content within injured and atherosclerotic vessels. For example, 
Ang-(1-7) has been demonstrated to reduce macrophage content within 
atherosclerotic lesions of Apo E-/- via Mas, thereby contributing to reduced VSMC 
content and plaque stability (Yang et al., 2013). While a role for Ang-(1-9) in 
reduced inflammation within the vasculature has yet to be demonstrated, 
administration of CGP42112, an AT2R agonist, to Apo E
-/- mice resulted in 
reduced macrophage content within the plaque and increased plaque stability 
(Kljajic et al., 2013). Despite the fact that little macrophage expression was 
observed in control vessels, is it possible that inhibition of both endogenous and 
exogenous Ang-(1-7) or Ang-(1-9) signalling via Mas and the AT2R, by A779 and 
PD123,319, respectively, has led to increased expression of macrophages within 
the vessel. However, further investigation would be required to fully assess this.  
During vascular injury the endothelial lining of the vessel is denuded, with re-
endothelialisation complete by 28 days post injury (Lindner et al., 1993). The 
results from this study are consistent with these findings; an intact endothelial 
cell layer was present in all groups. As re-endothelialisation was complete by 
this stage it is unclear if Ang-(1-7) or Ang-(1-9) affect the rate at which re-
endothelialisation occurs and earlier time points would be required to 
investigate this further. Furthermore, the new endothelial cell layer is often 
markedly dysfunctional, so it would be worthwhile to explore whether of Ang-(1-
7) or Ang-(1-9) improved the function of the re-endothelialised vessel. Ang-(1-7) 
has been shown to increase NO release from endothelial cells, thereby acting as 
a vasodilator and improving vascular endothelial function (Brosnihan et al., 
1996, Faria-Silva et al., 2005). Increase of NO is achieved directly via Mas-
mediated stimulation of eNOS and sustained Akt phosphorylation, or indirectly 
via production of bradykinin and receptor cross talk with the BK2R (Jackman et 
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al., 2002, Sampaio et al., 2007b). Additionally, in the rat stent model, Ang-(1-7) 
infusion improved endothelial function through enhanced prostaglandin function 
(Langeveld et al., 2005). Similarly, Ang-(1-9) has also recently been shown to 
improve endothelial function (Flores-Munoz et al., 2012). Ang-(1-9) infusion in 
the SHRSP improved aortic vasorelaxation and NO bioavailability via the AT2R 
(Flores-Munoz et al., 2012). While the mechanisms involved are currently 
unknown it is possible that Ang-(1-9) may increase NO bioavailability by 
stimulating bradykinin release, as previously documented in cardiac endothelial 
cells (Jackman et al., 2002), or by enhancing the activity of eNOS, as has been 
shown for Ang-(1-7) (Sampaio et al., 2007b). 
Cell apoptosis is a key process in vascular remodelling, however, apoptosis was 
not apparent within the injured vessel in any group. This may be due to the 28 
day time point studied. Various studies have been performed in models of 
vascular injury that may provide more insight into the role of apoptosis. 
Following balloon injury in ApoE-/- mice, cell apoptosis was found to be elevated 
within the first 24 hrs (Matter et al., 2006). Similar findings were observed in 
balloon injured rabbits where it was demonstrated VSMC apoptosis was highest 
within 24 hrs and was via a caspase 3-dependent mechanism (Spiguel et al., 
2010). These findings are consistent with those in the present study where cell 
apoptosis was minimal at the later time points studied. An assessment of the 
involvement of apoptosis as a mechanism for reduced neointimal formation at 
earlier time points would be worthwhile, particularly as the AT2R-induced 
apoptosis has previously been linked to reduced neointimal formation. For 
example, in the cuff injury model of vascular injury, AT2R-/- mice displayed 
increased neointimal formation associated with reduced VSMC apoptosis and 
increased VSMC proliferation in comparison to wild type mice at 14 days post 
injury (Suzuki et al., 2002).  
An interesting, yet unexpected finding from this present study was that a large 
proportion of vessels from animals co-infused with Ang-(1-7) and A779, or Ang-
(1-9) and PD123,319 developed more complex lesions with increased vessel 
remodelling and neovascularisation, largely within the media, in comparison to 
all other groups. The formation of complex lesions was associated with positive 
vessel remodelling and stretching, often disruption, of the elastic lamina. 
Analysis of the structural composition of these complex lesions revealed that 
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they were largely composed of disorganised ECM and were highly cellular, 
containing a large number of VSMC, macrophages and proliferating cells. Re-
endothelialisation had occurred on the lumenal lining of the vessels and 
neovascularisation of the complex lesion was also observed. There was no 
difference in the composition of the complex lesions observed in animals infused 
with Ang-(1-7) and A779 or Ang-(1-9) and PD123, 319. It is unclear what has led 
to the development of these complex lesions, however, based on their 
histological profile one possible explanation could be that it was due to the 
presence of an intra-mural thrombus. During the wire injury procedure, the 
endothelial layer of the vessel is denuded, exposing the blood to a highly 
thrombogenic surface. Additionally, the vessel is stretched, which can cause 
disruption of the internal elastic lamina. Normally, the elastic lamina is repaired 
within 7 days, however in circumstances with high thrombogenesis; the 
thrombus can become encapsulated within the damaged vessel, more often in 
the medial area (Wilensky et al., 1995). This is known as an intramural 
thrombus. Within the media, VSMC and macrophages migrate into the thrombus 
and begin to proliferate, resulting in the intramural thrombus becoming highly 
cellular (Wilensky et al., 1995). While this proliferative stage is most prevalent 
within 7 to 14 days post injury, due to the presence of inflammatory cells 
various growth factors and cytokines are secreted which may explain why there 
is still a high degree of proliferation within these complex lesions in this present 
study. Within the intramural thrombus the VSMC can differentiate into 
myofibroblasts, and together the VSMC and myofibroblasts synthesise and 
deposit large proportions of ECM (Wilensky et al., 1995). Both VSMC and 
myofibroblasts are positive for α-SMA, and the high proportion of positive 
staining observed within the vessels may be indicative of expression of both cell 
types (Shi et al., 1997). Re-endothelialisation of the vessel is found to be 
complete by around 4 weeks in most models of vascular injury, and this was also 
found to be the case in vessels with complex lesions (Lindner et al., 1993, Zou et 
al., 1998, Ali et al., 2007). However, it was also noted that neovessels had 
formed within the complex lesions, as indicated by the positive CD31 staining 
within the vessels. This phenomenon of neovessel formation has previously been 
described in atherosclerotic vessels and from failed human saphenous vein 
bypass graft tissue, and has been demonstrated to be associated with 
atherosclerotic lesion formation and intramural thrombus (Bobryshev et al., 
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2001, Motwani and Topol, 1998, Nielsen et al., 1997). Intimal neovascularisation 
in atherosclerosis has been linked to the development of complications such as 
intimal haemorrhage, plaque rupture and the formation of an occlusive 
thrombosis (Zhang et al., 1993, O'Brien et al., 1994, Ignatescu et al., 1999). 
Furthermore, the newly formed vessels are associated with inflammatory cell 
infiltration and increased cell proliferation (Kumamoto et al., 1995). While in 
this current study the vessels did not contain atherosclerotic plaques, the 
appearance of the neovessels is consistent with those found in atherosclerosed 
vessels, in that cell proliferation and macrophage expression are found to be 
associated with these neovessels, suggesting that they may be formed in a 
similar manner. Investigation into the formation of neovessels within 
atherosclerotic arteries has revealed that VEGF plays an important role in this 
process, in fact advanced atherosclerotic plaques containing a large number of 
VEGF-positive cells are much richer in neovascularisation than atherosclerotic 
lesions containing fewer VEGF-positive cells (Couffinhal et al., 1997, Inoue et 
al., 1998, Chen et al., 1999). Therefore, to gain further insight into the 
mechanisms involved in the formation of complex lesions and neovascularisation 
observed in this present study it would be worthwhile to assess the expression of 
VEGF within these vessels. 
It is unlikely that these complex lesions have occurred as a result of either the 
antagonists or peptides singularly, as no complex lesions were observed in mice 
infused with the peptides on their own or co infused with Ang-(1-9) + A779. 
However, as only one group of animals received PD123,319, it cannot be ruled 
out that this compound is not having an effect on its own. Furthermore, while it 
is widely used as an AT2R antagonist, PD123, 319 has also been demonstrated to 
have non AT2R- specific effects, for example it has recently been shown to be an 
agonist of the MrgD receptor (Lautner et al., 2013). Furthermore, in a mouse 
model of abdominal aortic aneurysm (AAA), PD123,319 was demonstrated to 
augment Ang II-induced AAA formation through an AT2R-independent mechanism 
(Daugherty et al., 2013). 
In addition to blocking the effects of Ang-(1-9), PD123,319 will block endogenous 
AT2R activity, potentially contributing to increased vessel remodelling as the 
AT2R has been linked to reduced vascular injury, as previously discussed (Wu et 
al., 2001, Suzuki et al., 2002, Akishita et al., 2000). Furthermore, the AT2R has 
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been demonstrated to possess constitutive activity, leading to ligand-
independent activation of various cell signalling pathways, particularly those 
linked to increased cell apoptosis, a processes which could contribute to reduced 
vascular remodelling (Miura and Karnik, 2000, Jin et al., 2002). It is therefore 
possible that PD123,319 could contribute to increased vascular remodelling via 
inhibition of the constitutive activity of the AT2R. One possible explanation is 
that due to blockade of their endogenous receptors, the peptides are converted 
to alternative peptides or interact with an alternative receptor, which enhances 
thrombus formation. For example, while Ang-(1-7) has been demonstrated to 
have anti-thrombotic effects (Kucharewicz et al., 2002, Heitsch et al., 2001, 
Fraga-Silva et al., 2011, Fraga-Silva et al., 2008), it may be converted to an 
alternative peptide with potential prothrombotic effects, such as Ang-(3-7). 
While a direct pro-thrombotic role for Ang-(3-7) has not yet been established, it 
has been reported to interact with the AT4R, which is known to upregulate PAI-1, 
a key protein involved in thrombogenesis (Gesualdo et al., 1999, Numaguchi et 
al., 2009). Furthermore, AT1R activation is widely accepted to be prothrombotic, 
and while Ang-(1-9) appears to display functional selectivity at the AT2R, is has 
been shown to have equal affinity at both the AT1R and AT2R (Flores-Munoz et 
al., 2011). In a recent study by Kramkowski et al (2010) it was indicated that 
Ang-(1-9) enhances electrically stimulated thrombosis and increases platelet 
aggregation in rats via the AT1R (Kramkowski et al., 2010). However, it is 
worthwhile to point out that electrical stimulation was used to injure the vessel 
and initiate thrombosis which is somewhat different to the wire injury model. 
Also, the pro-thrombotic effect of Ang-(1-9) was much lower than that of Ang II, 
and was in fact found to be due to direct metabolism of Ang-(1-9) to Ang II 
(Kramkowski et al., 2010, Drummer et al., 1988, Singh et al., 2005). 
While the current data set highlights the potential of Ang-(1-7) and Ang-(1-9) as 
therapeutic agents in the setting of vascular remodelling, one factor limiting the 
translational impact of these results is the delivery method used. Subcutaneous 
delivery via osmotic mini pump results in peptide delivery to the systemic 
circulation and although minimum infusion is a commonly used drug delivery 
method in animal models, which ensures that the drug is delivered at a constant 
rate over a set period of time without the need to cause the animal additional 
stress by daily dosing, this would not represent the situation in the clinic 
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(Theeuwes and Yum, 1976). Therefore, to represent a more clinically relevant 
delivery approach it was also investigated whether Ang-(1-7) or Ang-(1-9) could 
be delivered locally to the vessel via Pluronic F-127 gel immediately following 
vascular injury, and if so what effect this would have on the resultant 
remodelling.  
Delivery of Ang-(1-7) detected using an antibody for the peptide and it was 
shown that peptide levels were comparable between control and Ang-(1-7) at all 
time points, and Ang-(1-7) detection did not change over time. If Ang-(1-7) was 
delivered efficiently via Pluronic F127 gel it would be expected that higher 
levels of peptide would be detected in the Ang-(1-7) treated vessels and the 
levels would decline towards control levels over the course of the study. It is 
possible that the Ang-(1-7) had already been fully delivered by the time points 
chosen, as previous studies have shown that drug delivery via this method is 
optimal within the first week following application (Villa et al., 1995, Grassia et 
al., 2010, Shi et al., 2014). Therefore in this present data it is unclear if Ang-(1-
7) was delivered to the vessel. Furthermore, some positive immunostaining for 
Ang-(1-7) was observed in the lumen in areas which were acellular, suggesting 
that there may be some unspecific binding of the primary antibody. Importantly 
no positive staining was observed in sections treated with PBS instead of the 
antibody, suggesting that this is not due to the presence of residual unbound 
secondary antibody. However, it has previously been demonstrated that this 
antibody is specific for Ang-(1-7) in different tissues such as the heart and 
kidney, therefore further testing of the antibody specificity, by preincubation of 
vessel sections with Ang-(1-7) peptide, for example, is required (Giani et al., 
2012, Calo et al., 2010a, Zhang et al., 2010a).  
At the time of this study an Ang-(1-9) antibody was not commercially available, 
therefore, delivery of this peptide was assessed using a biotinylated Ang-(1-9). 
One benefit to this approach over antibody based detection is that only the 
exogenous biotinylated Ang-(1-9) will be detected, therefore it can be 
distinguished from endogenous Ang-(1-9) within the vessel. Ang-(1-9) was only 
detected in vessels which had the peptide delivered and levels declined over 
time, with the highest level of positive staining observed at 7 days post-
application. However, Ang-(1-9) was only detected in the periadventitial tissue, 
with no positive staining observed within the media or neointimal area, where 
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present. Therefore it is unclear if the peptide was effectively delivered to the 
vessel. Pluronic F-127 gel has previously been reported to mediate sustained 
release and reduced degradation of peptides such as gonadotropin-releasing 
hormone (GnRH) and deslorlin (a GnRH agonist) both in vitro and in vivo (Wenzel 
et al., 2002), thereby providing sustained delivery over time.  While this 
increased bioavailability has yet to be demonstrated for angiotensin peptides, 
one possible explanation for the observed results is that while in the gel Ang-(1-
9) is more stable, but once dissolved from the gel to the vessel it is rapidly 
metabolised, and therefore unlikely to be observed within the different layers of 
the vessel. Biotinylated Ang-(1-9) was still present in the periadventitial tissue, 
although at very low levels, at 28 days post application, and while previous 
studies have suggested that Pluronic F-127 gel is dissolved within 3 to 7 days in 
vivo and that drug delivery is maximal within this time, this finding of sustained 
drug levels post-gel degradation is not unheard of. In a study where the cell 
cycle inhibitor cilostazol was delivered via Pluronic F-127 gel following balloon 
injury in rats it was found that while the gel was dissolved by 7 days post 
application, tissue levels of the drug were still increased within the vessel and 
surrounding tissue at 14 days (Ishizaka et al., 1999). Similarly, in a study 
investigating the effects of NF-κB inhibition on neointimal formation following 
wire injury, Grassia et al delivered a biotinylated NF-κB essential modulator–
binding domain peptide, an antagonist of the inhibitor of kappa b (IκB) kinase 
complex, via Pluronic F-127 gel and found that while the gel was dissolved at 3 
days post application, the biotinylated peptide was still observed at the 
termination of the study at 14 days (Grassia et al., 2010). 
In summary, from this pilot study, it is unclear if Ang-(1-7) and Ang-(1-9) can be 
delivered to the vessel via Pluronic F-127, however, the decline in Ang-(1-9) 
levels over time suggests that this may be possible. To provide more conclusive 
evidence it would be beneficial to measure peptide levels directly within the 
vessel, surrounding tissue and in the systemic circulation. This can be achieved 
through the use of high-performance liquid chromatography-based 
radioimmunoassay with amino-terminal-directed antisera, a method which has 
been demonstrated to effectively measure angiotensin peptide levels in various 
settings (Campbell et al., 1995, Ocaranza et al., 2006, Lawrence et al., 1990).  
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While it could not be proven conclusively that the peptides had been delivered 
to the vessel via Pluronic F-127 gel, the results from the Ang-(1-9) portion of this 
study suggested that it may have been possible. Therefore, a full blinded study 
was performed to assess the effect of local application of Ang-(1-7) and Ang-(1-
9) on vascular remodelling and neointimal formation.  However, in this study 
very little neointimal formation was observed in gel only control vessels. As 
these vessels were a vehicle control it would be expected that a similar 
neointimal area would be observed to that of the control animals in the 
minipump study, however, both neointimal area and NI/MA ratio of the gel only 
controls were significantly lower than those of the minipump controls. This 
finding was unexpected as this gel based delivery approach has been utilised in a 
number of studies using various in vivo models of vascular disease/remodelling 
and has been demonstrated to have no effect on neointimal formation (Ishizaka 
et al., 1999, Grassia et al., 2010, Wenzel et al., 2002, Shi et al., 2014). While 
vessel morphology in the previous study to determine peptide delivery to the 
vessel was not quantified due to low numbers, neointimal area was present in 
gel only treated vessels at all time points, particularly at 28 days, therefore 
there was no indication that this finding would be expected in this present 
study. It is unclear as to why this impaired neointimal formation has occurred 
within this group, however as this was the only study where minimal neointimal 
area was present in control vessels it may be due to variability in batches of 
animals. Ultimately, due to the limited neointimal formation in the control 
groups it could not be determined if the small neointimal area in the Ang-(1-7) 
and Ang-(1-9) treated vessels was as a result of the peptides.  
There are a number of advantages to the mouse carotid artery wire injury 
model, namely that it is highly reproducible, results in the formation of a large 
neointimal area and is low cost. However, this is a very simple model of vascular 
remodelling and as with all rodent models, has a number of limitations. While 
the injury induced is similar to that of PCI this model involves disruption of the 
flow of blood due to the ligation, an effect which would not occur clinically. 
Furthermore, alternative, more clinically relevant animal models of vascular 
injury exist; however, these also are not without limitation. Traditionally 
porcine models have been used to investigate vascular injury in response to 
CABG surgery or stenting due to the fact that pigs are physiologically a lot closer 
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to human than rodents and that their blood vessels and response to injury are 
very similar to those in humans, however, these studies are extremely expensive 
and perhaps more relevant for preclinical work as opposed to an early stage 
investigation (Taylor et al., 2001, Miller et al., 1996, Angelini et al., 1990). 
Mouse models of vascular disease are therefore advantageous due to the high 
throughput of these animals, the low cost and the ability to use genetically 
modified strains. Mouse models of stenting and vein grafting have been 
developed which are more representative of the type of damage observed in 
humans compared to wire injury (Zou et al., 1998, Ali et al., 2007), however 
both are very complex to perform, are expensive due to the requirement for a 
donor mouse and come with their own disadvantages. The mouse model of vein 
grafting was developed by Zou et al in 1998 and involved the engraftment of the 
vena cava or external jugular vein from a donor mouse to the carotid artery of a 
recipient mouse (Zou et al., 1998). While this model is useful for studying the 
mechanisms involved in vein graft failure and closely represents the disease 
observed in humans, there are some important considerations. For example, the 
formation of accelerated atherosclerosis, which is present in human grafts 
beyond the first year after CABG surgery, would be difficult to investigate in the 
mouse model due to the shorter life span and the fact that mice do not develop 
spontaneous atherosclerosis (Zou et al., 1998). The mouse stent model was 
developed by Ali et al and involves the deployment of a small stent into the 
aorta of the donor mouse, which is then engrafted to the carotid artery of a 
recipient mouse (Ali et al., 2007). However, in contrast to human disease this 
model does not involve stenting of an atherosclerotic plaque or contain the 
inflammatory component associated with atherosclerosis in humans, and due to 
the absence of a plaque the vessel is not restored to its original diameter, but 
expanded to a lot wider than normal. Additionally, in the wire injury model it is 
easy to obtain a large length of carotid artery that has been injured to use 
process for histological analysis, however, due to the small size of the stent 
there is a limited amount of tissue available and the presence of metal struts 
makes it very difficult to process (Bradshaw et al., 2009). This greatly reduces 
the amount of sections available for analysis and therefore can restrict the 
depth of the investigation. Taking into consideration the aforementioned 
advantages and disadvantages of each model and the fact that the studies 
presented here were the first exploration of the effects of the peptides on 
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vascular remodelling, it was decided the wire injury model was the most 
appropriate. 
5.4 Conclusion 
In summary, the data demonstrates that the carotid artery wire injury model is a 
highly reproducible model of neointimal formation to act as a platform to 
investigate the effects of Ang-(1-7) and Ang-(1-9) on vascular remodelling. In this 
study it was demonstrated that infusion of Ang-(1-7) via osmotic minipump 
prevents wire injury induced vascular remodelling via the Mas receptor. 
Importantly, this study also demonstrates for the first time that infusion of Ang-
(1-9) via osmotic minipump is similarly capable of inhibiting wire injury induced 
vascular remodelling and that its effects are via the AT2R, and independent of 
conversion to Ang-(1-7) and signalling via Mas. This reduction in vascular 
remodelling observed following treatment with Ang-(1-7) or Ang-(1-9) was 
associated with reduced neointimal formation and reduced proliferation and 
migration of VSMC. Importantly, reendothelialisation of the vessel was unaltered 
by either peptide, although further investigation is required to assess the 
functioning of this new endothelial cell layer. While further studies are required 
to fully understand the signalling mechanisms involved in this Ang-(1-9)/AT2R 
interaction within the vasculature, these results highlight a novel action of Ang-
(1-9) that may be exploited therapeutically.  
Furthermore, it was also observed that infusion of Ang-(1-7) during Mas blockade 
or Ang-(1-9) during AT2R blockade resulted in the formation of complex lesions 
which were potentially indicative of the formation of an intramural thrombus. As 
this only occurred within these two groups it suggests that this phenomenon may 
occur as a result of conversion of Ang-(1-7) and Ang-(1-9) to an alternative 
peptide and/or interaction with an alternative receptor that enhances the 
occurrence of thrombosis. However, further work is required to fully investigate 
the mechanisms leading to the formation of these complex lesions. 
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6.2 Overall summary 
The main focus of this thesis was to investigate the interaction of Ang II and the 
counter-regulatory peptides Ang-(1-7) and Ang-(1-9) in the vasculature using 
primary HSVSMC and HSVEC and an in vivo model of acute vascular injury. First, 
a model of HSVSMC proliferation was established where it was demonstrated 
that addition of serum induced HSVSMC proliferation in a concentration-
dependent manner. Stimulation with Ang-(1-7) or Ang-(1-9) inhibited serum-
induced proliferation of HSVSMC via Mas and AT2R, respectively. While Ang II was 
unable to induce proliferation of HSVSMC at the concentration used, it was 
demonstrated to have potent pro-migratory effects. Ang II-induced HSVSMC 
migration via the AT1R, and this effect was inhibited by Ang-(1-7) or Ang-(1-9) 
via Mas or the AT2R, respectively. Further investigation into the functional 
interplay of Ang II, Ang-(1-7) and Ang-(1-9) in HSVSMC migration identified 
alterations in ERK1/2 activity and, MMP2 and MMP9 expression as potential 
mechanisms contributing to the observed results.  
Additionally, as Ang II has recently been demonstrated to regulate expression of 
the miR-132/-212 cluster in rat aortic VSMC, thereby regulating a number of 
target genes involved in VSMC migration including PTEN, MCP-1 and RASA-1, this 
pathway was also assessed in this present study (Jin et al., 2012). The data 
demonstrate that Ang II-mediated HSVSMC migration was associated with an 
increase in miR-132 but not miR-212 expression, and a decrease in PTEN 
expression at the mRNA level. These changes were found to be via the AT1R and 
were inhibited following addition of Ang-(1-7) or Ang-(1-9); the effects of Ang-
(1-7) and Ang-(1-9) were partially attenuated by antagonism of Mas or the AT2R, 
respectively, suggesting a role for these receptors. However, PTEN protein levels 
were unchanged. Similarly, there was no change in MCP-1 expression at mRNA or 
Akt at protein levels, both of which are key proteins involved in the downstream 
signalling pathways of PTEN, suggesting these changes in gene expression were 
not converted to protein within these experimental conditions. Additionally, in 
contrast to the findings in rat aortic VSMC, no changes in RASA-1 were observed.  
The role of miRNA-132 in Ang II induced HSVSMC migration was further 
investigated through the use of a miR-132 inhibitor, which blocks miR-132 
activity, and through siRNA-mediated downregulation of DICER, a key enzyme 
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involved in miRNA biogenesis. It was found that miR-132 or regulation of an 
alternative miRNA via DICER is not essential for Ang II induced HSVSMC 
migration. However, inhibition of miR-132 or DICER enhanced basal migration of 
unstimulated HSVSMC. While highlighting a potential mechanism involved in 
HSVSMC migration, these results also demonstrate key differences in the miRNA 
response to Ang II between rat and human VSMC.   
Next, the effect of Ang II, Ang-(1-7) and Ang-(1-9) on endothelial cell growth, 
migration and function was assessed. Ang II, Ang-(1-7) or Ang-(1-9) had no effect 
on growth or migration of primary adult HSVEC. A direct effect of Ang-(1-9) on 
NO release from both HSVEC and a cell line transiently expressing the AT2R was 
demonstrated. Although in cell culture Ang-(1-9) induced NO release in an AT2R 
sensitive manner, it was found that in vessels from AT2R
-/- mice the biological 
effect of Ang-(1-9) was maintained and lead to vasodilation of both aortic and 
mesenteric artery rings. Further investigation revealed that Ang-(1-9) induced 
relaxation of AT2R
-/- aortic rings, but not mesenteric artery rings was blocked by 
A779, suggesting that in large vessels Ang-(1-9) may mediate is vasodilatory 
effects via conversion to Ang-(1-7) and signalling via Mas, while in small 
resistance vessels of AT2R
-/- mice Ang-(1-9) promotes vasodilation through an 
unknown mechanism.  
Since data from the previous chapters demonstrated that Ang-(1-7) and Ang-(1-
9) blocked VSMC proliferation and migration, without affecting endothelial cell 
growth or migration, they could be potential therapeutic agents in vascular 
injury and remodelling. Prior to assessing the effects of Ang-(1-7) and Ang-(1-9) 
on vascular remodelling, a carotid artery wire injury model in mice was 
established.  Injury to the carotid artery using a synthetic nylon fibre induced 
significant vessel injury, manifesting in the production of a large neointimal area 
and increase medial remodelling at 28 days post injury. The effects of Ang-(1-7) 
or Ang-(1-9) in this setting were assessed by delivery of the peptide for 4 weeks 
via subcutaneously implanted osmotic minipumps. It was observed that Ang-(1-7) 
infusion reduced vascular injury in comparison to control vessels, as evidenced 
by the reduction in neointimal formation and NI/MA ratio. Ang-(1-7) had no 
effect on the medial area. Importantly, blockade of Mas using the 
pharmacological inhibitor A779 abolished the anti-remodelling effects of Ang-(1-
7). Similarly, Ang-(1-9) reduced neointimal formation and NI/MA ratio following 
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wire injury to the mouse carotid artery and interestingly, Ang-(1-9) appeared to 
be more efficacious than Ang-(1-7). Importantly, the effects of Ang-(1-9) were 
demonstrated to be via the AT2R, as PD123,319 blocked its effects. Conversely, 
co infusion of A779 with Ang-(1-9) produced similar results to those observed 
with Ang-(1-9) alone, indicating that the Ang-(1-9) mediated inhibition of 
neointimal formation was achieved via a direct effect of Ang-(1-9), as opposed 
to conversion to Ang-(1-7) and signalling via Mas. 
An interesting, yet unexpected finding from the in vivo study was that a large 
proportion of vessels from animals co-infused with Ang-(1-7) and A779, or Ang-
(1-9) and PD123,319 developed more complex lesions with increased vessel 
remodelling and neovascularisation, largely within the media, in comparison to 
all other groups. The formation of complex lesions was associated with positive 
vessel remodelling and stretching, often disruption, of the elastic lamina. 
Analysis of the structural composition of these complex lesions revealed that 
they were largely composed of disorganised ECM and were highly cellular, 
containing a large number of VSMC, macrophages and proliferating cells. Re-
endothelialisation had occurred on the luminal lining of these vessels and 
neovascularisation of the complex lesion was also observed. 
6.3 Future perspectives 
Ang II is a key peptide involved in the development and progression of vascular 
remodelling, largely through promoting VSMC proliferation and migration (Mehta 
and Griendling, 2007, Touyz and Schiffrin, 2000). In this present study it was 
observed that when utilising the same concentration, Ang II enhanced migration 
but not proliferation of quiescent HSVSMC. These divergent effects of Ang II 
reveal potential differences in the cell signalling mechanisms employed in 
HSVSMC; however this has not yet been assessed and further investigation is 
required. While it is important to study the processes of proliferation and 
migration in isolation to gain a more in depth understanding of the mechanisms 
involved, in vivo these processes occur concurrently and together contribute to 
remodelling of the vasculature. Furthermore, as one of the main aims of this 
thesis was to investigate the interaction of Ang II and the counter-regulatory 
peptides Ang-(1-7) and Ang-(1-9) in HSVSMC, an in vitro assay where Ang II 
induced both proliferation and migration of VSMC would be of great use. One 
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such model is the ex vivo HSV organ culture model, where both HSVSMC 
proliferation and migration contribute to the development of a neointimal layer 
within 14 days (Soyombo et al., 1990). Importantly, Ang II has been shown to 
increase HSVSMC migration and proliferation within this model via the AT1R 
(Ibrahim et al., 2000). Therefore, further investigation of the inhibitory effects 
of Ang-(1-7) and Ang-(1-9) on Ang II signalling in HSVSMC would benefit from the 
use of the ex vivo organ culture model.   
In the vasculature, Ang II activates various signalling pathways, via the AT1R, 
resulting in both acute responses such as vasoconstriction and increased blood 
pressure, and more long term responses such as cell proliferation and structural 
remodelling. While the signalling mechanisms of Ang II have been well defined 
[reviewed extensively by (Touyz and Schiffrin, 2000, Mehta and Griendling, 
2007)] less is known about the signalling mechanisms employed by Ang-(1-7) and 
Ang-(1-9). For example, in VSMC Ang-(1-7) has been shown to inhibit Ang II-
induced VSMC proliferation and migration largely through inhibition of Ang II-
mediated ERK1/2 activation and this was also demonstrated to be the case in 
this present study. However, the signalling mechanisms evoked by Ang-(1-7) 
upstream of ERK1/2 in the MAPK signalling pathway are unknown (Tallant and 
Clark, 2003, Zhang et al., 2010b). Similarly, in this present study Ang-(1-9) has 
also been demonstrated for the first time to regulate ERK1/2 activity in HSVSMC; 
at early time points (5 minutes post stimulation) Ang-(1-9) inhibits Ang II induced 
ERK1/2 activation, however, at later time points (60 minutes post stimulation) 
Ang-(1-9) enhanced ERK1/2 activation. Similarly, a role for Ang-(1-7) in NO 
release from endothelial cells has previously been reported (Sampaio et al., 
2007a), and while this has been demonstrated to involve eNOS phosphorylation, 
again the upstream signalling pathways have yet to be detailed. In this present 
study Ang-(1-9) was found to increase NO release from both primary HSVEC and 
cell lines via the AT2R. Therefore it is of great importance that future studies 
focus on defining the cell signalling pathways involved in the observed effects of 
Ang-(1-7) and Ang-(1-9) in primary vascular cells in order to gain an 
understanding of their mechanisms of actions. One of the main reasons there is 
little known about the signalling mechanisms involved in the effects of these 
peptides is that, to date, only western blot-based studies have been used to 
interrogate Ang-(1-7) signal transduction. While this western-blot based 
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approach has a number of advantages, such as high-sensitivity and specificity if 
good antibodies are available, it also has a number of limitations (Verano-Braga 
et al., 2012). For example, the number of simultaneously analysed proteins is 
limited using this approach, and only a relatively few phospho-specific 
antibodies with high specificity exist (Verano-Braga et al., 2012). Furthermore, 
discovery of unknown components of a signalling pathway by western blot 
analysis alone is not possible. Alternative methods of signalling pathways 
analysis, for example through the use of commercially available protein arrays or 
mass-spectrometry-based phosphoproteomics have emerged as alternative 
approaches to overcome these issues (Kopf et al., 2005, Yaghooti et al., 2010, 
Verano-Braga et al., 2012, Christensen et al., 2010). Protein arrays allow for the 
analysis of multiple proteins simultaneously on both a small and a large scale. 
Small scale protein arrays, such as the PathScan Antibody Array from Cell 
Signalling Technology, allows for the investigation of activation of distinct 
signalling pathways, including tyrosine kinase, EGFR and Akt signal transduction. 
These small scale array kits allow for the simultaneous detection of around 30 
phosphorylated proteins and are based upon the sandwich ELISA principle (Kopf 
and Zharhary, 2007). Cells can be stimulated with ligands and then the cell 
lysates are incubated on the array slide followed by incubation with a 
biotinylated detection antibody cocktail. Bound antibody is then visualised by 
chemiluminescence and can be accurately quantified (Yaghooti et al., 2010, 
Ketsawatsomkron et al., 2010). This approach has been effectively utilised to 
investigate Ang II-induced MAPK and Akt signalling pathways in monocytes and 
rat VSMC, respectively (Yaghooti et al., 2010, Ketsawatsomkron et al., 2010).  
Larger scale protein arrays allow for analysis of a vast number of proteins and 
numerous signalling pathways, for example the Panorama array from Sigma 
contains over 200 antibodies for key cell proteins involved in signal transduction 
(Kopf et al., 2005). In this type of array, cell lysates are directly labelled with a 
fluorophore or biotin, applied to the protein array and then bound proteins are 
visualised. This approach has yet to be used to assess RAS signalling, however, 
has been proven to be extremely useful in investigating key signalling pathways 
involved in cancer (Kopf and Zharhary, 2007). While this method is advantageous 
to assess the involvement of a large number of signalling proteins, this method is 
less sensitive than the sandwich ELISA method and is not quantitative (Kopf and 
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Zharhary, 2007), therefore any positive proteins must be confirmed using 
traditional methods such as western Blotting. 
Mass-spectrometry-based phosphoproteomics has been identified as a powerful 
method for analysis of cell signalling pathways (Christensen et al., 2010, Verano-
Braga et al., 2012, Mann et al., 2002). This approach has previously been 
employed to study Ang II and Ang-(1-7), in cell lines and primary human 
endothelial cells, respectively, and revealed a number of previously unidentified 
signalling pathways that may be involved in the signalling mechanisms of these 
peptides (Verano-Braga et al., 2012, Christensen et al., 2010). In summary, the 
use of these non-biased approaches would be greatly advantageous to 
investigate the cell signalling mechanisms of Ang-(1-9) in both HSVSMC and 
HSVEC, and would allow for an in depth comparison between the signal 
transduction pathways of Ang-(1-7) and Ang-(1-9).  
Evidence from the literature and the results of this present study in primary 
HSVSMC and HSVEC suggest that Ang-(1-9) mediates its effects in the 
cardiovascular system via the AT2R (Flores-Munoz et al., 2011, Flores-Munoz et 
al., 2012, Ocaranza et al., 2014, Cha et al., 2013). However, evidence of this 
interaction has relied on the use of the pharmacological antagonist of the AT2R, 
PD123,319 which has been demonstrated to have non-AT2R effects in vitro 
(Lautner et al., 2013). For example, alamandine binding to MrgD and alamandine 
induced-vasodilation of aortic rings from AT2R
-/- mice were inhibited by 
PD123,319, suggesting that in addition to being an AT2R antagonist, PD123,319 is 
also a MrgD antagonist/ligand (Lautner et al., 2013). Therefore, future studies to 
confirm the functional interaction of Ang-(1-9) at the AT2R using non 
pharmacological approaches would be beneficial. One approach would be to 
repeat these experiments following knockdown of AT2R expression through the 
use of a specific siRNA. However, there are a number of limitations with this 
approach. For example, confirmation of the level of knockdown of the AT2R at 
the protein level is limited due to poor antibody specificity at GPCRs (Michel et 
al., 2009). Additionally, while the scratch assay is an accurate method to study 
cell migration, only a limited number of cells in each well are analysed and 
therefore it is imperative that these cells are efficiently transfected with the 
siRNA (Liang et al., 2007). Together, the advantages and disadvantages of each 
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approach highlight the need for a combination of experimental approaches to 
fully investigate the interaction of Ang-(1-9) and the AT2R. 
It has also been demonstrated that Ang-(1-9) retains its biological function in 
isolated vessels from AT2R
-/- mice, suggesting that at least ex vivo Ang-(1-9) may 
act on the vasculature via an alternative receptor or mechanism. Ang-(1-9) 
induced vasodilation in pre-constricted aortic rings from both wild type and 
AT2R
-/- mice in an endothelium dependent manner (Prof R. Santos, Federal 
University of Minas Gerais, Brazil, personal communication, 2013). These 
findings in the AT2R
-/- mice were confirmed in this present study in both aortic 
rings and mesenteric artery rings, demonstrating that this effect is present in 
both large conduit vessels and small resistance arteries.  
One possible explanation for this finding in AT2R
-/- mice is that in the absence of 
the AT2R, Ang-(1-9) acts on an alternative receptor leading to vasodilation. 
While further work is required to assess the involvement of an alternative 
receptor, this has previously been demonstrated to be the case with Ang-(1-7) 
(Bosnyak et al., 2011, Walters et al., 2005). For example, in stable cell lines 
generated to express either AT1R or AT2R, but not the endogenous receptor for 
Ang-(1-7) Mas, Ang-(1-7) was found to bind the AT2R with higher affinity than the 
AT1R (Bosnyak et al., 2011). The Ang-(1-7)/AT2R interaction has also been 
observed in vivo. In isolated mouse hearts exposed to the AT2R antagonist 
PD123, 319, Ang-(1-7) increased perfusion pressure, an effect not observed 
following Ang-(1-7) infusion alone and which was independent of both the AT1R 
and Mas. It was also observed that in the presence of AT1R blockade, Ang-(1-7) 
reduced blood pressure in both normotensive rats and the SHRSP, an effect 
mediated via the AT2R (Walters et al., 2005). Therefore, it is possible that Ang-
(1-9) may also engage an alternative receptor under certain experimental 
conditions. One approach to investigate this would be to assess the affinity of 
Ang-(1-9) at receptors previously identified to function as part of, or alongside, 
the RAS leading to vasodilation, such as Mas, MrgD and the BK2R, through the use 
of radioligand binding assays (Hornig et al., 2003, Gorelik et al., 1998, Lautner 
et al., 2013, Santos et al., 2003). However, as little is known about the 
signalling mechanisms induced by Ang-(1-9) it is possible that this peptide may 
engage a receptor that has not been implicated in the RAS and therefore a less 
targeted approach may be required, for example, through the use of a GPCR 
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microarray. This technology is based upon assessment of binding of a 
fluorescently labelled ligand to a large panel of GPCRs, and has been used to 
assess binding of novel ligands such as ICI118,551, a drug compound designed to 
target adrenergic receptors and screening of functional ligands at orphan GPCRs 
(Fang et al., 2002, Fang et al., 2003, Hong et al., 2006). The use of a GPCR 
microarray would enable an assessment of the affinity of Ang-(1-9) at a number 
of receptors and possibly identify hit targets that could be validated further 
through the use of functional cell signalling assays. Ang-(1-9) has previously been 
included as a candidate ligand in a previous GPCR array to identify natural 
ligands for orphan GCPRs, however no positive binding results were observed for 
Ang-(1-9) (Southern et al., 2013). However, in this screen the functional read 
out for GPCR activation relied on β-arrestin recruitment only and analysis of 
other GPCR signalling mechanisms is required (Southern et al., 2013). 
Alternatively, Ang-(1-9) may be metabolised to an alternative peptide, such as 
Ang-(1-7), which also promotes vasodilation in an endothelium-dependent 
manner (Brosnihan et al., 1996, Faria-Silva et al., 2005).  As Ang-(1-7) has been 
shown to promote vasodilation via Mas this potential mechanism of action was 
explored in the current study using the Mas antagonist A779. Here we show that 
A779 blocked the vasodilator effects of Ang-(1-9) in aortic rings but not 
mesenteric artery rings, suggesting that in the aorta, but not mesenteric artery, 
Ang-(1-9) may be converted to Ang-(1-7) which acts via Mas to induce 
vasodilation. As ACE is the main enzyme involved in the conversion of Ang-(1-9) 
to Ang-(1-7), future myography experiments would benefit from the inclusion of 
an ACE inhibitor, such as captopril, to further investigate the potential 
involvement of Ang-(1-7) (Donoghue et al., 2000). While it appears that in large 
vessels of AT2R
-/- mice, such as the aorta, Ang-(1-9) may elicit its biological 
effects via conversion to Ang-(1-7), it is entirely possible that within mesenteric 
arteries Ang-(1-9) is converted to an alternative, unidentified peptide that also 
promotes vasodilation. With the emergence of the RAS as a system of 
interconverted peptides generated by a number of multifunctional enzymes 
including ACE, ACE2, and numerous aminopeptidases, carboxypeptidases and 
endopeptidases, this is a possibility (Santos et al., 1992, Donoghue et al., 2000, 
Nagata et al., 2006, Lautner et al., 2013, Zini et al., 1996, Ackerly et al., 1976). 
However, with the exception of Ang-(1-7) (Donoghue et al., 2000), other 
222 
 
functional peptide metabolites of Ang-(1-9) have yet to be identified and 
therefore further investigation would be required. One method used previously 
to assess generation of novel angiotensin peptides is through the use of matrix-
assisted laser desprption/ionisation mass spectrometry (MALDI-MS) (Jankowski et 
al., 2007). The use of this technique has identified the generation of Ang A from 
Ang II, and Alamandine from Ang A and Ang-(1-7) (Jankowski et al., 2007, 
Lautner et al., 2013). Importantly, this technique allows for the measurement of 
peptide levels in samples following organ/tissue perfusion, and therefore it 
would be possible for the vessels used in this present study to be incubated with 
Ang-(1-9) prior to sample analysis (Jankowski et al., 2007). 
It is currently unclear as to why this differential mechanism of action of Ang-(1-
9) between vascular beds occurs, however it is possibly linked to the differences 
in the mechanisms of vasodilation in conduit and resistance vessels. While in 
large conduit vessels such as the aorta, release of NO from the endothelium is 
the main mechanism of vasodilation, in smaller resistance vessels, such as the 
mesenteric arteries, EDHF emerges as an important mediator of vasodilation in 
addition to NO (Shimokawa et al., 1996, Waldron et al., 1999, Brandes et al., 
2000). Therefore it is possible that in the absence of the AT2R, in the aorta Ang–
(1-9) is metabolised to Ang-(1-7), a peptide which has previously been 
demonstrated to promote vasodilation via NO, while in the mesenteric arteries 
Ang-(1-9) activates an alternative signalling pathway that is potentially involved 
in EDHF signalling. However, further investigation is required in order to 
elucidate the mechanisms of relaxation in response to Ang-(1-9) and future 
studies involving the use of pharmacological antagonists of NO and EDHF 
signalling, such as L-NAME and potassium channel antagonists [including apamin 
(an inhibitor of small-conductance Ca2+-activated K+ channels) and 
charbybdotoxin (an inhibitor of large- and intermediate-conductance Ca2+-
activated K+ channels)], respectively, would contribute to a more thorough 
understanding of the signalling mechanisms involved (Hinton and Langton, 2003).  
As discussed in Chapter 3, Ang-(1-7) and Ang-(1-9) prevented VSMC migration and 
proliferation, via the Mas receptor or AT2R, respectively. Importantly, as shown 
in Chapter 4, these peptides did not affect endothelial cell proliferation and 
migration, indicating that they may prevent neointimal formation but not inhibit 
re-endothelialisation of the vasculature following injury in vivo, and are 
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therefore attractive novel therapeutic targets in the setting of vascular 
remodelling. While Ang-(1-7) has previously been demonstrated to reduce 
neointimal formation in a number of acute models of vascular injury (Strawn et 
al., 1999, Langeveld et al., 2005, Langeveld et al., 2008, Zeng et al., 2009, Wu 
et al., 2011), this present study is the first to characterise the role of Ang-(1-9) 
in vascular remodelling following acute vascular injury in vivo and provides a 
direct comparison between Ang-(1-7) and Ang-(1-9) in this setting. Using the 
mouse carotid artery wire injury model we demonstrated that Ang-(1-7) or Ang-
(1-9) inhibited neointimal formation at 28 days post-injury via Mas or the AT2R, 
respectively. However, the link between Ang-(1-9) and the AT2R was again 
demonstrated through the use of the antagonist PD123,319, which, in addition to 
its effects at the MrgD in vitro and ex vivo, has also been demonstrated to have 
AT2R-independent effects in vivo. For example, in a mouse model of abdominal 
aortic aneurysm (AAA), PD123,319 was demonstrated to augment Ang II-induced 
AAA formation through an AT2R-independent mechanism (Lautner et al., 2013, 
Daugherty et al., 2013). Furthermore, through the use of PD123,319 the Ang-(1-
9)/AT2R interaction was in fact demonstrated to lead to the development of 
enhanced vascular remodelling through the development of complex lesions in 
response to injury in this present study. Due to the fact that no complex lesions 
were observed in animals infused with Ang-(1-9) or co-infused with A779, this 
phenotype is not due to Ang-(1-9) and therefore either occurs as a consequence 
of the Ang-(1-9)/AT2R interaction, or due to PD123,319 and therefore this study 
would benefit from the inclusion of a group of animals infused with PD123,319 
alone.  
As discussed previously, Ang-(1-9) was demonstrated to retain its biological 
function in AT2R
-/- mice, therefore future in vivo studies in these mice to assess 
the effects of Ang-(1-9) on neointimal formation would be valuable. However, it 
is well known that the AT2R plays an important role in the foetal and early post-
natal periods, and that the absence of the AT2R negatively affects cardiac and 
renal maturation and growth, limiting the use of the AT2R
-/- mouse (Price et al., 
1997, Biermann et al., 2012). Thus, further studies using tissue-specific and 
inducible AT2R knockout mice would be of value. Alternatively, use of a 
combination of wild type and AT2R
-/- mice would be of great benefit in other 
models of acute vascular injury such as the mouse model of vein graft failure or 
224 
 
in-stent restenosis, both of which rely on the use of a donor vessel (Ali et al., 
2007, Zou et al., 1998). In these models the vein or stented artery from AT2R
-/- 
mice could be engrafted to the recipient vessel of the wild type mouse, and vice 
versa, as VSMC from both the donor and the recipient vessel have been 
demonstrated to contribute to neointimal formation (Hu et al., 2002). This 
would enable a more in depth mechanistic investigation of the role of this 
receptor within the remodelled vessel.  
Osmotic mini pumps have been a useful tool to investigate the physiological and 
pathophysiological role of various pharmacological agents in vivo. Subcutaneous 
delivery via osmotic mini pump results in drug delivery to the systemic 
circulation at a constant rate over a set period of time without the need to 
cause the animal additional stress by daily dosing (Theeuwes and Yum, 1976). 
Osmotic mini pumps have been widely used to study the effects of angiotensin 
peptides in vivo in a number of different models of cardiovascular disease which 
has greatly contributed to our knowledge of the RAS (Flores-Munoz et al., 2012, 
Ocaranza et al., 2010, Grobe et al., 2006, Langeveld et al., 2005). Osmotic mini 
pumps have not only expanded our knowledge of the effects of administration of 
Ang II in a number of different in vivo models of cardiovascular disease, but have 
also led to the development of the Ang II-infusion model of hypertension. In this 
model, infusion of Ang II induces increased blood pressure, accompanied with 
remodelling of both the heart and vasculature. Ang-(1-7) has also been delivered 
through osmotic mini pumps in several studies, enhancing our knowledge of the 
in vivo effects of this peptide in hypertension, atherosclerosis and remodelling 
of numerous organs such as the heart, kidney and blood vessels (Tesanovic et 
al., 2010, Zeng et al., 2009, Langeveld et al., 2005, Grobe et al., 2006, Grobe et 
al., 2007, Stegbauer et al., 2011). Furthermore, the first studies outlining a 
functional biological effect of Ang-(1-9) in vivo involved the use of osmotic mini 
pumps and demonstrated that delivery of Ang-(1-9) via this route effectively 
reduced cardiac fibrosis and hypertrophy (Flores-Munoz et al., 2012, Ocaranza et 
al., 2010). Additionally, data from this thesis demonstrate that osmotic mini 
pump-mediated infusion of Ang-(1-7) and Ang-(1-9) inhibit neointimal formation 
following vascular injury.  
However, one disadvantage of osmotic minipumps is their limited translational 
impact, as this delivery approach would not represent the situation in the clinic 
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(Theeuwes and Yum, 1976). One delivery approach utilised clinically is local 
delivery of therapeutic agents directly to the vessel; this approach enhances 
drug delivery at the site of action and reduces off target effects at other 
organs/tissues (Inoue and Node, 2009). For example in the case of CABG surgery 
the vein graft can be incubated with therapeutic agents prior to engraftment 
and several studies in animal models have shown that adopting this approach 
results in reduced neointimal formation, at least in the early phase of disease 
(Schachner et al., 2004, Murphy et al., 2007). For example, incubating pig 
saphenous veins for one hour with paclitaxel, sirolimus or cytochalasin D reduced 
neointimal formation at one but not three months following implantation 
(Murphy et al., 2007). Therefore, to represent a more clinically relevant delivery 
approach the findings of this present study were extended to assess if Ang-(1-7) 
or Ang-(1-9) could be delivered locally to the vessel immediately following 
vascular injury through the use of Pluronic F-127 gel, and if so what effect this 
had on the resultant remodelling. However, it could not be confirmed that Ang-
(1-7) or Ang-(1-9) was in fact delivered to the vessel and it was found that very 
little neointimal formation was observed in gel only control vessels; for this 
reason an assessment of the effects of locally applied Ang-(1-7) or Ang-(1-9) 
directly to the injured vessel could not be performed within this present study. 
This finding was unexpected as this gel based delivery approach has been 
utilised in a number of studies using various in vivo models of vascular 
disease/remodelling and has been demonstrated to have no effect on neointimal 
formation (Bennett et al., 1994, Abe et al., 1994, Ishizaka et al., 1999, Grassia 
et al., 2010, Shi et al., 2014). Despite the advantages of locally applied 
therapeutic agents the use of this approach is limited to invasive procedures and 
the therapeutic window of the drug is often limited due to the fact that it is 
applied once at the time of surgery. 
While oral delivery of therapeutic agents for cardiovascular disease is optimal, 
many protein and peptide drugs cannot be administered orally because they are 
degraded by stomach and intestinal digestive enzymes (Uekama, 2004). In an 
attempt to address this limitation, an oral formation of Ang-(1-7) has recently 
been developed where Ang-(1-7) has been incorporated into a cyclodextrin 
compound [HPβCD/Ang-(1–7)] (Lula et al., 2007). Cyclodextrins are 
pharmaceutical tools that are used to enhance drug stability, absorption across 
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biological barriers and provide gastric protection (Uekama, 2004). This oral 
formulation of Ang-(1-7) has been shown to effectively deliver this peptide to 
the systemic circulation where it retains its biological function. For example, 
administration of HPβCD/Ang-(1–7) results in improved cardiac function and 
remodelling following MI in rats, reduced thrombosis in the SHRSP, improved 
diabetic outcomes in Type 2 diabetic rats and improved plaque stability in 
atherosclerotic mice (Marques et al., 2012, Santos et al., 2014, Fraga-Silva et 
al., 2011, Fraga-Silva et al., 2014). An oral formation of Ang-(1-9) is currently 
being developed and while its efficacy in vivo has yet to be demonstrated this 
represents an attractive therapeutic agent which could potentially be used so 
further investigate the effects of Ang-(1-9) in the vasculature.  
6.4 Conclusion 
In summary the data from this thesis demonstrates for the first time a direct 
biological role for Ang-(1-9) in the vasculature through inhibition of HSVSMC 
migration and proliferation, and increase NO bioavailability from HSVEC in vitro 
and reduced neointimal formation in an in vivo mouse model of vascular injury. 
Furthermore, this study provides a direct comparison of Ang-(1-9) and Ang-(1-7) 
in the vasculature and while the end biological effects are similar, they act via 
different receptors, the AT2R or Mas, respectively and differences exist in their 
signal transduction mechanisms. Further work is required to dissect the cell 
signal transduction pathway of Ang-(1-7) and Ang-(1-9) in the vasculature and 
assess their effects in more translational in vivo models of vascular disease; this 
study highlights Ang-(1-7) and Ang-(1-9) as potential therapeutic agents in 
vascular remodelling.  
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